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Abstract 
 
Hepatitis C virus (HCV) infects hepatocytes of the liver causing progressive 
liver disease including; fibrosis, cirrhosis and hepatocellular carcinoma. 
However, the precise mechanism(s) underlying HCV induced liver injury 
are poorly understood. Hepatocytes are highly polarized with distinct 
apical and basolateral membranes separated by tight junctions that 
maintain a normal liver physiology. We studied the role of HCV infection in 
driving hepatic injury. Our studies show that HCV infection induces 
hepatocellular reprogramming via hypoxia inducible factor-1α (HIF-1α) 
stabilization and increased glucocorticoid receptor (GR) signaling. HIF-1α 
stabilization promoted epithelial to mesenchymal transition accompanied 
by reduced polarity and cell adhesion. Whereas GR signaling increased 
cholesterol synthesis and altered HCV receptor expression. Alterations in 
hepatocellular biology induced a cellular state conducive for virus entry 
and replication. 
Consequently, cells de-differentiate to acquire a malignant phenotype via 
HIF-1α target genes including vascular endothelial growth factor (VEGF) 
and transforming growth factor-beta (TGF). In addition, GR transcription 
induced by glucocorticoid treatment or HCV infection enhanced virus 
uptake, highlighting the caveat for glucocorticoid immunosuppression post 
liver transplantation.  Importantly, HIF-1α inhibitors and GR antagonist 
reversed the effects of both transcription factors on virus infection and 
hepatocellular biology. These findings suggest that HCV potentiate liver 
injury via indirect mechanisms.  
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1. INTRODUCTION 
 
1.1 Introduction to viral hepatitis 
 
World War II was a global conflict that began in 1939 and lasted for six 
years. Over 100 million allied troops were mobilized to subdue Nazi 
Germany conquering of continental Europe. On the surface there was a 
fight for freedom by brave men and women of the allied forces. Lurking 
below the surface was an elusive pathogen that caused hepatitis; a severe 
inflammation of the liver in a significant number of service personnel’s who 
received blood transfusion. Research carried out in the 1940’s identified 
two immunologically distinct viruses that were the putative agents of post 
transfusion hepatitis (159, 236, 300). The viral variants were named 
hepatitis A virus (HAV) and hepatitis B virus (HBV). HAV demonstrated a 
faecal-oral route of transmission, suggesting that HAV was not the agent of 
post transfusion hepatitis. In contrast, HBV transmitted via the blood; 
moreover, the discovery of the HBV surface antigen, also known as the 
Australia antigen (HBsAg) further strengthened an association between 
HBV and post transfusion hepatitis (203). By the early 1970’s screening of 
blood from volunteer donors for HBsAg became standardised in the USA, 
resulting in a  90% reduction of  post transfusion viral hepatitis (7).  
In the late 1970’s, Acquired Immuno Deficient Syndrome (AIDS) caused by 
the human immunodeficiency virus (HIV) was highly prevalent in the USA. 
In the backdrop of a looming HIV epidemic, a significant number of 
intravenous drug users and recipients of HBsAg negative blood 
transfusions developed hepatitis. Soon after, blood supplies across the 
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world became contaminated with a viral agent causing what was termed 
post-transfusion non-A, non-B hepatitis. Unlike HBV, the course of non-A, 
non-B hepatitis was characterised by a shorter incubation time with an 
increasing number of sufferers experiencing recurrent hepatitis (6, 160, 
327, 348). For several years the cause of non-A, non-B hepatitis eluded 
identification due to difficulties in isolating and culturing the virus. In 1978 
a report documented the successful transmission of  non-A, non-B hepatitis 
from man to chimpanzee (390).  Subsequent advances in recombinant 
DNA technology allowed Choo and colleagues (74)  to generate a cDNA 
library from the plasma of an infected chimpanzee and to identify a single 
clone that was reactive with non-A, non-B patient sera. Sequencing of this 
clone revealed a positive sense single stranded RNA genome that showed 
resemblance to several members of the Flaviviridae family of viruses which 
include (yellow fever, dengue and west nile viruses). The culprit was 
designated hepatitis C virus (HCV) and was classified to a new genus 
(Hepacivirus) of the Flaviviridae family.   
HCV particles range between 50-60nm in diameter; each particle is 
comprised of a lipid bilayer envelope bearing the E1E2 glycoprotein 
complex that facilitates particle and host cell interactions. The envelope 
surrounds a capsid that contains the positive sense single stranded RNA 
genome (Figure 1-1). The RNA genome is 9,600 nucleotides long, 
comprising of two untranslated regions at the 5’ and 3’ termini and a single 
open reading frame encoding a large polyprotein approximately 3000 
amino acids in length. The internal ribosome entry site (IRES) located 
within the 5’ NCR initiates translation of the polyprotein which is modified 
by host and viral proteases into three structural proteins (Core, E1 and E2) 
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Core protein (capsid)
Glycoproteins (E1E2)
Single stranded RNA genome
Lipid membrane
which are the capsid and envelope glycoproteins respectively, a small ion 
channel (p7) and six non-structural proteins (NS2, NS3,NS4B, NS5A and 
NS5B). The structural proteins comprise the building blocks for the new 
virion and the non-structural proteins replicates the viral RNA (400). HCV 
genome and replication will be described in more detail section 1.8.  
 
 
 
 
 
 
 
 
 
Figure 1-1. A cartoon of the HCV particle.  
 
 
 
 
 
 
4 
 
1.2 The hepatic microenvironment 
 
The major reservoir for HCV replication are hepatocytes of the liver, this is 
achieved via the utilization of four receptor molecules; scavenger receptor 
BI (SR-BI), CD81, Claudin-1 and Occludin (108, 314, 316, 357), this 
process will be uncovered in section 1.6. The liver is the largest organ in 
the human body, weighing between 1.2 and 1.5kg with central roles in 
metabolic, endocrine and secretory pathways including the storage, 
transport and synthesis of lipids (393). It is located below the diaphragm 
to the right of the stomach and possesses a unique location between the 
peripheral lymphoid organs and the gastrointestinal tract. Anatomically, 
the liver is divided into two major lobes when observed from the anterior; 
a large right lobe and a smaller left lobe. Both lobes are separated by the 
falciform ligament anteriorly, by the fissure for the ligamentum venosum 
posteriorly and by the fissure for the ligamentum teres inferiorly. Two 
additional minor lobes exist between the left and right lobes. They are the 
caudate lobe located on the posterior surface and the quadrate lobe on the 
anterior surface (35, 92, 311, 404). The liver has a dual blood supply from 
the hepatic artery and the hepatic portal vein; the hepatic artery supplies 
oxygenated blood from the heart and the hepatic portal vein provides 
deoxygenated nutrient rich blood from the gastrointestinal tract. Arterial 
and venous bloods traverse the liver parenchyma via the sinusoids, 
generating a mixed supply which is collected in the central vein. Blood 
from the central vein travels via the hepatic vein to the inferior vena cava 
where it becomes re-oxygenated (207). Figure 1-2 shows an outline of the 
liver anatomy.  
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Anterior view Posterior view
Inferior view
 
 
 
 
 
 
 
 
 
Figure 1-2. Anatomy of the liver. 
The liver is shown anteriorly, posteriorly and inferiorly (95).  
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The main cell type of the liver that performs most of its functions is the 
hepatocyte. Hepatocytes are also referred to as liver parenchymal cells and 
comprise 80% of the entire liver mass. They are the major epithelial cells 
of the liver; and possess a unique polygonal architecture compared to 
other epithelial cells. Hepatocytes have three faces that enable them to be 
in contact with neighbouring hepatocytes, the sinusoids and the bile 
canaliculus simultaneously (88, 118, 305, 368). As such, hepatocytes form 
a complex polarity, in which adjacent plasma membranes are separated by 
tight junction proteins into sinusoidal (basolateral) and apical (canalicular) 
domains. Polarity is crucial for the correct physiological functioning of the 
liver with the tight junctions separating the secretory bile from the blood 
flow. In contrast epithelial cells such as those lining the gut demonstrate 
simple polarity due to a single face resulting in single apical and 
basolateral domains (63, 88, 373).  
The remaining 20% of the liver mass consists of cells collectively termed 
non-parenchymal cells including; endothelial cells, kupffer cells, 
lymphocytes and stellate cells. Endothelial cells line the hepatic circulatory 
vessels known as sinusoids; the hepatocytes are in turn arranged into 
plates separated by sinusoids which provide a large surface area for 
nutrient absorption (46). The sinusoids possess a narrow lumen which is 
infiltrated by kupffer cells and lymphocytes. Kupffer cells are the resident 
macrophages of the liver, they are predominantly located in the peripheral 
region of the liver; this unique localization allows them to phagocytose 
invading pathogens or foreign particles that enter the liver via the portal 
blood flow (196, 378). Lymphocytes form part of the innate immune 
response that helps to protect the liver against infection. Between the 
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hepatocytes and the sinusoidal endothelium lies the Space of Disse which 
contains an extracellular matrix made up of fibronectin, collagen and 
hepatic stellate cells. These cells store vitamin A and are activated upon 
liver injury to become collagen synthesizing myofibroblasts that produce 
most of the factors that lead to hepatic fibrosis (393). In addition, the liver 
contains cholangiocytes also reffered to as biliary epithelial cells due to 
their unique localization in the biliary tracts. They are the first line of 
defence against pathogens invading the bile ducts due to the production of 
cytokines and chemokines (188).  An outline of the liver architecture 
including cell types and their localization is shown in Figure 1-3.  
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Figure 1-3. Architectural layout of the liver. 
A. Scanning electron micrograph of the liver showing hepatocytes (H), 
Kupffer cells (K), sinusoids (S), bile canaliculi (BC) and erythrocytes (E). 
Courtesy of the Wellcome Trust Image Library. B. Cartoon depicting the 
localization of liver cells in proximity to hepatocytes.  
 
A. 
B. 
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1.3 HCV disease 
Epidemiology and treatment   
Globally, an estimated 180 million people are infected with HCV, equating 
to around ~3% of the world’s population (370). It is difficult to obtain 
accurate estimates from different countries as acute HCV infection is often 
asymptomatic. However, HCV prevalence is divergent in different parts of 
the world with high incidence in India (3-5 million cases), North America 
(2-4 million cases), Europe (5-10 million) Asia (6-12 million cases) and 
Africa (10 million cases) (WHO epidemiological record, 2009). Up to 150, 
000 new cases occur annually in Europe and North America, of these only 
25% are symptomatic. More than 60% of infections will progress to chronic 
liver sequelae, 20% of whom will develop cirrhosis of the liver and 5-7% 
will develop end stage liver disease such as hepatocellular carcinoma 
(HCC) which becomes fatal (68, 365, 366). Intriguingly, 15-20% of 
infected individuals will spontaneously clear the virus following sero-
conversion, a mechanism which is poorly understood (352).  
Prior to 1992, the prevalence of HCV transmission was high amongst 
individuals who came into contact with contaminated blood; primary routes 
of transmission included the receipt of blood transfusion or organ 
transplantation, consequently HCV antibodies were detected in 80% of 
haemophilic patients (18). The establishment of robust clinical standards 
for blood screening significantly reduced the number of new HCV cases 
from blood transfusion or organ transplantation. Today, HCV is 
predominantly transmitted amongst intravenous drug users sharing 
contaminated needles. Other routes of transmission include perinatal and 
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sexual transmission which contributes moderately to the global HCV 
prevalence (54).  
HCV pathogenesis can be monitored by the detection of viral RNA; 
however viral load does not necessarily correlate with disease severity 
(352). Several factors including age, gender, immunological status, alcohol 
consumption and co-infection with HIV have been reported to affect HCV 
pathogenesis (366). Indeed, it was reported that HCV pathogenicity is 
greater amongst individuals from ethnic minority backgrounds; in the USA 
90-100% of new infections are detected in people of African origin, 70-
80% in Hispanics and 60-70% in Caucasians (367), these findings are 
unlikely to be biological but may reflect social living conditions.  
A classic feature of HCV replication is the generation of distinct variants 
with up to 35% nucleotide divergence, these variants are termed 
genotypes. There are six major HCV genotypes, many of which comprise 
related subtypes resulting in 11 distinct antigenic groups (377). More 
recently, a genotype 7 virus has been proposed (144). All genotypes share 
an identical set of genes similar in size. Even so, HCV genotypes show 
differences in their pathogenesis, sensitivity to antiviral therapies and 
geographical distribution. Genotypes 1, 2 and 3 have become widely 
distributed amongst intravenous drug users and are responsible for a 
significant proportion of infections in Europe, the Mediterranean and North 
America. Genotypes 4 and 5 are prevalent in developing countries such as 
South Africa and Egypt whilst genotype 6 is widespread in Asia (102, 183). 
Figure 1-4 shows the major HCV genotypes and their geographical 
distribution. 
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Figure 1-4. Phylogenetic analysis of HCV sequences from variant isolates 
showing the six major HCV genotypes, secondary groupings within some 
genotype and their geographical distribution (377).  
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To date there is no vaccine for HCV, antiviral therapy includes a 
combination of interferon-alpha (INFα) and ribavirin which is only partially 
effective and is dependent on early diagnosis of the disease; furthermore, 
the combination can be toxic and costly (161). The outcome of HCV 
infection is associated with the infecting genotype; individuals infected with 
HCV genotype 1 viruses are more likely to develop chronic hepatitis and 
HCC (249, 338). Furthermore, genotype 1 viruses are increasingly 
resistant to INFα and ribavirin with only a partial success rate of 50% 
(116, 442). Infection caused by genotypes 2 and 3 viruses are associated 
the hepatocellular steatosis and fibrosis with a successful treatment rate of 
up to 80% (116, 442). Patients with chronic liver disease have limited 
treatment options primarily because they respond poorly to INFα and 
ribavirin. Liver transplantation is the only viable option in most cases; 
however, circulating virus in the blood reinfects the new graft. Fatality 
rates 5 years post transplantation in HCV patients are around 70% due to 
reinfection and the progressive nature of the disease (358).  
Recently, two protease inhibitors (Telaprevir and Boceprevir) that target 
the NS3/NS4A serine protease have been licensed. Telaprevir 
demonstrated potent inhibition of HCV infection with a 50% inhibitory 
concentration of 354nM and a 50% cytotoxicity concentration of 83µM 
(204). Preclinical studies showed that telaprevir had sufficient liver 
exposure in dogs and rats and is synergistic with interferon-α and additive 
with ribavirin against genotype 1 viruses (223). The majority of patients 
receiving telaprevir had sustained virological responses; 79% compared to 
patients in receipt of standard interferon and ribavirin therapy (46%) 
(Vertex Pharmaceuticals, 2011). Telaprevir is associated with mild side 
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effects such as fatigue and nausea; however, these symptoms are 
normally manageable.  
Boceprevir is a serine protease inhibitor that binds reversibly to NS3 and is 
administered in combination with INFα and ribavirin. The combination 
treatment significantly increases the rate of sustained virological response 
in previously untreated individuals with chronic HCV genotype 1 infection 
(323).  
Tropism and immunobiology 
Although hepatocytes are the main reservoir for HCV replication, studies 
have shown extrahepatic manifestations associated with HCV infection. We 
and others have shown that neuroepithelioma cell lines are permissive for 
HCV infection suggesting that HCV may infect the central nervous system 
(52, 121). More recently, we have shown that HCV infects brain endothelial 
cells, highlighting the possibility that HCV perturbs the blood brain barrier 
in vivo resulting in neuropathology seen in many infected patients 
(Fletcher et al, 2011, in press). A minority of individuals infected with HCV 
developed the B-cell disorder cryoglobulinaemia (347) and peripheral blood 
mononuclear cells (PMBC) are also affected by HCV infection (210, 282). 
Together, these studies show that additional non-hepatic cellular reservoirs 
for HCV infection exist which implicates the virus in additional pathological 
disorders.  
Little is known about the frequency of HCV infected hepatocytes in the 
liver, due to difficulties in staining liver tissue for viral antigens. A study by 
Liang et al, used two-photon microscopy techniques to visualize HCV 
infected hepatocytes in liver tissue. The authors showed NS3 positive cells 
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that were focally distributed and suggested that around 10-15% of 
hepatocytes in vivo are actively infected (221). However, virus production 
is thought to be high with genomic RNA burden in the order of 1 x 1012 
RNA copies/day (284). HCV specific antibodies can be detected in patient 
sera as early as 8 weeks post infection (301). Nevertheless, the role of the 
humoral immune response is unclear as high antibody titres are often 
detected in patients with chronic infection suggesting limited neutralizing 
activity (232, 266). Studies have shown that a sustained T-cell response is 
crucial for viral clearance during acute infections. This response is 
associated with CD4+ and CD8+ T-cells (211, 375, 399). However, in 
persistent HCV infection CD4+ and CD8+ T-cells response is weak and are 
sometimes undetectable (83). It is not yet clear what factors governs a 
sustained immune response to virus infection, although a prolonged and 
specific immune response is likely to affect the outcome of HCV infection. 
Attempts to design HCV vaccines have largely focused on eliciting 
appropriate T cell response (45, 194, 383), however, inoculation of SCID 
uPA mice with patient immunoglobulin or anti-E2 antibodies resulted in 
immune protection against HCV to revitalise hopes for a B-cell vaccine 
(212, 407).     
HCV transmits via a cell free and cell-cell routes of transmission; recent 
evidence from our laboratory has shown that the cell-cell route is the 
preferred mode of transmission. This route provides a means for virus 
evasion of the immune response (50, 401). HCV infection is associated 
with a robust interferon response, however this does not correlate with the 
outcome of virus infection (103, 131, 385). Several virus proteins including 
core and NS3-4A block interferon signalling by modulating the JAK-STAT 
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pathway and IFNβ production respectively (128, 218). Furthermore, HCV 
NS5A blocks protein kinase receptor (PKR) signalling allowing virus escape 
from type 1 interferon signalling (187). IFNα therapy is administered to 
substitute for the disrupted IFN secretion in infected cells and to stimulate 
the activation of natural killer cells and dendritic cell maturation (116). The 
interferon inducible protein IP-10, a ligand for the chemokine receptor 
CXCR3 is upregulated in hepatocytes surrounded by lymphocyte infiltrates 
and may promote CXCR3 expressing T-cells to sites of inflammation (372).  
HCV associated carcinogenesis 
Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumour 
with limited treatment options and poor prognosis. It is the most common 
liver malignancy and rates fifth in incidence and third in mortality of 
cancers in the world (107). A rapid increase in HCC has been associated 
with HCV infections (25), HCV associated HCC accounted for 155,000 
deaths in the USA in 2002, although this figure is likely to underestimate 
the number of deaths today (306). HCV replicates in the cytoplasm and 
does not integrate into the host genome indicating that HCC occurs via 
indirect effects of HCV infection including the inflammatory response and 
the perturbation of cellular pathways (27, 253, 291). It is not known 
whether cancer arises in the infected hepatocyte or whether a bystander 
effect induces carcinogenesis in surrounding cells. This is difficult to 
ascertain as the detection of HCV RNA in transformed hepatocytes is 
unreliable because HCV circulates the blood and likely to be present in the 
tissue parenchyma.  
16 
 
In vivo, hepatocytes do not divide; however, there is an increase in the 
frequency of hepatocytes expressing the proliferation marker Ki67 in HCV 
infected livers (198). Furthermore, individuals with increased Ki67 
expression are more likely to develop HCC (104). It is not known whether 
proliferating hepatocytes are infected with HCV or whether surrounding 
uninfected cells are proliferating due to the loss of infected cells by virus 
induced apoptosis (253). This is difficult to ascertain due to difficulties in 
detecting infected hepatocytes in vivo (221).  
Small animal model studies have shown that the liver is highly 
regenerative. Following a partial hepatotectomy over 90% of quiescent 
hepatic cells enter the cell cycle. The mechanism of liver repair is highly 
complex involving cooperative signals from cytokines and growth factors. 
Damaged hepatocytes activate growth factors and cytokines that induces a 
significant alteration of the liver architecture including, increased 
fibronectin production and changes in cellular junctions to initiate liver 
repair (268, 269). During liver regeneration (Figure 1-5), it is believed that 
vascular endothelial growth factor (VEGF); a potent angiogenic cytokine 
binds to its receptors expressed on sinusoidal endothelial cells to initiate 
the release of hepatocyte growth factor (HGF) precursor proHGF from 
stellate cells. proHGF is cleaved by urokinase-type plasminogen activators 
which liberates HGF to bind to its receptors on hepatocytes (53). HGF-
hepatocyte interactions activate phosphatidylinositol 3-kinase (PI3K) and 
AKT signalling which in turn stimulate the expression of transforming 
growth factor alpha (TGFα), insulin growth factor binding protein-1 and 
various cellular kinases. These in turn induce cell cycle transition by 
increasing cyclins D and E expression (93, 216, 290). Subsequently, 
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several factors crucial for the innate immune response (lipopolysaccharides 
and complement molecules) activate kupffer cells resulting in increased 
tumour necrosis factor alpha (TNFα) synthesis. TNFα up-regulates 
interleukin 6 (IL-6) and together they activate neighbouring hepatocytes 
leading to the expression of various signalling molecules and inhibitory 
proteins including transforming growth factor beta (TGFβ) produced by 
stellate cells to terminate liver regeneration through repression of cyclins D 
and E. Subsequently, hepatocytes return to their normal quiescent state 
(246, 382). In this manner, a complex interplay between cytokines and 
growth factors is critical for liver repair, the role of cytokines and growth 
factors in liver repair is reviewed in (393). Figure 1-5 depicts growth 
factors and cytokines pathways during liver regeneration.  
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Figure 1-5. Growth factor and cytokine signaling during liver 
regeneration.  
A. The growth factor mediated pathway. Vascular endothelial growth factor 
(VEGF) stimulates the release of hepatocyte growth factor (HFG) precursor 
pro-HGF which is cleaved by urokinase-type plasminogen activator (uPA) 
and plasminogen proteases that liberates HGF. HGF activates 
phosphatidylinositol 3-kinase (PI3K), and other downstream factors leading 
to cell cycle transition via cyclins D and E. B. The cytokine mediated 
pathway. Lipopolysaccharides (LPS) complement factors (C3/C5) and 
others activate kupffer cells which secretes tumour necrosis factor-alpha 
(TNFα). This leads to interleukin-6 (IL-6) production. TNFα/IL-6 activates 
neighbouring hepatocytes resulting in the activation of several molecules 
including stem cell factor (SCF). Additionally, TGFβ, plasminogen activator 
inhibitor (PAI) and cyclin inhibitors are activated to terminate cell division 
(393).     
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Liver regeneration results in significant histological changes to the 
parenchyma, including the deposition of a fibronectin matrix associated 
with fibrogenesis (86, 393). It is believed that the liver reverts to an early 
embryonic state associated with signalling pathways important for 
morphogenesis and regeneration including; sonic hedgehog (SHh) 
signalling and epithelial to mesnchymal transition (EMT) (72). Both 
pathways are crucial for embryogenesis, organogenesis and development; 
however, as we will discuss later these pathways are also implicated in 
tumourgenesis. SHh signalling and EMT induces a cellular de-differentiation 
state resulting in the expression mesenchymal markers associated with the 
loss of adhesion and tight junction molecules. This is followed by increased 
proliferation, which is necessary for tissue regeneration (287, 292, 398). 
However, this process is transient as subsequent inhibitory signals leads to 
a reversal course known as mesenchymal to epithelial transition (MET) 
whereby cells regain their hepatic/epithelia features. When EMT activity 
exceed MET, repair is mainly fibrotic resulting in severe scarring of the 
liver (72).  
HCV infection has been linked to SHh signalling (71, 304) and EMT (28), 
suggesting the intriguing possibility that HCV exploits the regenerative 
events of the liver to promote its transmission. Figure 1-6 depicts EMT in 
polarized epithelial cells. We will continue this section by drawing upon 
experimental evidence demonstrating a role for cytokines and growth 
factors in regulating hepatocyte polarity, potentiating HCV infection and 
driving hepatic carcinogenesis.  
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Figure 1-6. EMT in polarized epithelial cells.  
EMT is associated with a gradual loss of epithelial properties resulting in a 
de-differentiation process whereby cells gain mesenchymal properties. 
Cartoon lists epithelial (orange) and mesenchymal (green) markers. Taken 
from (185). 
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HCV infection is associated with an inflammatory response that promotes 
fibrogenesis. The activation of stellate cells is most likely to drive this 
process although little is known about HCV-stellate cells activation. 
However, it is believed that detection of double stranded RNA produced 
during HCV replication by Toll-like receptor 3 (TRL3) and the induction of 
endoplasmic reticulum (ER) stress by HCV infection leads to the activation 
of NF-ќB and proinflammatory cytokines which in turn primes stellate cells 
to activate fibrogenesis (353, 419, 420).  
There is a growing body of evidence demonstrating a role for 
proinflammatory cytokines in regulating tight junction dynamics in 
epithelia and enodthelia phenotypes (reviewed in, (57)). For example, 
TNFα and IFNγ modulation of tight junction proteins causes inflammatory 
bowel disease, a severe inflammation of the colon. Whilst the pathobiology 
of this disease is complex, one prominent feature is increased paracellular 
permeability resulting in exposure of tissue to luminal pathogens (120). 
Tight junctions regulate the transcellular movement of molecules between 
apical and basolateral membranes (fence function) and create a semi-
permeable barrier between cells to restrict the flow of molecules through 
the paracellular space (barrier function), in doing so tight junctions 
establish cell polarity (373). The role of tight junctions in establishing 
hepatocyte polarity and HCV entry will be described in detail in section 1.6.  
Studies have shown elevated TNFα in serum from HCV infected patients 
which is associated with enhanced fibrosis (119, 449). Furthermore, HCV 
NS3 protein increases TNFα production in HepG2 cells reinforcing a link 
between infection and inflammation (158). A recent study from our group 
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showed that treatment of HepG2 cells with TNFα and IFNγ perturbed tight 
junction permeability (260), together these studies suggest that that 
cytokines produced during HCV infection may potentiate barrier breakdown 
leading to liver injury. Indeed, alterations in tight junction structure and 
distribution promote the malignancy of various carcinomas including HCC 
(166, 293). We have previously reported aberrant tight junction protein 
distribution in HCV infected liver tissue, indicating that virus infection 
affects tight junction dynamics in vivo (341). More recently, several 
reports have shown that HCV infection is associated with the stabilization 
of hypoxia inducible factor-1 alpha (HIF-1α) a transcription factor that 
regulates a variety of genes implicated in invasion and metastasis, 
providing new insights into the role of HCV in HCC (157, 280, 344).  
Solid tumours are characterized by low oxygen levels (hypoxia); the 
cellular response to hypoxia is mediated by HIF-1α and HIF-1β (HIFs). 
HIFs are heterodimeric transcription factors that are constitutively 
expressed in cells. During normoxia (high oxygen) HIF-1α transcription is 
regulated by hydroxylation of the alpha subunit at prolyl and asparagynyl 
residues followed by the binding of von Hippel-Lindau (VHL) E3 ligase that 
targets HIF-α for ubiquitination and degradation via the proteasome (179, 
180). During hypoxia HIF-1α hydroxylation is inhibited resulting in its 
stabilization and translocation to the nucleus where it dimerizes with HIF-
1β and binds to the HIF-1 responsive element in various genes involved in 
cell survival, proliferation and metabolism (369). Figure 1-7 depicts HIF-1α 
signalling in normoxia and hypoxia. 
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Proteomic analysis of HCV infected cells indicate a reprogramming of 
hepatocellular metabolism and biogenesis which favours virus replication 
and pathogenesis (37, 90, 425). It is believed that HIF-1α target genes 
play a major role in HCV induced changes in the hepatic environment. 
Importantly, several HIF-1α target genes are upregulated during HCV 
infection, of significance are VEGF and TGFβ. VEGF signalling plays a key 
role in driving angiogenesis; HCC is a hypervascular tumour requiring 
angiogenesis to promote tumour growth and metastasis. We and others 
have shown that HCV infection increases VEGF expression (157, 258, 280). 
Moreover, VEGF negatively regulates hepatocellular polarity by 
reorganizing Occludin distribution in polarized HepG2 cells to promote HCV 
entry. Anti-VEGF neutralizing antibodies and the receptor kinase inhibitor 
sorafenib restored polarity and reduced virus entry (258). Schmitt et al, 
reported that VEGF disrupts tight junctions in a protein kinase A dependent 
manner resulting in enhanced HCC spread into the normal liver 
parenchyma (362). Taken together, these data suggest that HCV 
promotion of VEGF expression may aid in HCC pathogenesis.  
TGFβ is a pleiotropic cytokine that regulates diverse cell signalling 
pathways including proliferation, apoptosis and invasion (264). Several 
reports demonstrated increased TGFβ levels in patients with chronic liver 
diseases (70, 130, 240, 381). In HCC, TGFβ signalling exerts tumour 
suppressor functions during the early stages of tumourgenesis by 
mediating hepatocyte apoptosis. During the latter stages, TGFβ switches 
from tumour suppressor to tumour promoter (264, 345). Ectopic 
expression of HCV core proteins isolated from patients with HCC modulates 
TGFβ plasticity from tumour suppressor to tumour promoter via SMAD 
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phosphorylation (28). In addition, HCV proteins induce oxidative stress and 
the production of reactive oxygen species (ROS) in a TGFβ dependent 
manner (44). Moreover, a recent study by Presser and colleagues showed 
that HCV infection promotes TGFβ expression resulting in increased virus 
replication, suggesting a role for TGFβ in the virus lifecycle (326).  
Several studies have shown the induction of EMT by TGFβ signalling (139, 
184, 438). As previously discussed EMT is required for various 
developmental processes including liver regeneration (185). Nevertheless, 
there is a growing body of evidence implicating EMT in driving the invasive 
and metastatic potential of human cancers including HCC (1, 213, 248, 
405, 431, 432). A balanced interplay between EMT and MET dictates the 
outcome of liver injury, in this regard, when EMT supersedes MET liver 
repair is mainly fibrotic leading to increased migration of hepatic cells 
(reviewed in, (72)). Battaglia and colleagues reported that HCV core 
protein induces EMT in a TGFβ dependent manner (28). Furthermore, Li et 
al; demonstrated that HCV core protein induces EMT via the lysyl oxidase-
like 2 (LOXL2) pathway to drive cholangiocarcinoma; a malignant growth 
of the bile ducts, suggesting that HCV may also induce other hepatic 
malignancies (219). The LOXL2 pathway is regulated by TGFβ indicating a 
role for TGFβ in driving this process. Figure 1-8 depicts EMT in cancer 
progression.            
These data indicate that HCV in not an oncogenic virus per se; however, 
virus infection results in an inflammatory response to initiate liver repair. 
HCV may in turn hijack the repair mechanism. Consequently, the hepatic 
environment is modified to favour virus replication and transmission. In 
25 
 
response to uncontrolled repair mechanisms, cells maintain a 
mesenchymal phenotype resulting in increased fibrosis, migration and 
invasion that promotes hepatic carcinogenesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
Normoxia
HIF-1α
PDH
HRE HIF-1 target genes
Ub
Hypoxia
O2
Proteolytic degradation
Nucleus
HIF-1α HIF-1α
HIF-1α
HIF-1α HIF-1α
VHL
OHOH
VHL
OHOH
Ub
Ub
Ub
HIF-1α HIF-1β
Angiogenesis (VEGF) EMT 
(TGFβ)Cell proliferation 
and invasion  (TGFβ)
Cell surface  
 
 
 
 
 
 
 
 
 
Figure 1-7. HIF-1 signaling in normoxia (black arrows) and hypoxia 
(red arrows).  
In normoxia, HIF-1α is hydroxylated by proline hydroxylases (PHD). 
Hydroxylated HIF-1α (OH) is recognised by VHL (von Hippel–Lindau 
tumour suppressor gene) which, together with a ubiquitin (Ub) ligase 
complex, tags HIF-1α for proteasome degradation. In response to hypoxia, 
proline hydroxylation is inhibited and HIF-1α is stabilized resulting in HIF-
1α accumulation and translocation to the nucleus. There, HIF-1α dimerizes 
with HIF-1β, binds to hypoxia-response element (HRE) within the promoter 
region of target genes to affect their transcriptional activity. A range of cell 
functions are regulated by HIF-1α target genes including VEGF and TGFβ 
as indicated.  
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Figure 1-8. EMT during cancer progression.  
During cancer progression cells lose their polarity and detach from the 
basement membrane. The basement membrane also changes via re-
modeling of the extracellular matrix. The next stage of EMT involves an 
angiogenic factor that facilitates tumour growth through vascularisation 
leading to the detachment of de-differentiated epithelial cells that becomes 
invasive. Invasive cells enter the circulation and exit the blood stream at a 
distal site where they form a secondary tumour or reverse via MET to 
regain a normal phenotype (185).  
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1.4 Model systems to study the HCV lifecycle  
 
The study of a new virus is made possible by the availability of model 
systems to study entry and replication. The liver is a highly specialized and 
complex organ and the development of in vitro systems that reflect the 
complexity of the liver has proven difficult. Consequently, studies of the 
HCV life-cycle were hindered for many years due to a lack of appropriate in 
vitro models. Indeed, host cell receptor molecules that potentiate HCV 
infection were identified over a decade after the virus was discovered. This 
section will outline breakthroughs made in the past two decades of HCV 
research that enables us to study the virus in vitro.  
Primary hepatocytes and immortalized hepatocyte based models 
Initial studies of the HCV lifecycle capitalized on the hypothesis that virus 
infection was dependent on host factors expressed in highly differentiated 
cells.  As such, primary hepatocyte cultures from humans or chimpanzees 
chronically infected with HCV were used for infection studies. However, the 
use of primary cell cultures were inadequate for several reasons; 1) they 
supported low levels of HCV replication; 2) the infectivity of the sera did 
not correlate with the HCV RNA levels making experiments difficult to 
reproduce; 4) heterogeneous virus populations and HCV specific antibodies 
in the sera of infected patients impaired the levels of infection; 5) primary 
cells were difficult to obtain and isolation techniques varied in different 
laboratories (reviewed in (20, 141)). In addition to primary cell culture, 
several immortalized human hepatocyte cell lines were reported; PH5CH 
and HuS-E cells were generated by immortalizing primary human 
hepatocytes (PHHs) with the large T antigen of simian virus 40 and the 
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E6/E7 genes of human papiloma virus, respectively (8, 176). Both cell lines 
supported HCV replication; however, the production of virus particles were 
restricted and the levels of RNA replication were low making them non-
viable for long term studies. Further studies utilised reverse transcriptase 
polymerase chain reaction (RT-PCR) to detect HCV RNA levels which was 
indicative of virus replication (356).  This technique proved useful in 
detecting low levels of HCV RNA; however, it also presented new 
challenges including the potential for random priming by cellular nucleic 
acids, contamination of RNA samples and lack of strand specificity due to 
RNA self-priming (209, 391). As such additional criteria were introduced to 
validate HCV replication, these included treatment of infected cells with 
interferon-α (IFNα) to cure viral RNA and sequence analysis to 
demonstrate genome variability.  
HCV replicons 
The low levels of HCV replication in primary hepatocytes made it difficult to 
manipulate the viral genome to study its lifecycle in detail. In 1999, 
Lohmann and colleagues created bicistronic sub-genomic replicons from 
the liver RNA of a chronically infected patient (233). The regions encoding 
core to p7 genes were replaced with a neomycin selective marker and the 
IRES of the enchephalomyocarditis virus (EMCV) (233). Translation of the 
first cistron (neomycin gene) was directed by the HCV IRES and the second 
cistron (NS2 or NS3 to NS5B and the 3’ UTR) by the EMCV IRES (Figure 1-
9). Replicons are genetic elements that can replicate autonomously. The 
recombinant HCV construct was able to replicate autonomously when 
introduced into several hepatoma cell lines allowing for the identification of 
permissive cell types and adaptive mutations that promote HCV replication 
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in vitro. These mutations were at the N-terminus of NS3, in two positions 
of NS4B/NS5A and in the C-terminus of NS5B (39, 41, 201). Importantly, 
when introduced into full length HCV genomes, these adaptations allowed 
for the complete replication of the viral genome in vitro (40). In the 
following years, several groups successfully generated full length and sub-
genomic replicons (177, 190, 313). HCV replicons made it possible to 
identity permissive hepatoma cell lines that support efficient HCV 
replication. Blight and colleagues transfected Huh-7 hepatoma cells with 
sub-genomic replicons and selected cells containing replicating RNA for 
prolonged INFα treatment to cure cells of the viral RNA. Sustained INFα 
treatment resulted in clonal populations that were tested for their ability to 
support HCV replication after re-transfection with HCV replicons (41). One 
clone in particular; denoted Huh-7.5, showed a significant enhancement in 
HCV replication compared to other clones. Efficient virus replication in 
these cells was partly attributed to a defective retinoic-acid-inducible gene-
I (RIG-I) pathway which essential for an antiviral immune response (208, 
384). The replicon system made it possible to study host and viral 
signalling necessary for virus replication and echoed a new dawn in HCV 
research. However, the process of viral entry and assembly could not be 
realised using this system. Figure 1-9 outlines the HCV replicon system. 
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Figure 1-9. HCV replicon system.  
A. Huh-7 cells are electroporated with replicon RNA. Cells efficiently 
replicating HCV replicons were selected by G418 treatment. (Ba). In 
parallel, Huh-7 sub-clones that are highly permissive for HCV replication 
can be obtained by G418 treatment of cells transfected with HCV replicons, 
followed by treatment with interferon-α (IFN) to eliminate the HCV replicon 
resulting in clones that are permissive for HCV replication (Bb). Taken 
from(336).  
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HCV pseudoparticles (HCVpp) 
One approach employed by researchers to realise how HCV interacts with 
host cells was to express the viral encoded glycoproteins (E1E2) in 
isolation from other viral encoded proteins. However, high level expression 
of E1E2 resulted in misfolded aggregates which affected their 
transmembrane domains (80). To overcome these problems researchers 
expressed chimeric glycoproteins incorporating transmembrane regions of 
E1E2 known to be expressed at the plasma membrane or truncated 
glycoproteins lacking transmembrane domains (414). Deletion of the HCV 
E2 transmembrane domain resulted in the secretion of a soluble form of E2 
(sE2) (267); sE2 was used to identify two putative HCV receptors (SR-BI 
and CD81) which will be described later in the context of HCV entry. The 
identification of two putative receptors using sE2 indicated that E2 is the 
major glycoprotein responsible for receptor binding.  However, E1E2 exist 
as heterodimers suggesting that sE2 was unlikely to recapitulate functional 
HCV glycoproteins.  
The development of infectious HCV pseudoparticles (HCVpp) enabled 
studies of the entry aspect of the virus lifecycle (171). Pseudoparticles take 
advantage of the ability of retroviruses to incorporate heterologous 
glycoproteins in their membrane during budding. HCVpp’s were generated 
by co-transfecting three plasmids into human embryonic kidney (293T) 
cells; (1) the gap-pol gene of HIV or murine leukaemia virus (MLV), (2) a 
GFP or luciferase reporter gene which allows for the rapid assessment of 
viral entry and the HCV E1E2 glycoproteins. Gag-pol expression resulted in 
the formation of retroviral particles into which the provirus genome 
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encoding the reporter is packaged. During budding E1E2 is incorporated 
into the pseudo-envelope, because there are no retroviral glycoproteins in 
the system cell entry is determined solely by the HCV glycoproteins. Entry 
results in the delivery of the retroviral nucleocapsid protein into the 
cytoplasm followed by reverse transcription and incorporation of the viral 
genome into the host cell genome. The reporter gene is then expressed 
allowing for a read out of HCVpp entry into the cell (reviewed in, (336, 
411, 414). A schematic representation of HCVpp generation is depicted in 
Figure 1-10. HCVpp infection of hepatoma cells was ablated by specific E1 
and E2 neutralizing reagents to confirm that both E1 and E2 are 
indispensible for HCV entry (24, 171, 205) and provided the first functional 
assay to screen the effects of neutralizing antibodies on virus entry. HCVpp 
from diverse genotypes has allowed for the analysis of genotype specific 
neutralization and entry efficacy (24). HCVpp’s were critical in the 
identification of HCV co-receptors Claudin-1 and Occludin, the identification 
of these receptors and their role in the HCV lifecycle will be described later. 
To date, HCVpp have allowed comprehensive studies of HCV binding, 
attachment and internalization.   
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Figure 1-10. A cartoon depicting the generation of HCV 
pseudoparticles modified from (411). 
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Cell culture derived HCV (HCVcc) 
2005 hallmarked a major breakthrough in HCV research. Several 
laboratories reported an HCV strain that replicates and release infectious 
particles in cell culture (HCVcc) (225, 415, 447). The strain was cloned 
from a genotype 2a virus isolated from a Japanese patient with severe 
acute HCV infection. This unique clone was referred to as Japanese 
Fulminant Hepatitis 1 (JFH-1). The efficient replication of HCVcc meant that 
the full lifecycle of the virus could be realized in vitro. Unlike all previous 
HCV genomes tested JFH-1 infection of hepatoma cells resulted in the 
release of progeny virus capable of infecting naive cells. Importantly, 
HCVcc was infectious for chimpanzees and mice transplanted with human 
hepatocytes (227). JFH-1 replication was not robust in certain cell lines 
which were susceptible to HCVpp infection suggesting that the limitation 
was not occurring at entry but rather at the level of replication. HCVcc 
confirmed major findings made using HCVpp including the identification of 
HCV co-receptors and continues to increase our understanding of the virus 
lifecycle. The successful isolation of JFH-1 paved the way for the 
development of several chimeric HCVcc constructs representing diverse 
genotypes (143, 144, 360). In conclusion, our understanding of HCV has 
been hindered for many years primarily because of a lack of robust model 
systems to study the virus lifecycle. The development of in vitro systems 
has greatly enhanced our understanding of key aspects in the virus 
lifecycle. 
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1.5 Mechanisms(s) of virus entry 
 
Viruses gain entry into a host cell by binding to specific receptors or 
attachment molecules expressed on the cell membrane. Following 
attachment bound virus particles internalizes by one of two major routes; 
namely fusion of the viral envelope with the plasma membrane or uptake 
via endocytotic vesicles. The final stage of entry is the uncoating of the 
viral genome which is necessary for replication in the appropriate cellular 
environment (reviewed in (241)). Entry into a host cell is a complex 
process where the virus is likely to encounter environmental and 
immunological barriers; however, viruses have evolved to prime their 
target cells for entry. For example, studies of the entry mechanisms of 
murine leukaemia virus (MLV) have shown “virus surfing” an actin-
dependent lateral transport of virus particles towards target cells, this 
conformational change in the cells cytoskeleton prepares the cell for next 
stage of virus entry be it receptor attachment or membrane fusion (214, 
371).  Receptor distribution restrict the cellular entry of some viruses, to 
overcome this viruses interact with signaling molecules which act in two 
distinct ways. 1) Remodeling the cell to potentiate entry (281); 2) utilizing 
signaling molecules as chaperones to cellular receptors (91). An example 
of the latter is the entry process of group B coxsackieviruses (CBV), CBV 
utilize the tight junction component CAR as a receptor. However, CAR is 
unattainable to CBV as it approaches the apical cell surface, realizing this 
CBV engage an apically expressed protein called decay-accelerating factor 
(DAF). DAF engagement induces signaling events which mediate the 
translocation of DAF to tight junctions where CAR is accessible to CBV; 
successful interaction CAR allows CBV to enter the cell (85, 241).    
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1.6 HCV entry 
 
HCV targets hepatocytes by a complex multi-step process involving four 
host molecules or receptors to initiate productive infection. Although 
significant progress has been made over the past few years, the precise 
mechanism(s) of HCV entry is still unknown. Nevertheless, it is likely that 
entry is a balanced interplay between, co-receptor interactions in the 
correct cellular domain and virus induced host cell signalling. This section 
will outline our current understanding of HCV entry.  
HCV attachment factors 
In biology, a receptor is defined as a specific molecule expressed on the 
membrane of a cell to which complementary ligands such as antibodies, 
hormones and pathogens bind. The definition of a virus receptor is open to 
interpretation as there are so-called low affinity molecules expressed at the 
cell surface which viruses utilize to aid in tethering but do not initiate 
infection or internalize the virus. For example, vaccinia virus binds to 
cytoskeletal components and uses them as chaperones to secure binding 
to its major receptors; therefore, this initial targeting of the cytoskeleton is 
not considered as receptor binding but is essential to bring virus particles 
close to its receptors (94).  These low affinity molecules are commonly 
referred to as attachment factors. HCV associates with several attachment 
factors before engaging receptor molecules expressed on target cells. The 
following sections outline the attachment factors required for HCV 
engagement of its receptor molecules.  
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C-type lectins 
HCV travels from the initial site of infection to the liver. Virus particles 
approach the liver via the sinusoidal endothelium which is highly 
fenestrated and acts as a molecular sieve that filters debris between the 
blood and hepatocytes. Leaving the circulation HCV interacts with 
attachment factors expressed on the sinusoidal endothelium. Studies have 
shown that liver sinusoidal endothelial cells (LSEC) express liver and 
dendritic specific intracellular molecule 3-grabbing non-integrins (L-SIGN 
and DC-SIGN). L-SIGN and DC-SIGN are type II membrane proteins 
belonging to the C-type lectin family of proteins, they play a major role in 
liver sinusoidal and dendritic cell interaction(s) with T-cells due to their 
ability to bind intercellular adhesion molecules (ICAMs) (79). L-SIGN and 
DC-SIGN mediate the attachment of many viruses including HIV, feline 
caronavirus and dengue virus (5, 335, 417), more recent evidence 
demonstrated that both molecules bind HCV E2, suggesting a role to 
capture virus particles from the blood and transcytose them to the 
underlying hepatocytes  (206, 234, 321). Importantly, L-SIGN and DC-
SIGN engagement of HCV was inhibited using anti-L-SIGN and DC-SIGN 
antibodies (136, 235, 322) suggesting a specific interaction. Nevertheless, 
since both molecules are not expressed on hepatocytes, their role may 
involve capturing virus at the sinusoidal endothelium/dentritic cells and 
transcytosing them to the underlying hepatocytes (206, 234, 321). 
Glycosaminoglycans (GAGs) 
GAGs are cell surface polysaccharides ubiquitously expressed throughout 
the body and are post translationally linked to proteoglycans (34). Heparan 
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sulphates (HS) are highly sulphated GAGs expressed on proteglycans at 
the cell surface and offer a ubiquitous target for viral attachment. Indeed 
studies have shown that several viruses including dengue and sindbis 
associate with HS (167, 448). Once HCV has traversed the sinusoidal 
endothelium, it is believed that HS recruits virus from LSECs (22, 149, 
234, 242, 279), and concentrate them at the basolateral surface of 
hepatocytes. This interaction is mediated by the virus encoded glycoprotein 
E2 via the HVR1 region (21, 437). In vitro, soluble forms of HS inhibit 
HCVpp infection of cells as does treatment of cells with heparanase 
supporting an association between HCV and GAGs (409). However, a study 
by Callens et al, showed that E2 and HS association inhibited HCVpp entry 
(56) raising questions as to the exact role of HS in the HCV lifecycle.  
Low density lipoprotein receptors  
In vivo HCV exist in high and low density fractions that are closely 
associated with apoliproteins B and E (64, 168, 178, 181), high density 
lipoproteins (HDL), low density lipoproteins (LDL) and very low density 
lipoproteins (VLDL) (10, 138, 285, 295, 324). As such, HCV represents a 
lipo-viro-particle (LVP) due its high lipid content. The liver is the primary 
site of VLDL assembly with key roles in regulating plasma lipoprotein 
concentrations. (305). Hepatocyte lipid receptors such as low density 
lipoprotein receptor (LDL-R) have been proposed as a candidate 
attachment molecule for HCV (242, 274, 279, 295, 307). In vivo, 
successful interaction between LDL and LDL-R initiates cholesterol 
endocytosis and trafficking. Serum derived HCV interacts with LDL-R 
resulting in enhanced cellular binding and endocytosis. Furthermore, HCV 
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endocytosis was inhibited by specific LDL-R antibodies and competition 
from LDL-R ligands including LDL and VLDL (3). These findings were 
unsuccessfully reproduced using HCVpp, suggesting that the LDL-R 
pathway is dependent on HCV association with lipoproteins (428). Ectopic 
expression of LDL-R in cells expressing all the other attachment factors 
does not confer susceptibility to HCV infection, suggesting that other 
factors are required to mediate HCV entry into hepatocytes.  
HCV entry factors  
Following a series of successful interactions with attachment factors, HCV 
particle uptake into hepatocytes is dependent on four receptor molecules. 
It is believed that HCV initially interacts with SR-BI, followed by CD81-
Claudin-1 complexes and Occludin (108, 189, 440) . However, the exact 
nature and timing of these interactions is not well understood. Visualising 
HCV internalisation has been complicated by the heterogeneous nature of 
the virus particle, in terms of shape density, and its association with lipids. 
The following section outlines our current understanding of the complex 
yet fascinating process of HCV entry via its receptor molecules.  
Scavenger Receptor Class B member I  
Once HCV has traversed the sinusoidal endothelium and becomes 
concentrated at the basolateral hepatocyte membrane, the exact sequence 
of virus-receptor engagement is not fully understood; however, the lipid-
rich nature of HCV particles favours an initial interaction with the 
scavenger receptor class BI (SR-BI) protein. SR-BI is a 509 amino acid 
glycoprotein with a C-terminal cytoplasmic tail, an N terminal domain and 
two transmembrane domains separated by a large extracellular loop (LEL) 
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(79). SR-BI functions as a multi-ligand lipoprotein receptor that is 
ubiquitously expressed throughout the body but is predominantly found in 
the liver and adrenal glands (79). It facilitates the binding and transfer of 
lipids from HDL, LDL and VLDL accounting for its varied roles in cholesterol 
metabolism including the removal of unesterified cholesterol and 
steroidogenesis (55, 200). In hepatocytes SR-BI mediates the selective 
uptake of cholesteryl ester from HDL and incorporates it into the plasma 
membrane to maintain lipid homeostasis between hepatocytes and plasma 
(61).  
SR-BI is highly expressed on the sinusoidal face or basolateral membranes 
of hepatocytes consistent with the hypothesis that HCV enters the liver by 
interacting with basolateral expressed receptor molecules adjacent the 
hepatic portal blood flow (156). SR-BI was identified as an HCV entry 
receptor in 2002 by Scarselli and colleagues based on their observation 
that sE2 binds efficiently to SR-BI in HepG2 cells (357). To validate their 
findings and determine species specificity, Scarselli and colleagues 
transfected Chinese hamster ovary (CHO) cells with human SR-BI (hSR-
BI). Only cells expressing hSR-BI efficiently bound sE2 demonstrating that 
hSR-BI is required for HCV E2 interaction (357). More specifically, this 
interaction was mapped to the first hypervariable region (HVR1) of HCV E2 
as binding of sE2 was impaired by deletion of the HVR1 (357). Other 
studies have shown that HCVpp lacking the HVR1 were poorly infectious 
suggesting that this region is critical for entry (23). Importantly, anti-SR-
BI antibodies and siRNA knockdown of SR-BI successfully reduced HCV 
infection in a genotype specific manner as some genotypes demonstrated 
increased sensitivity to SR-BI neutralization (62, 99, 146, 412). 
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Lipoprotein ligands were shown to modulate SR-BI-E2 interactions, where 
HDL enhanced virus uptake (409, 410) and offered protection against anti-
E2 neutralizing antibodies to promote HCV entry (410). Conversely, 
oxidised LDL inhibited HCV infection in an SR-BI dependent manner (99, 
413), this inhibition of infection did not occur by disrupting SR-BI-E2 
association but through potential changes in the biophysical properties of 
the virus (412). These studies suggest the relationship between HCV and 
SR-BI is more complex than a simple virus-receptor interaction but is 
highly dependent on the lipid exchange function of SR-BI.  Several studies 
have sought to map the exact role of SR-BI in the virus lifecycle. Bankwitz 
et al., reported that deletion of HVR1 decreased SR-BI dependence and 
increased HCV binding to CD81 (19). This finding is consistent with our 
observation that a single mutation at residue G451 in HCV E2 reduced SR-
BI dependence and increased CD81 binding (147). Indeed, HVR1 masks 
conserved binding epitopes in CD81 to protect them from neutralizing 
antibodies (19); and mutation of specific N-linked glycans on E2 at 
positions 417, 532 and 635 increased E2–CD81 association (163). Taken 
together, these studies suggest that a conformational change in E2 is 
required to promote CD81 association. This conformational change may be 
mediated directly by HCV engagement of SR-BI, although this is yet to be 
determined.  
The exact nature of E2-SR-BI interaction is unknown; however, it was 
reported that HCV E2 links directly to SR-BI (165). This association may in 
turn induce a membranous or cytoplasmic rearrangement that brings the 
SR-BI-virus complex in close proximity to other entry receptors. An SR-BI 
mutant that negates interaction with PDZK-1, a cytoplasmic adapter 
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protein that regulates SR-BI expression and localization, did not affect HCV 
entry (98). Conversely, mutations in the SR-BI C-terminus prevented its 
palmitoylation and association with lipid raft microdomains resulting in 
decreased HCV entry (98, 148); these findings suggest that SR-BI 
localization to specific membrane microdomains plays a role in HCV entry. 
Several reports have shown that SR-BI localizes to plasma membrane lipid 
rafts (15, 342), these are low density membrane microdomains enriched 
with cholesterol and are crucial for transport and endocytotic events that 
could potentiate virus internalization or targeting of co-receptors molecules 
via SR-BI binding (reviewed in (241)). 
SR-BI may also play a role in HCV internalization due to its ability to 
endocytose its natural ligands via its C-terminal cytoplamic tail (429). 
Ectopic expression of SR-BII an mRNA splice variant of SR-BI that differs 
only by its C-terminus induced a rapid internalization of HDL (106) but 
inhibited HCVpp entry compared to SR-BI (98). This data demonstrate that 
SR-BI and not SR-BII is essential for HCV entry. Interestingly, the 
introduction of SR-BII dileucine endocytic motif in the C-terminal tail of 
SR-BI promotes SR-BI/HDL internalization but reduced HCV entry (98, 
105), suggesting that determinants within the SR-BI cytoplasmic tail that 
controls endocytosis is different from those controlling HCV entry. 
Furthermore, these findings indicate that if SR-BI does induce HCV 
endocytosis it does not occur in a binary SR-BI virus interaction manner 
but may occur through SR-BI engagement of other HCV co-receptors.   
To determine whether an association exists between HCV receptor 
expression levels and viral replication kinetics post liver transplant, Mensa 
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and colleagues studied entry receptor levels 24hrs post transplantation 
(263). The authors noted a significant association between SR-BI 
expression levels and HCV RNA, suggesting that SR-BI levels may limit 
HCV entry and replication in the new allograft. However, the authors did 
not discriminate between endothelial or hepatocyte SR-BI expression, 
which may lead to an alternate conclusion that SR-BI on the sinusoidal 
endothelium, defines HCV clearance rates. Further studies are needed to 
determine the role of hepatocyte SR-BI expression levels in defining HCV 
entry into the liver, especially given the interest in therapeutically 
targeting SR-BI to limit HCV infection post transplant (389, 424) 
Tetraspanin CD81 
It is believed that HCV engagement of SR-BI induces a conformational 
change in HCV E2 that allows its association with CD81. CD81 is a member 
of the tetraspanin family of proteins that includes CD9 and CD151, 
tetraspanins are type III glycoproteins ubiquitously expressed throughout 
the human body. They are organized into tetraspanin webs, which allow 
them to interact with other tetraspanins or integrins (305). They have 
multiple regulatory roles in cell signaling pathways including proliferation, 
migration and adhesion (244). CD81 is a 26-kDa protein made up of four 
hydrophobic transmembrane helices separating two extracellular (EC) 
loops, defined as EC1 and EC2. It has varied roles in signaling events 
including immune cell activation and morphology. Furthermore, CD81 is 
essential for Plasmodium infection of hepatocytes (217, 376). CD81 was 
the first molecule reported to interact with sE2 and was therefore proposed 
as a putative candidate receptor (314). HCV entry is highly dependent on 
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CD81 since anti-CD81 antibodies can neutralize diverse genotype 
transmission (50). CD81 EC2 binds HCV E2 via three domains; including 
amino acids 480–493, 544–551 and 612–619, along with several individual 
residues W420, Y527, W529, G530, and D535 (89, 296, 297). Importantly, 
sE2-CD81 interaction is species specific as sE2 only interacts with cells 
from human and not mouse origin. Furthermore, antibodies against CD81 
or HCV patient sera inhibited the sE2 interaction (314, 427).  Additional 
studies showed that siRNA knockdown of CD81, anti-CD81 monoclonal 
antibodies and recombinant forms of CD81 EC2 ablated HCVpp infection of 
primary human hepatocytes and hepatoma cells (26, 84, 443). Moreover, 
ectopic expression of CD81 in non permissive HepG2 cells induced 
susceptibility to HCVpp infection (254, 260).  
Anti-CD81 antibodies or HCV E2 engagement of CD81 has been reported to 
activate Rho GTPase family members Rac, Rho and CDC42 (cell division 
cycle 42) and MAPK (mitogen-activated protein kinase) signaling cascades 
(48), to induce actin remodeling that allowed the lateral movement of 
CD81 necessary for HCV entry. However, we observed high levels of MAPK 
activation in a number of hepatoma cells and inhibiting these pathways 
with a variety of kinase inhibitors had no significant effect on HCV entry 
(113), highlighting the caveats of studying signaling pathways in 
transformed tumour cell lines. Further work is required to study the 
consequences of CD81 ligation in primary hepatocytes. CD81 has no 
endogenous ligand and does not possess an internalization motif 
accounting for its slow internalization rate (32, 308). However, recent data 
from our lab suggest a role for CD81 trafficking in HCV entry. CD81 
antibodies and HCV engagement promotes CD81 internalization in a 
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clathrin mediated endocytosis dependent manner. Furthermore, anti-CD81 
antibodies neutralized HCV infection post internalization suggesting an 
intracellular site for CD81 neutralization. These data suggest that HCV 
engagement of CD81 may promote its endocytosis which in turn 
potentiates virus entry (Farquhar et al, manuscript submitted).  
CD81 is expressed on the basolateral membranes of hepatocytes where it 
co-localises with SR-BI and Claudin-1 (341). To understand how receptor 
complexes coordinate HCV entry, Harris et al, (156) utilized fluorescence 
resonance energy transfer (FRET) imaging techniques to identify CD81-
CD81 and CD81-Claudin-1 protein complexes. Treatment of hepatoma cells 
with recombinant HCV E1E2 gycoproteins did not modulate FRET 
association between co-receptor complexes suggesting that FRET occurs in 
the absence of viral proteins. However, an anti-CD81 monoclonal antibody 
reduced FRET between CD81-CD81 but not CD81-Claudin-1 associations 
highlighting differences between homo and heterotypic co-receptor 
complexes in HCV entry (156). These data suggest that the correct 
localization and association of CD81 with other co-receptor molecules 
coordinates HCV entry.  
A recent study implicated CD81 in HCV replication, HCV RNA replication 
occurred in cells expressing high levels of CD81. In contrast, cells 
expressing low CD81 levels demonstrated reduced RNA replication. 
Interestingly, over expression of CD81 increased HCV RNA synthesis, these 
findings suggest diverse and multiple roles for CD81 in the HCV lifecycle 
(445). CD81 interacts with two immunoglobulin proteins EWI-F and EWI-2 
(66, 444) that link CD81 to the actin cytoskeleton by interacting with 
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Ezrin-Radixin-Meosin (ERM) protein (354). Expression of a EWI-2 cleavage 
product designated EWI-2wint (without its N terminus) abrogated HCVpp 
and HCVcc infection of hepatoma cells by blocking CD81-E2 interaction 
(346, 363). However, the role of EWI-2 in HCV entry is unclear as it is not 
expressed by primary human hepatocytes.  
CD81 expression levels affect the efficiency of HCV infection as a minimum 
threshold of CD81 at the cell surface is necessary to render Huh-7 
hepatoma cells susceptible to virus infection (199). Cells expressing SR-BI 
and CD81 failed to support HCV entry suggesting that additional receptor 
molecule(s) are required.   
Claudin-1 
Crucial to the functioning of all organs in the human body is the 
compartmentalization and directional trafficking of solutes in a specific 
manner. For example, the liver regulates the directional flow of bile by 
separating it from the blood flow (222). This is achieved by tissue 
polarization; hepatocytes have distinct membrane surfaces termed apical 
and basolateral. Each surface have a specific protein expression profile 
suitable to the tasks it performs (418). Tissue polarity is regulated by tight 
junction proteins, in the liver tight junctions separates the apical 
canalicular membrane where bile flow takes place from the basolateral 
sinusoidal membranes adjoining the blood flow. Tight junctions are multi-
protein complexes that seal the paracellular space between adjacent cells 
in a way that prevents the free movement of solutes between distinct 
membranes (299). Sealing of the paracellular space is achieved through a 
series of interactions between transmembrane proteins including Occludin, 
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Claudin’s, and junctional adhesion molecules (JAM). Tight junctions 
interact with the cells cytoskeletal structure; an association mediated 
through scaffolding or signaling partners such as the Zona Occludens (ZO-
1/2) and Cingulin (4, 16). Figure 1-11 depicts transmembrane tight 
junction components.   
 
 
 
 
 
 
 
 
 
 
 
Figure 1-11. Organization of tight junction components.  
Cartoon shows tight junction components and scaffolding partners that 
provide a link to the cytoskeleton. Arrows depict the movement of solutes 
via a paracellular or transcellular pathway, modified from (286).   
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Claudin-1 is 21 kDa in size and belongs to the Claudin family of 
transmembrane proteins. There are 24 members of the Claudin family that 
are highly conserved and share a basic structure consisting of four 
transmembrane domains that anchors a large and small extracellular loop 
(EC1 and EC2, respectively). EC1 is responsible for sealing of the 
paracellular space and the formation of ion channels, whereas EC2 is 
associated with the correct conformation and positioning of the protein 
(11). The cytoplasmic terminus of Claudin-1 has a PDZ-binding domain 
through which Claudin-1 interacts with the zona occludens that tether 
Claudin-1 to the cytoskeleton. Perturbation of this interaction leads to 
aberrant tight junctions; a phenotype associated with malignant tumours 
(251). Claudin-1 is predominantly expressed at the apical membrane of 
hepatocytes; however, a pool of Claudin-1 is observed at the basolateral 
membranes and this portion is believed to play a role in HCV entry (341).  
In 2007, Evans and colleagues identified Claudin-1 as the third HCV co-
receptor. The authors showed that the human embryonic kidney cell line 
(293T) that expresses SR-BI and CD81 but not Claudin-1 was resistant to 
HCV infection subsequent to Claudin-1 transduction (108). Importantly, 
silencing of Claudin-1 in permissive hepatoma cells ablated HCV entry 
(108, 446). However, Claudin-1 expression levels did not modulate HCV 
infectivity suggesting a putative indirect role for this molecule in the entry 
process. Generation of chimeric Claudin-1 molecules expressing domains of 
Claudin-7 showed that Claudin-1 EC1 domain is required for functional 
receptor activity. Claudin-1 and -7 share a highly conserved EC1 domain 
that differs by 5 residues only, mapping of these sites demonstrate that 
residues E48 and I32 define Claudin-1 co-receptor activity (108). To 
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further confirm the role of the EC1 in HCV entry, a Flag epitope was 
inserted into this region resulting in the inhibition of HCVpp entry using an 
anti-Flag antibody. Furthermore, the use of anti-Flag and anti-CD81 
antibodies to inhibit HCVpp entry at various time points suggested that 
HCV-CD81 interaction precedes Claudin-1 engagement (108). 
Nevertheless, the precise role of Claudin-1 in HCV entry is not yet 
determined as no direct association between Claudin-1 and the viral 
glycoproteins has been reported to date. Several studies have suggested 
that Claudin-1 plays a role in HCV internalization as anti-Claudin-1 
antibodies neutralized viral infection post attachment (123, 202). Indeed, a 
study has shown that Claudin-1 endocytose and fuse with Rab5 expressing 
early endosomes, indicative of a putative pathway for HCV to hijack during 
its internalization (113). Recent data from our group showed increased 
Claudin-1 endocytosis induced by HCV infection, suggesting that HCV 
modulate Claudin-1 internalization during entry (Farquhar et al, manuscript 
submitted). 
Claudin’s share a similar topology with tetraspanins and associate with 
CD81 at the plasma membrane. Data from our lab using FRET showed the 
formation of Claudin-1-CD81 complexes in the membranes of hepatoma 
cells and hepatocytes in the liver tissue. Perturbation with a protein kinase 
A (PKA) antagonist (112) and anti-CD81 antibodies (156) decreased FRET 
between these two molecules and inhibited HCVcc and HCVpp infection. 
More recent observations has shown that the Claudin-1-CD81 association 
is localized to the basolateral membrane of polarized HepG2 cells, whereas 
tight junction or apical associated pools of Claudin-1 demonstrated minimal 
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association with CD81, suggesting that Claudin-1-CD81 association at the 
basolateral membrane potentiates HCV infection (154).  
Haid and colleagues developed a receptor complementation system in Huh 
6 hepatoma cells that express low levels of endogenous Claudin-1 to 
assess the functional properties of Claudin-1 (151). Naive Huh 6 cells were 
resistant to HCV infection; however, expression of human, hamster or rat 
Claudin-1 supported HCV entry. In contrast, expression of mouse Claudin-
1 showed moderate effects. The differences between mouse, human and 
rodent (hamster and rat) Claudin-1 were mapped to mouse-specific 
residues in the EC2. The authors suggested that these determinants could 
prevent optimal interaction with other co-receptors thus limiting efficient 
HCV infection and identified Claudin-1 as a contributory factor to HCV 
species specificity (151).   
Two additional Claudin family members; Claudin-6 and 9 were also 
implicated in HCV entry (261, 446). Expression of Claudin-1, 6 and 9 but 
not other Claudin’s rendered 293T cells susceptible to HCVpp entry. 
However, Claudin-6 and 9 expression levels in the liver and primary human 
hepatocytes is moderate and their role in particle entry is unclear, studies 
to characterise their interaction with HCV are ongoing.  
Occludin 
Whilst the presence of SR-BI, CD81 and Claudin-1 are essential for HCV 
infection; when expressed together they do not allow HCV infection of non-
permissive cells. Benedicto and colleagues demonstrated that HCV E2 
glycoprotein perturbed the cellular distribution of tight junction proteins in 
Huh-7 hepatomas resulting in the intracellular co-localization of Occludin 
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(30). This study represents the first indication of a putative role for 
Occludin in HCV entry although it was not fully grasped at the time. The 
role of Occludin was not formally identified until a year later when two 
independent studies implicated it in the virus lifecycle. In the first study, a 
short hairpin RNA (shRNA) library was used to reduce Claudin-1, Occludin, 
and ZO-1 expression. Reduction of all four proteins inhibited HCVpp and 
HCVcc infection. However, knockdown of ZO-1 alone had no effect on HCV 
entry, whereas modulation of Claudin-1 and more specifically Occludin 
reduced HCVpp entry (229). Ploss and colleagues expanded further on the 
role of Occludin in HCV entry (317). Expression of human Occludin and 
human CD81 in murine cells expressing endogenous SR-BI and Claudin-1 
allowed for productive HCV infection. Conversely, silencing of Occludin 
expression in permissive Huh-7.5 cells reduced HCV entry (317).  
Occludin is 60 kDa in size and consists of four transmembrane domains 
with two extracellular loops. Similar to Claudin-1, Occludin regulates the 
tight junction barrier and is tethered to the cytoskeleton through 
interactions with binding partners such as ZO-1 and Cingulin (117).  
One of the greatest challenges in HCV research is the lack of a small 
animal model that supports HCV infection in which vaccine candidates can 
be evaluated. Apart from humans, the chimpanzee is the only known host 
for HCV replication and is not widely available for research use. The 
observation that Occludin allows HCV to infect murine cells is an exciting 
prospect because at least one species specific barrier has been removed to 
support the development of small transgenic animal models for HCV 
research (17, 312, 317, 319). Using a panel of inter-species chimeras and 
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alanine scanning mutagenesis of the extracellular domain of Occludin 
Michta et al, reported that the latter half of the extracellular 2 domain  is 
critical for HCV entry and a further 2 cysteine residues flanking this region 
may facilitate interactions by forming a specific loop conformation 
mediated by disulfide bonding (271). Mapping the regions of Occludin 
essential for HCV entry represents significant progress in understanding its 
role in HCV entry. Occludin is predominantly expressed at the apical 
membrane of hepatocytes in normal liver concomitant with minimal 
expression at the basolateral surface (259). Recent data from our 
laboratory showed that perturbing Occludin localization with cell 
penetrating Occludin peptides (109) promotes HCV entry and suggests a 
role for intracellular Occludin in HCV entry (Mee et al, manuscript 
submitted). This data is consistent with one study demonstrating a post 
binding role in HCV entry (31). Furthermore, an observed co-localization of 
Occludin, CD81 and Claudin-1 in early endosomes supports a model where 
HCV exploits the dynamic intracellular trafficking of receptor proteins (Mee 
et al, manuscript submitted). Figure 1-12 shows the HCV receptor 
complex. 
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Figure 1-12. HCV receptor molecules.  
CD81, Claudin-1 and Occludin receptor activity is dependent on residues in 
EC2 EC1 and EC2 domains respectively. SR-BI receptor activity is 
dependent on residues within its C-terminus. CD81 and SR-BI interacts 
directly with HCV E2 glycoprotein and aid in virus internalization and 
attachment respectively. The role of Claudin-1 and Occludin in the virus 
lifecycle is unclear as no direct association with HCV has been reported. 
However, it is believed that both proteins are important for virus 
internalization. Modified from (400). 
 
 
 
 
 
 
EC1         EC2 
55 
 
1.7 HCV endocytosis and fusion 
 
Following successful attachment to cell surface receptors, HCV particles 
internalize by crossing the cell membrane. HCV enters the cell via clathrin 
mediated endocytosis in a low pH compartment, (reviewed in (241)). This 
was demonstrated by silencing the clathrin heavy chain protein involved in 
endocytosis and blocking clathrin polymerization which inhibited HCVpp 
and HCVcc entry (38, 81, 262). Furthermore, inhibitors of endosomal 
acidification blocked HCVpp infection of hepatoma cells confirming a role 
this pathway (38, 81, 172). There is a 20 minute delay between HCV 
endocytosis and genome penetration suggesting that low pH is not 
sufficient to trigger fusion and other molecular events such as receptor 
engagement maybe required. This finding was substantiated by the 
observation that low pH pre-treatment of HCV particles had no effect on 
HCVcc infectivity (402). Indeed, studies have shown that clathrin mediated 
endocytosis transport viruses in conjunction with their receptors (reviewed 
in (241)). 
Imaging studies have shown colocalization of HCV and Rab5, an early 
endosomal marker suggesting that HCV is delivered to early and not late 
endosomes. As such HCV entry is reduced in Huh-7 cells expressing 
dominant Rab5 GTPase mutants that interferes with cargo delivery to early 
enodsomes compared to cells expressing a Rab7 GTPase mutants which 
perturbs delivery to late endosomes (262). The acidic pH inside early 
endosomes triggers virus uncoating and penetration; penetration occurs 
via membrane fusion initiated by fusion peptides in the envelope 
glycoproteins (379). Fusion peptides are hydrophobic domains that are 
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inserted into the host cell membrane to induce the formation a hair-pin 
structure that brings the virus into close proximity to the lipid bilayer (192, 
193). HCV fuses to the host lipid membrane to allow trafficking of the viral 
RNA into the cytoplasm.  
Fusion of viral envelopes and cellular membranes is mediated by two 
classes of fusion proteins, namely class I and class II (241). Analysis of 
HCV glycoproteins revealed a folding pattern reminiscent of class II fusion 
proteins (137). Class II fusion proteins potentiate virus penetration 
following endocytosis in a low pH endosomal compartment as low pH is 
necessary for exposure of the fusion peptide (193). Clathrin and other 
proteins assemble at the cell membrane to form clathrin coated pits in a 
dynamin dependent manner (276). Clathrin coated pits are matured in 
early endosomes by shedding of the protein coat and acidification. 
Subsequent to HCV entry, the low pH of the endosome induces a 
conformational change that enables HCV glycoprotein fusion with the 
endosomal membrane resulting in the release of the viral genome into the 
cytoplasm. To date the precise mechanisms of HCV fusion are unclear; 
however it has been suggested that fusion resembles other flaviviruses due 
to pH and temperature dependence (162, 439).  
 
 
 
 
 
57 
 
1.8 HCV replication, assembly and release 
 
Release of the RNA genome into the cytosol is closely followed by 
translation and replication. As previously discussed HCV consists of a single 
strand positive sense RNA genome composed of a 5’ non coding region 
(NCR), an open reading frame that encodes a large poly protein precursor 
of about 3000 amino acids and a 3’ NCR. The 5’ NCR contains an internal 
ribosome entry site (IRES) that is responsible for cap-dependent 
translation of the viral RNA (13, 51, 275, 343). Studies have shown that 
the liver specific micro-RNA (mIR-122) binds to the 5’ NCR to enhance HCV 
replication (182, 309, 334) suggesting that HCV exploits cellular micro-
RNA pathways to further its lifecycle. The 3’ NCR consists of a poly (U/UC), 
a 98 RNA nucleotide element called the X-tail and a short variable region, 
which is indispensible for replication of the viral genome (275).  
HCV translation is initiated through the formation of a complex between 
the IRES and a 40s ribosomal unit followed closely by the assembly of a 
48s complex at the AUG start codon after interacting with the eukaryotic 
initiation factor-3 (eIF3) (294). Translation of the open reading frame 
results in the large polyprotein precursor that is post translationally 
modified by host and viral proteases into mature structural (core, E1 and 
E2), a small ion channel (p7) and non-structural proteins (NS2, NS3, 
NS4A, NS4B, NS5A and NS5B) (228). The structural proteins and p7 
peptide are cleaved by endoplasmic reticulum (ER) peptidases; separation 
of the core protein by host peptidases results in an immature 23 kDa core 
protein that undergoes further processing to yield a mature 21 kDa core 
which is anchored to the ER membrane and on the surface of lipid droplets 
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where it aids in virus packaging and assembly of new capsids (257). Core 
protein association with lipid droplets has been suggested to modulate lipid 
metabolism resulting in the development of hepatic steatosis often seen in 
patients with HCV infection (14). The envelope glycoproteins E1 and E2 
form heterodimers that are retained in the ER by their C-terminal 
hydrophobic domain, their N-terminal ectodomains translocate to the ER 
lumen where they are glycosylated to form a non-covalent complex which 
is believed to be the building block for the new viral envelope (100). ER 
retention mediate the interaction of E1 and E2 with the core protein, as 
such it is believed that the viral nucleocapsids derived from the core 
protein buds through the ER membrane where they acquire their lipid 
bilayer envelopes. p7 is a 63 amino acid hydrophobic polypeptide that is 
located between the structural and non-structural proteins in the HCV 
genome; although it is not yet classified as a structural or non-structural 
protein. p7 has been designated the virion ion channel capable of 
mediating cation flow across a membrane. However, more recent studies 
have shown an essential role for p7 in HCV assembly and release by 
regulating pH gradient in intracellular compartments resulting in HCV 
particle maturation (78, 145, 394, 426).  
Whilst the structural proteins are the building blocks for the new virion; the 
non-structural proteins replicates the RNA genome. Cleavage of the non-
structural region is achieved through the NS2-3 autoprotease which 
cleaves at the NS2/3 junction and the NS3-4A serine protease which allows 
full processing of the remaining non-structural proteins (reviewed in (47, 
228)). The NS2-3 autoprotease is essential for full virus replication; its 
enzymatic activity resides in the C-terminus of NS2 and the N-terminal of 
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NS3. Cleavage of the polyprotein between NS2 and 3 liberates NS3 which 
serves as an RNA helicase capable of unwinding double stranded RNA 
molecules in a 3’ to 5’ direction. Liberated NS3 is in complex with NS4A 
that functions as a cofactor for the NS3 serine protease (423). Studies 
have shown that NS3-4A catalyses the mitochondrial antiviral signalling 
protein (MAVS) which is important for inducing interferon response. 
Processing of MAVS by HCV proteases leads to impaired function and 
provides a means for HCV to escape the host immune response (220). HCV 
polyprotein cleavage sites are depicted in Figure 1-13. 
Positive sense RNA viruses replicate their genomes via the formation of a 
membrane associated replication complex composed of viral proteins, 
altered cellular membranes and the replicating RNA (237). HCV replication 
occurs at ER membrane sites which have been modified by NS4B into 
cellular protrusions or scaffolds known as membranous webs. This process 
is closely intertwined with the host lipid metabolism as studies have shown 
that replication is stimulated and inhibited by fatty acids and antagonists of 
fatty acid synthesis, respectively (435). The replication cycle continues 
with the synthesis of a complementary negative strand RNA template from 
the original viral genome. This negative strand template is used to produce 
nascent HCV genomes, both steps are governed by NS5B which is the virus 
RNA-dependent-RNA polymerase; a highly error prone proof reading 
enzyme that results in nascent divergent virus variants (29, 430). NS5B 
has been studied extensively and is a major target for antiviral strategies 
due in part to the solving of its crystal structure. Also known as a tail 
anchored protein, NS5B is anchored to the ER lumen via a 21 amino acid 
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residue sequence in its C-terminal, which serves as a docking site for 
protein interactions (361).  
NS5A is a phosphoprotein that can be found in a basally phosphorylated 
(56 kDA) or a hyperphosphorylated (59 kDa) form (329). Studies have 
shown that that NS5A potentiates HCV replication via interactions with 
NS5B and various cellular pathways (374, 403). NS5A consists of three 
distinct structural domains, namely domain I, II and III (396). Foster et al 
demonstrated that all three domains bind HCV RNA which is essential for 
genome replication (126). Further studies have shown that a single serine 
residue deletion in domain III inhibits phosphorylation of the casein kinase 
II domain motif in NS5A and inhibits the production of infectious virus 
particles (395). Additional evidence has demonstrated a role of NS5A in 
HCV particle assembly (12, 395), mutations in domains I and III prevented 
NS5A targeting of lipid droplets containing the core protein, leading to a 
reduction in secreted virus particles (273).  NS5A also dampens the host 
immune response and promotes viral resistance by inactivating the double 
stranded RNA kinase PKR (132). Furthermore, NS5A induces oxidative 
stress (142) suggesting an integral role in HCV associated liver disease. 
The role of NS5A in the HCV lifecycle is still the focus of ongoing 
investigations. Figure 1-13 depicts HCV genome organization and 
polyprotein cleavage.  
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Figure 1-13. HCV genome organization.  
A. The genome is organized into 3 structural proteins, a small ion channel 
and 6 non-structural proteins. B. The genome is cleaved by host and viral 
enzymes resulting in cleavage products shown in an endoplasmic reticulum 
(ER) membrane web. Arrow heads depicts cleavage sites and the function 
of each protein where known is shown.  
 
 
 
A. 
B. 
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Little is known about the late steps in the viral lifecycle; however, as 
discussed the non-structural proteins are recruited to lipid droplets sites 
coated by the core protein (256, 392) where RNA replication occurs at 
specialized ER sites to provide genomes for packaging into capsid 
structures composed of the core protein. In this manner, it is believed that 
lipid droplet associated membranes are sites of HCV particle assembly. In 
hepatocytes, lipid droplets constitute the bulk of lipids incorporated into 
VLDLs (421). Lipoproteins deliver dietary lipids to tissues throughout the 
body and it is believed that HCV utilizes this pathway to secrete infectious 
virus particles. Infectious HCV particles are characteristically low density 
around 50-70nm in diameter and complexed with lipoproteins. Inhibition of 
VLDL assembly with using microsomal transfer protein (MTP) inhibitors and 
depletion of apolipoproteins ApoB and ApoE blocked the release of HCV 
particles (64, 138, 173) to demonstrate that HCV release is associated with 
VLDL production. The assembly of VLDL occurs in two stages; firstly, 
nascent ApoB particles are lipidated by MTP to produce immature precursor 
lipoparticles. The second stage involves the addition of precursor 
lipoparticles to other lipoprotein components such as triacylglycerol and 
ApoE that gives rise to mature VLDL particles (140). After packaging of the 
viral genome into capsids formed by the core protein HCV assembly occurs 
through an unknown pathway in which the envelope glycoproteins are 
added to the capsids and combine with the VLDL pathway to release so 
called lipoviroparticles from the cell (255). Figure 1-14 depicts the HCV 
lifecycle.  
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Figure 1-14. The HCV lifecycle.  
HCV interacts with attachment molecules (heparin sulphate [HS] and low 
density lipoprotein receptor [LDLR]) on the basolateral membrane of 
hepatocytes. This is followed by a series of interactions with SR-BI, CD81-
Claudin-1 complex and Occludin to potentiate virus internalization in a 
clathrin mediated manner. Fusion to the endomsomal membrane is 
followed by release of the viral genome into the cytoplasm where 
translation and replication occurs on ER membrane webs. HCV particle 
assembly is associated with apolipoproteins (ApoE and ApoB) synthesis, 
accounting for the lipid nature of virus particles released from cells. Tight 
junction proteins (junctional adhesion molecule [JAM], Zona Occludens 
[ZO-1], Claudin-1 [CLDN1] and Occludin [OCLN] are shown sealing the bile 
canalicular lumen (BC). Cartoon modified from  (439).  
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1.9 Project aims 
 
The work presented here provides insights into the mechanisms of HCV 
perturbation of hepatocellular homeostasis. HCV infection leads to chronic 
liver sequelae including HCC via undefined mechanism(s). Virus infection is 
a leading indicator for liver transplantation often culminating in graft failure 
due to exacerbated reinfection in the post-operative period. It has been 
suggested that glucocorticoids enhances HCV infection of the newly 
transplanted liver. However, the mechanism(s) governing this phenotype 
remains undefined. As such steroid treatment is still administered to HCV 
liver transplant patients.   
Hepatocytes demonstrate a complex polarity, making in vitro studies to 
recapitulate in vivo HCV infection difficult. Current in vitro infection models 
are based on HCC derived cell lines which do not reflect normal hepatocyte 
physiology. Primary hepatocytes are perceived as a physiological in vitro 
model for HCV infection. However, there are relatively few reports 
describing HCV infection of primary hepatocytes due to difficulties in 
procuring liver specimens. Herein, we have obtained primary hepatocytes; 
allowing for the study of HCV infection in a relevant cell culture model.   
The project objectives are as follows;  
 To investigate whether HCV infection of primary hepatocytes and 
hepatoma cell lines are comparable. We aim to validate the use of 
hepatoma models as physiologically relevant for the study of HCV 
entry and replication.  
 To provide insights into the role of HCV in driving HCC pathogenesis.  
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 To elucidate the underlying mechanism(s) of glucocorticoid 
exacerbation of HCV infection and liver injury in the post-operative 
period.  
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2. MATERIALS AND METHODS  
 
2.1 Cell lines and tissue culture.  
 
Hepatoma cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco, USA), supplemented with 10% foetal bovine serum (FBS), 
1% L-Glutamine, 1% nonessential amino acids and 50units/ml 
penicillin/streptomycin (Gibco) at 37°C, 20% O2 and 5% CO2. For hypoxic 
conditions cells were maintained at 37°C, 1% O2 and 5% CO2.  
Name Tissue Growth 
Media 
Source 
Huh -7.5 Human Hepatoma DMEM C Rice, Rockefellar University, NY, USA 
HepG2 Human Hepatoblastoma DMEM American Type Culture Collection  
HepG2-CD81 Human Hepatoblastoma DMEM In House 
HepG2  (E1E2) Human Hepatoblastoma DMEM In House 
HepG2  (VSV-G) Human Hepatoblastoma DMEM In House 
Hep3B Human Hepatoma DMEM C Rice, Rockefellar University, NY, USA 
293-T Human Embryonic Kidney DMEM American Type Culture Collection  
Primary hepatocytes Human Liver  Williams E Ragai Mitry, Kings College London, UK 
 
Table 2-1. List of cell lines used. 
 
2 . 1.1 Isolation of primary human hepatocytes  
 
Primary human hepatocytes were a kind gift from Dr Ragai Mitry (Kings 
College, London). Cells were obtained from unused donor liver tissue 
rejected for transplantation due to long ischaemia time. Isolation and 
preservation were performed in accordance with good laboratory practice 
guidelines using pharmaceutical grade reagents to ensure reproducibility 
(272). Appropriate ethical approval and signed consent forms were 
obtained prior to tissue processing.  
For hepatocyte isolation the liver tissue was digested; in doing so, the 
major blood vessels were cannulated and sutured to prevent fluid leakage 
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during perfusion, the minor blood vessels were also sutured.  Thereafter, a 
short connector was fitted to the free end of each cannula and attached to 
perfusion tubes on a perfusion pump with bottles containing perfusion 
solution 1 [P1] (500mls Hanks Balanced Salt Solution without calcium or 
magnesium [Cambrex Bioscience, UK], 1ml 250mM EGTA [Sigma, UK], 
2.5mls of 1M HEPES [Sigma, UK]). Bottles containing P1 were incubated in 
a water bath at 37˚C.  
P1 was used to prime the perfusion lines and the perfusion pump was set 
to 60-80 ml/minute flow. The perfusion pump was switched on and the 
liver perfused with using P1, P2 (Hanks Balanced Salt solution) and P3 
(Minimal Essential Eagles Medium, containing 25mM HEPES without phenol 
red and calcium [Lonza, UK], 0.5g collagenase P [Roche Diagnostics, UK]).  
Digested tissues were transferred to sterile containers and the cannulae 
and sutures removed. Thereafter, the tissue was immersed in ice-cold 
wash solution (Minimal Essential Eagles Medium, 25mM HEPES and 50g 
Bovine Serum Albumin [Sigma, UK]) and minced with scalpels or scissors 
to release hepatocytes. Liberated hepatocytes were filtrated using two 
single layers of sterile swabs. The filtered cell suspension was aliquoted 
into 50ml Falcon tubes (Becton Dickinson) and pelleted by centrifugation at 
50 x g and 4˚C for 4 minutes. The supernatant was discarded and each 
pellet resuspended in ice-cold wash solution and the centrifugation process 
was repeated twice. The viability of freshly isolated hepatocytes was 
determined by trypan blue exclusion. Briefly, a small aliquot of cells were 
diluted 1:2 with trypan blue solution and cell viability was determined 
using a haemocytometer and light microscope.  
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2 . 1.2 Cryopreservation of isolated primary human 
hepatocytes 
 
Cryopreservation ensures the availability of hepatocytes for long term use 
or continuous usage. The following protocol for hepatocyte preservation is 
based on an optimized, clinically approved protocol from the hepatocyte 
transplantation unit at Kings College London (328).  
The cryopreservation solution consists of ViaSpan™ reagent (Bristol-Myers 
Squibb, Sweden) + 5% glucose (Hamlin Pharmaceutical Ltd, UK) and 10% 
DMSO (WAK-Chemie, Medical GmbH, Germany). Isolated hepatocytes were 
added to the cryopreservation solution at a density of 1.5 x 107 cells/ml. A 
50ml syringe was used to deliver hepatocyte suspension to ice cold (2-
8˚C) cryopreservation bags. The bags were sealed and transferred to a 
control rate freezer for preservation. The stepwise freezing programme is 
shown in table 2-2.  
At the end of the freezing process, cryopreserved cells were transported on 
dry ice to a liquid nitrogen tank for long term storage.  
 
Table 2-2. Stepwise control freezing for the cryopreservation of 
primary human hepatocytes, modified from (272).   
Start temperature (˚C) Rate (˚C/min) Time End temperature (˚C) 
8 -1.0 8 minutes 0 
0 HOLD 8 minutes  0 
0 -2.0 4 minutes  -8 
-8 -3.5 33 seconds -28 
-28 -2.5 2 minutes -33 
-33 +2.5  2 minutes  -28 
-28 -1.0 32 minutes -60 
-60 -10.0 4 minutes -100 
-100 -20.0 2 minutes -140 
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2.1.3 Thawing of cryopreserved hepatocytes 
 
Thawing reagent was prepared by adding 20% ice-cold Human Serum 
Albumin (Baxter AG, UK) to Minimal Essential Eagles Medium containing 
25mM HEPES without phenol red and calcium (Lonza, UK) at 1:100 
dilution. Thawing was initiated by immersing cryopreserved bags 
containing hepatocytes into a water bath with sterile water set to 37˚C.  
Thereafter, cryo-bags were sprayed with 70% ethanol, transferred to a 
laminar flow hood and cut opened using sterile scissors or blades. The cell 
suspension was placed into 50ml falcon tubes. Cells were pelleted at 50 x 
g, 4˚C for 5 minutes. The supernatant was discarded and cells were 
resuspended in thawing reagent + 25% Percoll (GE Healthcare, UK) 
followed by centrifugation at 50 x g, 4˚C for 20 minutes to separate viable 
cells from non-viable cells. The cell pellet was resuspended in thawing 
reagent and cell viability determined by trypan blue exclusion and 
haemocytometer counting. Hepatocytes were maintained at 37˚C and 5% 
CO2 in Williams Essential Eagles Medium (Sigma, UK) supplemented with 
10% human serum, 1% L-Glutamine, 50units/ml penicillin/streptomycin 
(Gibco),  1M HEPES, 1% Insulin,  (Sigma, UK). 
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2.2 Antibodies, cytokines and treatments   
 
 
Primary Antibodies  
Antibody Name Antigen Type Specificity  Species  Source  
Anti-Claudin-1 (JAY.8) Human Claudin-1 Purified IgG Polyclonal Rabbit Zymed, CA 
Anti-Claudin-1 Human Claudin-1 Purified IgG Polyclonal  Rat R&D System, Europe 
Anti-Occludin (Z-T22) Human Occludin Purified IgG Polyclonal Rabbit Zymed, CA 
Anti-CD81 (2s131) Human CD81 Purified IgG Monoclonal Mouse In House 
Anti-SR-BI (PF-71,-71,-73) Human SR-BI Purified IgG Monoclonal Human Pfizer, UK 
Anti-SR-B1 (Clone 25) Human SR-BI Purified IgG Monoclonal Mouse BD Biosciences, UK  
Anti-E-cadherin Human E-cadherin Purified IgG Monoclonal Mouse  Invitrogen, CA 
Anti-von Willebrand Factor Human von Willebrand Purified IgG Polyclonal  Rabbit Dako, UK 
Anti-E2 (3/11, 9/27) HCV E2 Purified IgG Monoclonal  Rat In House  
9E10 HCV NS5A Hybridoma Supernatant Monoclonal  Mouse Charles Rice, Rokefellar University, NY 
Anti-MRP-2 Human MRP-2 Purified Monoclonal Mouse Abcam, UK 
Anti-VSV-G VSV Glycoprotein Purified IgG Monoclonal Mouse Abcam, UK 
Anti-HIF-1α (Clone 67) Human HIF-1α Purified Monoclonal Mouse Novus Biologicals, Europe 
Anti-TGFβ (ID11) Human TGFβ Purified IgG Monoclonal Mouse R&D Systems, Europe 
Anti-VEGF (VG76e) Human VEGF Purified IgG Monoclonal Mouse Roy Bicknell, University of Birmingham 
Anti-Snail Human Snail Purified IgG Polyclonal Rabbit Abcam, UK 
Anti-Twist (2C1a) Human Twist Purified IgG Monoclonal Mouse Abcam, UK 
Anti-β-actin Human β-actin Purified IgG Monoclonal Mouse Sigma Aldrich, MO, USA 
Anti-GR receptor Human  Purified IgG Monoclonal Mouse Invitrogen, CA 
 
 
     Secondary Antibodies  
Rabbit Alexa Fluor 488 Rabbit IgG Purified IgG (H+L) Polyclonal  Goat Molecular Probes, Invitrogen, CA 
Mouse Alexa Fluor 488 Mouse IgG Purified IgG (H+L) Polyclonal Goat Molecular Probes, Invitrogen, CA 
Rat Alex Fluor 488 Rat IgG Purified IgG (H+L) Polyclonal Goat Molecular Probes, Invitrogen, CA 
Human Alexa Fluor 488 Human IgG Purified IgG (H+L) Polyclonal Goat Molecular Probes, Invitrogen, CA 
Rabbit Alexa Fluor 594 Rabbit IgG Purified IgG (H+L) Polyclonal Goat Molecular Probes, Invitrogen, CA 
Rabbit Alexa Fluor 633 Mouse IgG Purified IgG (H+L) Polyclonal Goat Molecular Probes, Invitrogen, CA 
Mouse/Rabbit Universal Mouse/Rabbit IgG Purified IgG Universal  Goat Vector Laboratories, CA 
Anti-Rabbit HRP Rabbit IgG Purified IgG Polyclonal Donkey GE Healthcare, PA 
Anti-Mouse HRP Mouse IgG Purified IgG Polyclonal Sheep GE Healthcare, PA 
Anti-Rat HRP Rat IgG Purified IgG Polyclonal Goat Jackson Immuno Research, UK 
Table 2-3. List of antibodies used.   
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Table 2-4. Antibody concentrations used.  
IF, indirect immunofluorescence; FC, flow cytometry; WB, western 
blotting; IHC, immunohistochemistry.  
 
 
Primary antibodies  
Antibody Application Working concentration (µg/ml) 
9E10 IF 2 
Anti-Claudin-1 IF, WB, IHC, FC 1 
Rabbit anti-Occludin IF, WB, IHC, FC 1 
Anti-SR-BI IF, WB, IHC, FC 1 
Anti-CD81 IF, WB, FC 1 
Anti-E-cadherin IF, WB 1 
Anti-von Willebrand Factor IF 5 
Anti-E2 IF, WB, FC 2 
Anti-MRP-2 IF 2 
Anti-VSV-G IF, FC 2 
Anti-HIF-1α IF, IHC 5 
Anti-Snail IF, WB 1 
Anti-Twist IF, WB 1 
Anti-Glucocorticoid receptor IF 2 
Anti-β-actin WB 0.5 
Anti-TGFβ Blocking 1.5 
Anti-VEGF Blocking 1.5 
 
Secondary Antibodies  
Alexa Fluor 488, 594, 633 IF, IHC, FC 1/500 
Anti-Mouse/Rabbit Universal IHC 1/200 
Anti-Mouse HRP WB 1/1000 
Anti-Rabbit HRP WB 1/1000 
Anti-Rat HRP WB 1/1000 
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Table 2-5.  Cytokines, growth factors and drugs used in this study. 
Drug toxicity was measured using an MTT Cell Proliferation Assay Kit 
(section 2.3.5).   
 
 
 
 
 
 
 
 
 
 
 
Name Source Working 
concentration 
Median 
toxicity  
Dexamethasone Sigma, UK 100nM 260nM 
Geneticin (G418) Sulfate Invitrogen, CA, USA 1mg/ml 3mg/ml 
HIF-1α inhibitor (NSC-134574) Margret Ashcroft, University College London 1µM 2µM 
ITX 5061 Itherx, CA, USA 5µM 1mM 
Mitomycin C Sigma, UK 10µg/ml 20µg/ml 
Prednisolone Sigma, UK 100nM 500nM 
RU-486 Sigma, UK 5µg/ml 10µg/ml 
Interferon gamma R&D Systems, USA Various NA 
Tumour necrosis factor alpha  R&D Systems, USA Various NA 
TGFβ R&D Systems, USA 10ng/ml NA 
VEGF-A R&D Systems, USA 10ng/ml NA 
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2.3 Routine techniques 
 
2 . 3.1 Flow cytometry 
 
Flow cytometry was used to quantify total or plasma membrane expression 
of proteins of interest. Cells were grown in tissue culture flasks (Corning, 
NY, USA) and trypsinized (Gibco) for 3-5 minutes at 37°C. Thereafter, cells 
were resuspended in 10% DMEM and counted using a haemocytometer. 
Cells were pelleted in a 5804R centrifuge (Eppendorf, Germany) at 1200 
revolutions per minute (rpm) for 3 minutes and diluted to 2x105 cells/ml in 
PBS + 0.5% bovine serum albumin (BSA) (Sigma, UK).  
For intracellular/total protein detection, cells were incubated in 3% 
paraformaldehyde (PFA) on ice (TAAB, UK) for 20 minutes followed by a 
PBS wash and resuspension in PBS + 0.5% BSA. To permeabilize, fixed 
cells were resuspended in PBS + 0.5% BSA + 0.01% saponin (Sigma) and 
all subsequent steps carried out in this buffer. For live (surface) staining, 
cells were resuspended in PBS containing 0.1% sodium azide and no 
permeabilization was required.  
To block non-specific antibody binding, cells were incubated for 30 minutes 
at room temperature. Antibody staining was performed in 96 well U-
bottomed microplates (Corning, NY, USA) with 2x105 cells/well. Briefly, 
100μl of cell suspension was transferred to each well and cells pelleted by 
centrifugation at 1200rpm for 3 minutes, followed by resuspension in 70-
100μl of primary antibody diluted in PBS + 0.5% BSA (+0.01% saponin) 
or PBS + 0.5% BSA (+ 0.1% sodium azide). Species matched IgGs were 
used as controls throughout. 
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Primary antibody incubation was carried out for 45 minutes and cells were 
washed three times with PBS and resuspended in 70-100µl of fluorescent 
conjugated antibodies, antibody working dilutions are listed in table 2-4. 
Cells were incubated in the dark for 45 minutes to prevent photo-bleaching 
and washed three times in PBS as above. For live cell staining cells were 
fixed prior to analysis, protein expression was measured using a 
Facscalibur flow cytometer (Becton Dickinson, Europe), and the data 
analyzed using FlowJo software (Tree Star, OR, USA).  
 
2 . 3.2 Indirect immunofluorescence  
 
Fluorescent microscopy  
To visualize cellular protein expression by immunofluorescence cells were 
seeded at 4 x104 cells/ml in 24 well plates (Becton Dickinson). Cells were 
fixed prior to staining by incubation with ice-cold methanol (Fisher 
Scientific, UK) or 4% PFA (TAAB, UK) for 5 minutes and 20 minutes, 
respectively. Thereafter, cells were blocked for 20 minutes with PBS + 
0.5% BSA followed by a permeabilizing step with PBS + 0.5% BSA and 
0.01% of permeabilization detergent (saponin or Triton X-100). Primary 
antibody staining was performed by incubation for 1 hour at room 
temperature with antibody or control isotype diluted in the appropriate 
buffer. The antibody concentrations used in this study are listed in table 2-
4.  
After 1 hour the antibody diluents were removed by aspiration followed by 
a PBS wash, this process was repeated twice. Secondary antibody staining 
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was achieved with a fluorescent conjugated antibody diluted in the 
appropriate buffer and incubation in the dark at room temperature for 1 
hour.  
Cells were washed in PBS as described, the nuclei were counterstained by 
incubation in 4’,6-diamidino-2-phenylindole [DAPI] 10g/ml (Sigma, UK) 
for 1 minute at room temperature in dark. Finally, stained cells were 
visualised using a fluorescent microscope (Nikon TE200, Japan) and 
images were taken using a digital camera (Hammatsu, Japan).  
Laser scanning confocal microscopy   
To visualize cellular protein expression by confocal microscopy cells were 
seeded at 4 x104 cells/cm2 into 24 well plates containing 13m glass 
coverslips. Prior to cell seeding, coverslips were sterilized in 70% ethanol 
and washed once with PBS. Cell staining was achieved as described in 
fluorescence microscopy. Coverslips were mounted onto glass slides using 
Prolong Gold Antifade mounting reagent (Invitrogen, CA).  
Laser scanning confocal microscopy was performed using a Zeiss Metahead 
Confocal (Zeiss, Germany) utilizing the 63x water-immersion objective. 
The background fluorescence of each sample was corrected based on the 
fluorescent levels of the isotype matched control samples.  
 
2 . 3.3 Enzyme linked immunosorbent assay (ELISA) 
 
Human VEGF and TGFβ levels were quantified using ELISA development 
kits specific for each growth factor (Peprotech, USA) according to the 
manufacturer’s instructions. 100µl of a capture antibody (rabbit anti-
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human VEGF or TGFβ diluted in PBS to 100µg/ml) was added to wells of a 
96 well microplate, the plates were sealed and incubated overnight at 
room temperature. Thereafter, the liquid was removed and wells washed 4 
times with excess wash buffer (0.05% Tween-20 in PBS). Any residual 
wash buffer was removed by inverting the plate with gentle tapping on a 
paper towel after the last wash.  
 
300µl of blocking buffer (1% BSA in PBS) was added to each well followed 
by incubation at room temperature for 1 hour, after which the wells were 
washed 4 times. 100µl of conditioned media harvested from hepatoma or 
primary human hepatocytes after 24 hours in culture or 24 hours post 
infection was diluted 1:2 in diluent buffer (PBS + 0.05% Tween-20 + 0.1% 
BSA) and added to each well followed by incubation at room temperature 
for 2 hours. Wells incubated with buffer alone served as negative controls.  
 
Wells were washed 4 times and 100µl of an Avidin-HRP conjugated 
antibody diluted 1:1000 in diluent buffer was added to each well followed 
by incubation at room temperature for 30 minutes. Wells were washed 4 
times followed by incubation at room temperature with TMB liquid 
substrate (BioFix, USA) at 50µl/well for 5-10 minutes. HCV stop solution 
(BioFix) was used once colour development had occurred and absorbance 
measured with an ELISA plate reader (Thermo Scientific, USA) at 650nm.   
 
Albumin ELISA 
96 well microplates were coated with goat anti-human albumin (0.5mg/ml) 
(Bethyl Laboratories, USA) diluted in coating buffer (0.5M Na2CO3, pH 9.6) 
and incubated for 4 hours at 37˚C. Wells were washed with washing buffer 
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Step 
Albumin 
ng/ml 
Calibrator 
RS10-110-3 
Sample 
Diluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10000 
400 
200 
100 
50 
25 
12.5 
6.25 
0 
2 µl 
100 µl from step 1 
250µl from step 2 
250µl from step 3 
250µl from step 4 
250µl from step 5 
250µl from step 6 
250µl from step 7 
5000 µl 
2400 µl 
250µl 
250µl 
250µl 
250µl 
250µl 
250µl 
250µl 
(500mM Tris, 0.14M NaCl, 0.05% Tween-20, pH 8.0). Wells were blocked 
by adding 100µl of blocking solution (500mM Tris, 0.14M NaCl, 1% BSA, 
pH 8.0). Wells were washed 3 times and standards were diluted in sample 
buffer (50mM Tris, 0,14M NaCl, 1% BSA, 0.05% Tween20, pH 8.0) as 
tabulated below.  
 
 
  
 
 
Sample media was harvested from primary human hepatocytes (4 x 104 
cells) at 24 hour intervals and diluted 1:2 in sample buffer. The growth 
media was refreshed daily to ensure that albumin read out was reflective 
of each time point. Standards ranging from 400-6.25ng/ml and samples 
were added at 50µl/well in triplicates followed by incubation for 4 hours at 
37˚C. After which wells were washed 4 times and incubated with 50µl goat 
anti-albumin HRP (Bethyl Laboratories) diluted 1:1000 in sample buffer for 
4 hours at 37˚C. Thereafter, wells were washed 4 times and 50µl of TMB 
substrate (BioFix) added for 5-10 minutes. The assay was stopped by the 
addition of 1M H2SO4. The absorbance was read at 450nm using an ELISA 
plate reader, albumin levels in each sample was determined using a linear 
plot of the albumin standard absorbance values. Albumin ELISA was 
performed with the kind help of Sukhdeep Galsinh.   
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2 . 3.4 Western blotting  
 
Cell lysates were prepared from adherent cells (control or HCV infected) 
seeded at 4 x 104 cells/well in 6 well plates and maintained in culture for 
24 hours. Cells were treated overnight with HIF-1α inhibitor (NSC-134574) 
1µm or prednisolone (100nM) diluted in DMEM or Williams E media.  The 
culture media was removed and cells washed in PBS. All subsequent steps 
were carried out using ice-cold buffers to prevent protein denaturation. 
2mls of ice-cold PBS was added to each well and adherent cells remove 
using a cell scraper (Corning, UK). The cell suspension was transferred to 
universal tubes and pelleted by centrifugation at 1500 rpm at 4˚C for 5 
minutes.  The supernatant was discarded and the pellet resuspended in 
lysis buffer (PBS, 1% Brij97, 20mM/L Tris [pH 7.5], 300 mM/L CaCl2, and 
2mM/L MgCl2) supplemented with protease and phosphate inhibitors 
(Roche, UK) and incubated on ice for 30 minutes. The lysate was 
centrifuged at 15000rpm for 20 minutes at 4˚C to separate nuclei and 
unsolubilized cell membranes from protein. The supernatant was collected 
and stored at -20˚C.  
Protein concentration was determined using the BCA Protein Assay Kit 
(Thermo Scientific, USA) according to the manufacturer’s instructions. 
Briefly, 100µl of each sample or BSA standard were mixed with 200µl of 
BCA Working Reagent in a 96 well plate in triplicates. After which the plate 
was incubated at 37˚C for 30 minutes. The plate was allowed to cool at 
room temperature and the absorbance read at 490nm using an ELISA plate 
reader.  
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The protein concentration of each sample was determined using a standard 
curve prepared by plotting the average blank corrected 490nm 
measurement for each BSA standard versus its concentration in µg/ml.  
 
 
 
 
 
 
 
 
Fugure 2-1. BCA protein assay standard curve.  
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE). 
Proteins were separated on 8% SDS gels. Samples were prepared by 
adding defined amounts of protein to 3x Laemmli loading dye (H2O, 30% 
v/v Glycerol, 6% w/v SDS, 0.02% v/v Bromophenol Blue and 0.2M Tris-
HCV; pH 6.8). With (reducing conditions) or without (non-reducing 
conditions for CD81 detection) 10% 2-β-mercaptoethanol. The total 
volume was adjusted to 25µl with H2O and samples were denatured by 
heating at 95˚C for 5 minutes followed by cooling at room temperature 
before loading.   
Proteins were separated by gel electrophoresis using the Mini Protean 3 
System (Bio-Rad Laboratories, USA) according to the manufacturer’s 
instructions. Briefly, 20µg of protein lysates were loaded onto 8% sodium 
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dodecyl sulphate-polyacrylamide gels and gels run at 200 volts constant 
for 20-30 minutes.  
Proteins were transferred to polyvinylidene membranes (Millipore, USA) 
using a Mini Trans-Blot Electrophoresis Transfer System (Bio-Rad). Briefly, 
polyvinylidene membranes were cut to appropriate sizes to match the 
diameter of the gel and pre-treated with methanol for 2 minutes, rinsed 
with H2O and incubated in transfer buffer (25mM Trizma Base, 0.2M 
Glycince, 200ml methanol and 10% SDS) at room temperature for 5 
minutes. Gels were equilibrated in transfer buffer to prevent shrinking and 
transfer was carried out at 350mA for 90 minutes at room temperature.  
 
Immuno-blotting and chemiluminescent detection of proteins.  
Following successful transfer, membranes were placed in 50ml falcon 
tubes; to block non-specific antibody binding, membranes were incubated 
in antibody buffer (10mM Trizma base, 0.1M Sodium Chloride, 10% v/v 
Tween-20 and 5% Marvel dry milk) for 45 minutes at room temperature.  
The antibody blocking buffer was removed and the membranes were 
incubated in primary antibodies (table 2-4) diluted with antibody buffer 
overnight in 50ml falcon tubes and gentle agitation on a tube roller 
(Barloworld Scientific, UK) at 4˚C.  
The following day membranes were washed 4 times for 5 minutes with 
washing buffer (10mM Trizma base, 0.1M Sodium Chloride and 10% v/v 
Tween; pH 7.5).  Incubation with HRP-conjugated secondary antibodies 
was carried out for 1.5 hours at 4˚C followed by excess washing. 
Chemiluminescent detection of HRP-conjugated antibodies was achieved 
with an ECL Western Blotting Detection System (Amersham, UK). Briefly, 
membranes were incubated in ECL detection reagent for 1 minute, 
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wrapped in plastic and exposed to CL-Xposure X-Ray Films (Thermo 
Scientific) for 1-10 minutes.  
 
Co-immunoprecipitation 
Cells were lysed as described in western blotting and lysates were pre-
cleared by adding 50-100µl of an irrelevant isotype control antibody, 
followed by incubation on ice for 1 hour. Thereafter, 100µl of protein G 
sepharose beads (GE Healthcare, UK) was added to each lysate, followed 
by incubation at 4˚C on a tube roller for 1 hour. The lysate-bead mixture 
was centrifuged at 2500 rpm for 10 minutes at 4˚C. The supernatant was 
harvested for immunoprecipitation and the pellet discarded.  
In separate tubes 2mg/ml of anti-E2 antibodies or an isotype control were 
added to 100µl of pre-cleared lysates followed by incubation at 4˚C 
overnight with gentle agitation. Thereafter, 100µl of protein G beads was 
added to each sample and the mixture was incubated at 4˚C for 4 hours 
under gentle agitation.  
After 4 hours the tubes were centrifuged at 3,000 rpm for 1 minute and 
washed three times in ice-cold lysis buffer by centrifugation (PBS, 1% 
Brij97, 20mM/L Tris [pH 7.5], 300 mM/L CaCl2, and 2mM/L MgCl2) 
supplemented with protease and phosphate inhibitors. After each 
centrifugation, the supernatants were discarded and the beads coupled 
with antibody/protein complex were kept.  
After the final wash supernatants were removed and beads resuspended in 
30-50µl of loading buffer and boiled at 95˚C for 5 minutes to dissociate 
protein G beads from the antibody/protein complex. The tubes were 
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centrifuged and the supernatants kept for SDS-PAGE and 
chemiluminescent detection. Membranes were probed with antibodies 
against HCV E2, CD81 and Occludin, a positive signal showed that HCV E2 
antibody successfully immunoprecipitated the above proteins to 
demonstrate a specific interaction.  
 
2 . 3.5 Cell proliferation assay 
 
Cell proliferation was determined using the CellTiter Solution Cell 
Proliferation (MTT) Assay (Promega). In essence, cells were seeded at 4 x 
104 cells/well in a 96 well microplate containing DMEM +3% FBS and 
incubated overnight. Thereafter, cells were treated with or without 
Mitomycin C [10µg/ml] or γ-irradiation for 20 minutes [32mSv] using a 
Gammacell 3000 Elan. 24 hours later cells were washed with PBS and 
200µl of MTT reagent was added per well.  
Cells were incubated at 37˚C for 1 hour and 100µl of the supernatant was 
transferred to wells of a 96 well plate. The absorbance was read at 490nm 
using an ELISA plate reader. Final proliferation values were determined by 
subtracting the absorbance recorded from a control empty well.  
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2.4 Transfections and virus based work 
 
2 . 4.1 Plasmids  
 
Table 2-6. List of plasmids used in this study.  
 
2 . 4.2 Generation of HCV pseudoparticles (HCVpp) 
 
The HCVpp system is based on a replication deficient HIV gag-pol core that 
carries the HCV E1E2 glycoproteins. Infection is quantified by detecting a 
GFP or Luciferase reporter gene packaged into the HCVpp. As the particles 
do not encode any HCV non-structural proteins they are incapable of 
replication and only imitate the entry process of HCV. 
HCVpp particles were generated by transfecting 293-T cells seeded at 5 x 
105 cells/ml into 6 well plates coated with 0.1mg/ml poly-L-lysine (Sigma, 
UK) in DMEM +10% FBS  and no penicillin/streptomycin 24 hours before 
transfection. The media was removed and replaced with 
penicillin/streptomycin free DMEM +3% FBS 1hour before the addition of 
DNA. 
Cells were transfected using Fugene (Roche); briefly, 6µl of Fugene 
reagent was mixed with 100µl Optimem (Gibco) and added to a cocktail of 
Name Source 
HCVcc J6/JFH-1 Charles Rice, Rokefellar University, NY 
HCVcc SA13/JFH-1 Jens Bukh, Copenhagen Hospital, Denmark  
JFH-1 and H77 Replicons Tajika Wakita, National Institute of Infectious Diseases, Tokyo 
H77 E1E2  Zie Zhang, Rokefellar University, NY 
JFH-1 E1E2 Zie Zhang, Rokefellar University, NY 
OH8 E1E2 Zie Zhang, Rokefellar University, NY 
Con-1 E1E2 Zie Zhang, Rokefellar University, NY 
H91A6 E1E2 In House 
Johns Hopkins (JHU)  E1E2 clones Stuart Ray, Johns Hopkins Centre , USA 
VSV-G Aaron Diamond AIDS Research Centre 
Luciferase Reporter Aaron Diamond AIDS Research Centre 
HIV Gag-pol Aaron Diamond AIDS Research Centre 
TRIP Occludin In House 
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plasmids encoding HCV E1E2 (600ng), HIV gag-pol (600ng) and a 
luciferase reporter (600ng). For VSV-Gpp or a no-envelope control, the 
Fugene/Optimem mix was added to plasmids encoding these respective 
genes instead of HCV E1E2.  
The Fugene/DNA mix was incubated at room temperature for 25 minutes 
and then added to cells. Cells were incubated with transfection mixture for 
8 hours at 37˚C, the media was removed and cells refreshed with DMEM 
+3% FBS and penicillin/streptomycin.  
Culture media containing HCVpp was harvested 48-72 hours later, the 
media was clarified by centrifugation at 2000rpm for 5 minutes and used 
to infect target primary hepatocytes or hepatoma cells immediately. 
  
Luciferase infection assay 
Target cells were seeded at a density of 4 x 104 in 96 well microplates and 
inoculated for 8 hours (unless stated otherwise) with HCVpp diluted 1:2 in 
DMEM +3% FBS and penicillin/streptomycin. Thereafter, the inoculums 
were removed and cells replenished with fresh media. Luciferase activity 
was detected at 72 hours post infection (unless otherwise stated) using a 
Luciferase Assay System (Promega). Briefly, 1x lysis buffer was prepared 
according to the manufacturer’s instructions and stored at -20˚C. 
Luciferase assay reagent was prepared by adding 10mls of assay buffer to 
a vial containing lyosophilized luciferase substrate.  
The media was removed from cells followed by a PBS wash; 50µl of lysis 
buffer was added to cells followed by incubation for 2 hours at -20˚C. After 
2 hours the plates were allowed to thaw at room temperature resulting in 
complete lysis of the cells. 40µl of cell lysate was added to wells of a white 
polystyrene 96-well fluorescent assay plate (Corning, USA) and mixed with 
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40µl of luciferase substrate reagent and luciferase activity detected with a 
5 second delay using a Centro LB960 Luminometer (Berthold Technologies, 
UK). The luciferase activity was detected as relative light units (RLU) and 
the no-envelope signal which is typically in the order of 2 x 103 RLU was 
subtracted from each HCVpp/VSV-Gpp signal.  
To ascertain the effects of cell division on HCVpp luciferase activity, target 
cells were seeded as described into 96 well microplates and treated with 
Mitomycin C 10µg/ml or γ-irradiated for 20 minutes using a Gammacell 
3000 Elan (MDS Nordian, Canada) at 32 mSv/minute. 24 hours later the 
media was removed and cells infected with HCVpp or VSV-Gpp.  
To determine the effects of HCV neutralizing reagents (anti-CD81 and ITX 
5061) or HIF-1α inhibitor on virus entry, target cells were treated prior to 
infection with anti-CD81 (5µg/ml) for 3 hours or ITX 5061 (10µM) and HIF-
1α inhibitor (1µM) overnight. At these concentrations anti-CD81 and ITX 
5061 were reported to neutralize HCVpp entry (154, 389).  
 
2 . 4.3 Generation of TRIP viruses 
 
The TRIP system consists of a retrovirus gene expression vector that 
produces virus particles via a replication deficient HIV gag-pol core bearing 
the envelope glycoprotein of vesicular stomatitis virus (VSV-G). TRIP virus 
particles can incorporate a gene of interest as an RNA transcript. 
Subsequent transduction of cells results in reverse transcription of the 
target gene and insertion into the host genome (441). In this study, 
transduced cells were not subjected to antibiotic selection; however, they 
maintained exogenous gene expression for up to 4 weeks. 
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TRIP particles were produced by Fugene transfection of 293T cells seeded 
at 5x105 cells/well in DMEM +3% FBS in 6-well culture microplates coated 
with 0.1 mg/ml poly-L-lysine. The following day, VSV-G (400ng), HIV gag-
pol (600ng) and 600ng of gene of interest (human-Occludin or human-
CD81) were introduced into the cells by overnight transfection at 37˚C.  
Thereafter, the culture media was replaced with DMEM +3% FBS and 
penicillin/streptomycin. Culture media containing TRIP virus particles was 
harvested 48-72 hours later and clarified by centrifugation at 2000rpm for 
5 minutes to pellet any contaminating 293T cells. 
Harvested supernatants were pooled and stored at 4˚C where it was stable 
for up to 24 hours. Huh-7.5 cells seeded at 4 x 104 cells/well in 6 well 
plates 24 hours before transduction were transduced with TRIP 
supernatants diluted 1:2 in 3% DMEM containing 1.6µg/ml polybrene 
(Sigma) overnight. Transduction efficiency was determined 72 hours later 
by monitoring gene expression by flow cytometry or immunofluorescence 
staining.   
 
2 . 4.4 Generation of HepG2 cells expressing viral 
glycoproteins 
 
Successful expression of HCV and VSV-G glycoproteins was achieved by 
Magnet Assisted Transfection (Fisher Scientific, UK) according to the 
manufacturer’s instructions. Briefly, the DNA of interest is coupled to 
charged nanoparticles. A mixture containing the DNA:nanoparticle complex 
is added to target cells and a strong magnetic force is applied beneath 
cells. The magnetic force pulls the DNA:nanoparticle complex onto the cells 
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resulting in close contact with the cell membrane followed by endocytosis. 
Successful endocytosis results in expression of target gene.  
Herein, diverse HCV E1E2 glycoprotein strains (H77, JFH-1, OH8 and Con-
1) encoded on pCCAGs plasmids containing a G418 resistance marker were 
delivered into HepG2 cells. Cells were seeded at 4 x 104/ml onto 24 well 
plates coated with collagen, followed by incubation overnight at 37˚C in 
DMEM +10% FBS and penicillin/streptomycin. Thereafter, the media was 
replaced with antibiotic free DMEM +3% FBS. 600ng of pCCAGs plasmid 
containing HCV E1E2 or VSV-G was added to 100µl of serum free DMEM 
followed by incubation at room temperature for 5 minutes.  
 
The DNA/DMEM mixture was supplemented with 50µl of the manufactures 
transfection reagent which contains charged nanoparticles. The mixture 
was incubated at room temperature for 1 hour and used to treat target 
cells. Cells were placed onto a magnet and incubated at 37˚C overnight. 
The following day the media was replaced with DMEM +3% FBS and 
antibiotics and cells allowed to incubate for a further 72hours. Thereafter, 
cells were treated with G418 (1mg/ml) in DMEM + 3% FBS. Following 
multiple rounds of G418 selection stable cell populations expressing HCV or 
VSV-G glycoproteins remained and gene expression was confirmed by flow 
cytometry. The resulting cell clones were designated H77 E1E2, JFH E1E2, 
OH8 E1E2, Con-1 E1E2 and VSV-G.    
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2 . 4.5 Generation of cell culture HCV (HCVcc) 
 
HCVcc viruses are based on the non-structural (replicase) proteins of HCV 
JFH-1 strain, a unique isolate that is able to produce infectious particles in 
Huh-7.5 cells (415). All subsequent HCVcc strains incorporate JFH-1 non-
structural proteins and differ only by the structural proteins.    
RNA Synthesis 
RNA transcripts of HCV genomes SA13 and J6/JFH-1 were produced using 
the T7 RNA Polymerase Kit (Promega, UK) according to the manufacturer’s 
instructions. Essentially, 5µg’s of plasmid containing a cDNA clone of the 
HCV genome was linearised by restriction digest using the Xbal enzyme 
(New England Biolabs, UK). 1µg of the linearized plasmid was used as 
template for RNA transcription; this was achieved by incubating the 
reaction mix (T7 RNA polymerase mix from the manufacturer’s kit) at 37˚C 
for 4 hours. Thereafter, the RNA was purified using the RNAeasy MiniElute 
Kit (Qiagen, Netherlands) according the manufacturer’s instructions. RNA 
quality was assessed by gel electrophoresis on a 1% agarose gel (Bioline, 
UK). RNA yields were quantified using a spectophotometer (Amersham, 
UK) with typical yields between 100-1500ng/µl.  
Electroporation 
Early passage (passage 1-35) Huh 7.5 cells were grown in T175 tissue 
culture flasks until 80-90% confluent. Cells were trypsinized and 
resuspended in DMEM. Thereafter, cells were washed in ice-cold PBS and 
pelleted by centrifugation at 2500rpm for 5mins at 1˚C; this process was 
repeated and pellets were resuspended in ice-cold PBS at 1.5x107 cells/ml.  
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400µl of the cell suspension was mixed with 5µg of HCV genomic RNA and 
transferred to electroporation curvettes (Sigma). Electroporation was 
carried out at 600 volts in an Electro Square Porator (Harvard Apparatus, 
USA). Electroporated cells were allowed to stand for 5 minutes at room 
temperature to rest before transferring them into 10mls of pre-warmed 
IMDM +10% human serum, 1% L-glutamine and penicillin/streptomycin.  
8mls of the cell suspension was transferred to a T75 tissue culture flask 
and the remainder placed into wells of a 24 well tissue culture plate for the 
monitoring of HCV protein expression. Cells were incubated at 37˚C in a 
category 3 containment laboratory and the media was replaced with DMEM 
+3% FBS the following day.  
At 72 hours post electroporation, viral replication was quantified by 
staining the cells seeded in 24 well plates for NS5A using 
immunofluorescence as described in section 2.3.2 with mouse 9E10 anti-
NS5A monocloanal antibody (mAb). Providing 60-80% of cells expressed 
NS5A, HCVcc particles were harvested from the T75 flasks between 4 and 
14 days post electroporation after which cells were discarded. Briefly, cells 
were cultured in 4mls serum free DMEM and media containing secreted 
virions harvested at 4 hour intervals and pooled. Harvested virus was 
clarified by centrifugation at 3000rpm for 5 minutes and stored at -80˚C.  
HCVcc infection assay 
All HCVcc infection in this study was performed as follows (unless stated 
otherwise); harvested virus was used to infect target primary human 
hepatocytes or hepatoma cells seeded at 4 x 104 cells/ml on a 48 well 
tissue culture plate 24 hours before infection. To infect cells, the media 
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was removed and replaced with 100µl of HCVcc virus diluted in DMEM 
+3% FBS, L-glutamine and penicillin/streptomycin. 
Cells were incubated for 8 hours at 37˚C, the HCVcc inoculum was 
removed and cells washed with PBS to remove any unbound virus. The 
cells were refed with 300µl of DMEM +3% FBS, L-glutamine and 
penicillin/streptomycin and infection allowed to proceed for 48-72 hours at 
37˚C as stated in the figure legends.  
Cells were methanol fixed and NS5A positive cells were determined by 
immunofluorescence with 9E10 antibody as described above. Viral 
infectivity was enumerated by counting NS5A foci or individual infected 
cells using a fluorescence microscope. Alternatively HCVcc infection levels 
were quantified by quantitative reverse transcriptase polymerase chain 
reaction, see section 2.5.1.  
 
 
 
 
 
 
 
 
 
Figure 2-2. HCV NS5A positive foci. 
Huh-7.5 cells were infected with HCVcc J6/JFH-1, at 72 hours post 
infection cells were methanol fixed and stained for HCV NS5A (green) 
using 9E10 monoclonal antibody and an Alexa Flour 488 secondary 
antibody. Scale bar represents 10µm.  
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Cell to cell transmission assay 
To determine whether prednisolone increases HCV cell-cell transmission we 
employed an infectious co-culture assay (50). Huh-7.5 target cells were 
seeded at a density of 12.5 x 104 cells/well on collagen coated 12 well 
plates. To ascertain a role for prednisolone in HCV cell-cell transmission 
cells were seeded in the presence of prednisolone (100nM), RU-486 
(5µg/ml) or a combination of both compounds overnight.  
HCVcc J6/JFH-1 infected producer cells (infected as described in HCVcc 
infection assay) were labelled with CMFDA (5µM) by incubation at 37˚C in 
DMEM +3% FBS for 30 minutes. Thereafter, producer cells were washed 
with PBS and removed from the tissue culture plastic with trypsin. 12.5 x 
104 labelled producer cells were seeded into co-culture with target cells. 
Final co-culture contained a 1:1 ratio of producer and target cells, each 
well totalling 25 x 104 cells/well in DMEM + 3% FBS. 
48 hours later supernatants were collected and used in a standard 
infectious assay to quantify cell free infectivity. Cells were trypsinized and 
seeded into 96 well round bottom plates, followed by centrifugation at 
10,000rpm for 3 minutes and fixing for 5 minutes with 1% PFA. Cell-cell 
transmission from producer to target cells was measured by staining for 
HCV NS5A and analysed by flow cytometry (Figure 2-3). This allowed 
determination of de novo transmission events.  
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Figure 2-3. Cartoon of HCV co-culture assay to determine cell-cell 
transmission.  
Target and producer cells were co-cultured as described; 48 hours later 
cells were fixed and stained with a labelled antibody (red) against NS5A 
followed by flow cytometry analysis. The supernatants were used to 
confirm cell-free infection. The flow cytometry scatter plot is divided into 4 
populations; infected targets (red), infected producers (yellow), uninfected 
targets (unstained) and uninfected producers (green). This allows us to 
generate plots of HCV transmission in the presence or absence of 
prednisolone or RU-486. A general overview of the results that can be 
obtained is given on the right, where red dots represent NS5A foci. 
Prednisolone treatment is associated with an increase in foci size which is 
indicative of enhanced cell-cell transmission.  
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2.5 Specific assays  
 
2 . 5.1 Quantitative RT-PCR (qRT-PCR) 
 
HCV genome copy number was measured by qRT-PCR, using a Cells Direct 
Kit (Invitrogen) according to the manufacturer’s instructions. Cells were 
infected as per a standard infection assay (section 2.4.5) in the presence 
or absence of prednisolone (100nM), RU-486 (5µg/ml) and HIF-1α inhibitor 
(1µM). Alternatively, cells were infected in a Hypoxic incubator (New 
Brunswick Scientific, UK) set to 1% O2 and 5 % CO2. 72 hours post 
infection cells were lysed and total RNA purified using the MiniElute RNA 
Extraction Kit (Qiagen) as per the manufacturer’s instructions. The qRT-
PCR reaction mixture was made up with specific primers targeting the Core 
protein (Primer Design, UK) and GAPDH house-keeping gene control 
primers (Invitrogen).  
qRT-PCR was carried out in a MicroAmp 96 well optimal reaction plate 
(Applied Biosystems, USA) with samples tested in triplicates. A standard 
curve was devised with in vitro transcribed HCV RNA of known copy 
number. The reaction was performed in a quantitative PCR machine 
(Stratagene, USA) and the data analysed using the associated MXpro 
software.  
The PCR reaction was performed using the following program; 
30 minutes           50˚C 
5 minutes             95˚C 
15 seconds           95˚C} 50 cycles 
60 seconds           60˚C} 50 cycles 
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Quantification of HCV receptor mRNA levels  
To quantify HCV receptor mRNA levels in hepatoma and primary human 
hepatocytes; cells were seeded at a density 4 x 104/ml of a 24 well plate. 
For primary cells, total cellular RNA was purified as above at 1, 2 and 3 
days post seeding. For Huh-7.5 cells RNA was purified at day 1 which is 
optimal of HCVcc infection of these cells. Purified RNA samples were 
amplified as described above for CD81, SR-BI, Claudin-1 and Occludin 
using the Cells Direct Kit and specific primers. In all reactions, the house-
keeping gene GAPDH was included as an internal endogenous control for 
RNA quantification.   
Quantification of hepatocyte differentiation phenotype 
Primary human hepatocytes from 3 donors were seeded at 4 x 104/ml of a 
24 well plate and allowed to grow for a period of 12 days. Each day cells 
were lysed and total RNA purified. Hepatocyte differentiation was 
determined using the reaction mix from the Cells Direct Kit according to 
the manufacturer’s instructions and primers specific for hepatocyte 
differentiation markers (alpha-Fetoprotein, HnF4α and CYP3a4). GAPDH 
was used as an internal reaction control. The amplification reaction was 
performed as described above. qRT-PCR reactions were performed with the 
help of Sukhdeep Galsinh and Nicola Fletcher.  
 
2 . 5.2 Determination of HepG2 polarity 
 
Polarity is regulated by tight junction proteins that separate apical and 
basolateral membrane domains. HepG2 polarity was determined by 
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enumerating the expression of the apically expressed multi-drug resistant 
protein (MRP-2) per 100 nuclei. HepG2 polarity increases overtime 
consistent with increased MRP-2 expression at the apical bile canalicular 
membrane.  
Cells were seeded at 4 x104 cells/ml and allowed to grow for 1, 3, and 5 
days in order to quantify polarity over time. Cells were fixed at each time 
point with 3% PFA at room temperature for 20 minutes. Cells were washed 
in PBS and permeabilized using 0.1% Triton X-100 + 0.5% BSA in PBS for 
30 minutes. Primary and secondary antibody staining was achieved as 
described in fluorescent microscopy (section 2.3.2) using anti-MRP-2 
(Abcam, UK) and Alexa-Fluor 488 conjugated antibodies. Antibodies were 
diluted in PBS +0.5% BSA and 0.1% Triton X-100.   
Cell nuclei were visualized using DAPI and the polarity index determined by 
counting the number of MRP-2 positive apical structures per 100 nuclei 
from 5 representative fields of view using a Nikon Eclipse TE200 
fluorescence microscope and phase contrast microscopy. Figure 2-4 A, 
shows MRP-2 expression in polarized HepG2 cells.  
To ascertain the effects of HIF-1α inhibitor on polarity cells grown for 4 
days were treated with the inhibitor (1µM) for 24 hours and polarity index 
measured immediately after. To ascertain the effects of HCV infection of 
polarity cells were infected 24 hours post seeding and the polarity index 
determined at 72 hours post infection.  
 
2 . 5.3 Determination of tight junction integrity 
 
Tight junction integrity assesses the functionality (integrity) of apically 
expressed bile canalicular structures. This is performed using a 
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fluorochrome which diffuses across the cell membrane and is trafficked to 
the bile canaliculi. Providing the canalicular structures are functional the 
fluorochrome is retained. However, permeable or leaky junctions results in 
diffusion of the fluorochrome to the medium.  
HepG2 cells were grown for 5 days to achieve polarity, followed by 
incubation with 5mM 5-chloromethylfluorescein diacetate [CMFDA] 
(Invitrogen) at 37˚ C for 15 minutes to allow internalization and 
translocation to bile canalicular lumen. After washing extensively with PBS, 
the capacity of bile canaliculi lumens to retain CMFDA was enumerated 
using a fluorescence microscope and phase contrast microscopy. Figure 2-
4 B shows CMFDA retention at the bile canaliculi in HepG2 cells.  
To ascertain the effects of HIF-1α inhibitor (1µM), anti-TGFβ and VEGF 
(1.5µg/ml) neutralizing antibodies on tight junction integrity, cells were 
treated with the respective compounds 24 hours prior to tight junction 
integrity quantification.  To assess the effects of cytokines on tight junction 
integrity cells grown for 4 days were treated with increasing concentrations 
of interferon-γ (IFNγ) and tumour necrosis factor-alpha (TNFα) for 24 
hours. Tight junction integrity was determined as above.  
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Figure 2-4. MRP-2 expression and CMFDA retention in HepG2 cells. 
A. Immunofluorescent detection of MRP-2 (green) in HepG2 cells grown for 
3 days, DAPI nuclear stain is shown (blue). B. Phase contrast and 
fluorescent images of bile canalicular structures retaining CMFDA (green). 
Arrows indicate bile canaliculi localization. Scale bars represent 20µm.  
 
Measurement of tight junction remodeling  
 
Tight junction formation is calcium dependent and its depletion perturbs 
junction formation. To study tight junction dynamics in parental and 
glycoprotein expressing HepG2 cells, we incubated cells in calcium free 
media (Minimum Essential Eagle Spinner Modification) +3% FBS, 1% non-
essential amino acids and 0.5mM EGTA [Sigma] for 16 hours to deplete 
calcium from cells. Thereafter, the cells were supplemented with growth 
media containing calcium and tight junction formation was monitored over 
time by enumerating CMFDA retention at the bile canaliculi as described 
above. 
 
2 . 5.4 Tight junction solubility to Triton X-100 
 
Pools of tight junction proteins reside in detergent insoluble membranes, to 
study whether HCV glycoproteins affect tight junction solubility we treated 
cells with TX-100. Briefly, HepG2 cells were seeded at 4 x 104 cells/ml onto 
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24 well plates containing 13m glass coverslips for 5 days to achieve 
polarization. Thereafter, the media was removed and cells washed in PBS 
followed by incubation with PBS containing 0.1% Triton X-100 for 2 
minutes at room temperature.  
The Triton X-100/PBS solution was removed and cells were washed 3 times 
in PBS to neutralize any residual Triton X-100.  Thereafter, cells were fixed 
in ice-cold methanol for 5 minutes. Cells were washed with PBS and 
blocked for 1 hour at room temperature in PBS +1% BSA. Primary and 
secondary antibody staining was achieved as previously described in 
fluorescence microscopy. And mounting and confocal analysis was 
described in laser scanning confocal microscopy (section 2.3.2).  
 
2 . 5.5 Reactive Oxygen Species (ROS) assay.  
 
Accumulation of increase ROS is indicative of increased cellular oxidative 
stress; ROS was detected using a Fluorescence Assay Kit (Calibochem, 
Europe). The assay uses a cell-permeable fluorogenic probe 2’, 7’ 
Dicholorodihydrofluorescin diacetate (DCFH-DA). DCFH-DA is diffused into 
cells and is deacetylated by cellular enzymes to non-fluorescent DCFH 
which is readily oxidised to highly fluorescent DCF by ROS. The fluorescent 
intensity is proportional to the ROS levels within the cell.   
We measured cellular ROS according to the manufacturer’s instructions. 
Briefly, cells were seeded at 2 x 106 per well of a 6 well plate for 48 hours. 
The media was removed and cells washed 3 times with PBS, 500µl of RPMI 
media supplemented with 10% FBS (Gibco) was added to each well 
followed by the addition of DCFH-DA (100µl).  
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Cells were incubated in the dark at 37˚C for 1 hour, after which the 
RPMI/DCFH-DA mixture was removed and the washing step was repeated. 
The fluorescent intensity was detected by flow cytometry and analysed 
with the Flow Jo software as described in section 2.3.1. 
 
2 . 5.6 Cholesterol assay 
 
Cellular cholesterol was measured using the Amplex Red Cholesterol Assay 
Kit (Invitrogen) according to the kit guidelines. Cells of interest were 
enumerated using a haemocytometer to a working density of 25 x 105 
cells. Thereafter, cells were pelleted by centrifugation at 10,000rpm for 5 
minutes and lysed with 250µl of 1x Reaction buffer. 50µl of the lysed 
samples were added to wells of a 96 well plate and cholesterol reference 
standards from the Amplex Red Kit was added to separate wells. All 
samples were added in triplicates; 50µl of Amplex Red Reagent was added 
to each sample followed by incubation at 37˚C for 30 minutes. 
Fluorescence was read using an ELISA plate reader at excitation 530nm 
and emission detection 590nm. Cholesterol values were subtracted from 
the absorbance recorded for a control empty well. For each assay a 
standard curve was produced (Figure 2-5) using the cholesterol reference 
standards allowing cholesterol levels to be expressed as µM cholesterol per 
1x105 cells. 
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Figure 2-5. Cholesterol assay standard curve.  
 
2 . 5.7 Invasion assay  
 
Cells of interest were seeded at 4 x 104 cells/ml into T75 culture flasks for 
24 hours followed by infection with HCVcc J6/JHF-1 (see section 2.4.5). 72 
hours later cells were serum starved overnight. Cells were labelled with 
CMFDA by incubation at 37C with 5M CMFDA (DMEM +3% FBS) for 30 
minutes. Labelled cells were washed with PBS followed by trypsinization. 
Cells were pelleted by centrifugation at 12000 rpm for 5min followed by 
resuspension with serum free DMEM.    
Cells were counted using a haemocytometer and trypan blue exclusion. 
4x104 cells (200l) were seeded into the top well of a collagen coated (calf 
collagen, Sigma) 8m pore transwell (BD Falcon,  USA) in a 24 well tissue 
culture plate. Cells were also seeded onto a 24 well plate as a control. The 
bottom chamber was filled with 400l serum free DMEM and cells were 
cultured for 24 hours at 37C. Non-migrated cells (top chamber) were 
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mechanically removed with a cotton bud and confirmed under light 
microscope. Migrated and control cells were fixed with ice cold methanol 
for 5 minutes and stained for HCV NS5A (see section 2.4.5). Three fields of 
view per well were captured on a Nikon TE2000 fluorescence microscope. 
The number of invaded cells was enumerated per field of view. The 
proportion of infected invaded cells and those in the control wells were also 
determined.  
To ascertain the effects of hypoxia and HIF-1α inhibitor on invasion, cells 
were cultured at 37˚C in 1% CO2 for 24 hours in the presence or absence 
of HIF-1α inhibitor (1µm) on 8µm pore transwells. To study the effects of 
anti-VEGF and TGFβ (1.5µg/ml) on invasion cells were cultured on 8µm 
pore transwells for 24 hours in the presence or absence of both 
compounds.  
 
2 . 5.8 Migration assay  
 
Cell migration was measured using a wound healing assay. Cells of interest 
were seeded at 5 x 105 cells/well into 12 well plates 24 hours prior to the 
start of the assay and serum starved overnight.  A P200 tip was used to 
create a scratch wound in the cell monolayer and the media was refreshed 
with serum free DMEM. If treatment was required (HIF-1α inhibitor, anti-
VEGF or anti-TGFβ) the media was refreshed with serum free DMEM 
containing the respective compounds. Images of the wound were taken 
immediately (0 hours).  Cells were incubated at 37˚C for 24 hours when 
further images were taken. To ensure the same area of the wound was 
being imaged at the different time points a black marker pen was used to 
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mark the exact location of the wound in each well.  Images were taken 
using a Nikon TE2000 fluorescence microscope and area of wound at 0 and 
24 hours determined using ILab 4.0 software (BD Biosciences).  
To ascertain the effects of HCVcc infection on migration, cells were infected 
with J6/JFH-1 and 48 hours later a wound was created as above and media 
refreshed with serum free DMEM. Wound healing was measured as 
outlined.  
 
2 . 5.9 Human liver tissue and immunohistochemistry  
 
Formalin fixed needle biopsies or whole tissue blocks were obtained from 
patients undergoing liver transplantation for HCV, cirrhosis due to non 
alcoholic steatohepatitis (NASH), hepatitis B (HBV), primary biliary 
cirrhosis (PBC) and hepatocellular carcinoma (HCC). Disease in each case 
was characterized as early or late; diagnosed according to the severity of 
fibrosis where early = no/mild fibrosis (Ishak stage <2) and late = 
cirrhosis. Normal liver tissues were obtained from surplus donor liver used 
for reduced-size transplantation. All donors were anonymised and tissues 
were obtained from the Centre for Liver Research, University of 
Birmingham with regional ethics committee approval (reference number 
06/Q702/61).  
Representative 3µm tissue specimens were placed onto charged glass 
slides (Surgipath, UK) and stored at room temperature until ready to use. 
For immunohistochemistry, specimens were de-parafinized in Xylene 
(Surgipath, UK) for 10 minutes and rehydrated in H2O. Thereafter, 
specimens were subjected to incubation in 0.3% hydrogen peroxide made 
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up in H2O to block endogenous peroxidise activity, followed by agitated 
low-temperature epitope retrieval. Briefly, tissue specimens were placed in 
eDTA pH 8.0 (Binding Site, UK) and microwaved for 20 minutes. Slides 
were allowed to cool by standing for 10 minutes and washing in cold H2O.  
Slides were mounted onto a Shandon Sequencer (Thermo Scientific, UK) 
and blocked in 2% Casein (Vector Labs, USA) diluted in Tris-buffered saline 
pH 7.5. Specimens were incubated with antibodies specific for Claudin-1, 
Occludin, SR-BI and HIF-1α or an irrelevant isotype control. Final antibody 
concentrations are listed in Table 2-4 and were determined after titration 
of each antibody on the liver tissue. All antibodies were diluted in Tris-
buffered saline with 0.1% Tween-20 (TBS-Tween) for 1 h at room 
temperature. 
Specimens were washed with excess TBS-Tween three times followed by 
incubation for 1 hour in a secondary antibody reagent (ImPress Universal 
anti-mouse IgG/anti-rabbit IgG Peroxidise Kit) (Vector Labs, USA) 
according to the manufacturer’s instructions. Briefly, two drops of reagent 
which equates to 200µl was added to each specimen. Specimens were 
washed with TBS-Tween as above; bound antibodies were visualized using 
ImPact DAB Diluent and Chromogen Kit (Vector Labs, USA) followed by 
counterstaining with hematoxylin (Surgipath).  Slides were mounted after 
dehydration in Xylene for 5 minutes and sealed to 24mm coverslips with 
DPX mounting reagent (VWR, UK). Slides were dried in a laminar fume 
cupboard overnight and examined the following day.  
Images were obtained using a Nikon Eclipse E400 microscope (Nikon). 
Acetone-fixed frozen sections of normal liver tissue were stained in a 
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comparable manner to confirm that the expression pattern of Claudin-1 
and Occludin had not been altered during paraffin wax processing and 
formalin fixation (Figure 2-6). 
 
Confocal analysis of human liver tissue 
For confocal analysis; the methodology described in section 2.3.2 was 
employed. The tissue’s endogenous autofluorescence was quenched by 
incubating specimens in Harris’s Haematoxylin (Surgipath) for 5 minutes 
prior to Casein blocking and the addition of primary antibodies. Secondary 
antibody staining was achieved by incubation with conjugated Alexa 488 
and 594 antibodies diluted 1:200 with TBS-Tween. Specimens were 
washed in TBS-Tween and incubated with DAPI for 15 minutes, after a final 
TBS-Tween wash specimens were mounted onto 24mm coverslips with 
Fluorescent Mounting Medium (Dako) and  analysed by laser scanning 
confocal microscopy.  
 
2 . 5.10 Statistical analysis  
 
Statistical tests were performed using the Prism 5.0 software (GraphPad, 
CA). Results are expressed as mean ± 1 standard deviation, unless 
otherwise stated.  Tests were performed using non-parametric means 
allowing for the prediction of statistical significance without assuming a 
particular data distribution. In other instances the Student’s t test was 
employed. A probability (P) value of <0.05 was considered as statistically 
significant. The relevant tests and level of significance are noted in the 
figure legends.  
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Figure 2-6. Tight junction protein expression in paraffin embedded 
and frozen liver specimens from normal liver tissue (x100).  
IgG depicts an irrelevant isotype control. Arrows indicate Occludin and 
Claudin-1 expression at the bile canaliculi (BC) and on bile ducts (BD).  
  
106 
 
3. RESULTS  
 
3.1 A comparative analysis of hepatoma cells and primary human    
hepatocytes to support HCV infection.  
Our understanding of HCV entry and replication in vivo is limited due to the 
lack of small animal models to study the virus lifecycle. Primary human 
hepatocyte (PHH) cultures are believed to provide the ‘gold standard’ 
physiological model to study HCV infection of the human liver in vitro. 
Compared to many immortalized hepatic cell lines, PHHs demonstrate 
metabolic liver functions including urea and albumin production. 
Furthermore, they are highly differentiated, although this phenotype is 
short lived and elicits an anti-viral response to virus infection (310). These 
traits are uncommon in most transformed hepatic cell lines making PHHs a 
close physiological match to hepatocytes in vivo. However, there are 
relatively few reports studying HCV infection of PHHs due to the limited 
access to human liver tissue. Consequently, the majority of reports utilize 
transformed hepatoma cell lines to study virus entry and replication.  
The development of HCVpp and HCVcc systems has enabled detailed and 
robust studies of HCV entry and replication, respectively (171, 225, 415). 
Both systems are capable of infecting poorly-differentiated human 
hepatoma cell lines such as Huh-7.5 (41). Huh-7.5 cells contain a mutation 
in the RIG-I gene, a key regulator of the interferon induction pathway 
(386). Consequently, HCV can establish and maintain prolonged infection 
of these cells. However, the tumour derived nature of Huh-7.5 cells results 
in cell division when cultured (101, 170, 436). In vivo, HCV dissemination 
occurs mainly in highly differentiated non-dividing hepatocytes (393). 
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Similarly, isolated PHHs in vitro do not divide although they are known to 
de-differentiate overtime. A comparative analysis of hepatoma infection 
models and PHHs to support entry and replication has not been performed. 
As such it is not known whether PHHs supports HCV infection that is 
comparable to hepatoma cell lines. We investigated HCV infection of 
hepatoma and PHHs with a view to validate hepatoma cells as relevant 
culture models to study the HCV lifecycle.  
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3.1.1 Phenotypic characteristics of primary human hepatocytes 
in culture.  
Hepatocyte morphology was monitored over a period of 12 days; cells 
maintained a characteristic cobble stone like appearance for 10 days 
before de-differentiating to a more fibroblastic phenotype (Figure 3-1 A). 
We monitored liver specific metabolic function by measuring albumin 
secretion and expression of hepatocyte differentiation markers. Albumin 
secretion decreased over time consistent with the observed change in 
hepatocyte morphology (Figure 3-1 B). The expression of hepatocyte 
differentiation genes; including alpha-fetoprotein [α-FP], HnF4α and 
CYP3a4 (regulatory genes with crucial roles in maintaining hepatocyte 
phenotype) also declined over time albeit at varying levels (Figure 3-1 C). 
The decline in hepatocytic markers is in line with published data (310). 
Taken together, these data demonstrate the expression of hepatocyte 
phenotypic characteristics in PHHs from multiple donors that declined over 
time.  
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Figure 3-1. Phenotypic characteristics of primary human 
hepatocytes in culture.  
A. Representative phase contrast images of cultured PHHs morphological 
appearance; the images represent hepatocytes from three donors, where 
the scale bar represents 10µm. B. ELISA detection of albumin production 
from 4x 104 cells, data shows 3 PHH donors. C. qRT-PCR quantification of 
hepatocyte gene expression, the data is representative of the 3 PHH 
donors from parts A and B and is presented relative to the housekeeping 
gene GAPDH.  
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3 . 1.2 Primary human hepatocytes support HCV glycoprotein-
dependent virus entry (HCVpp). 
HCVpp comprise a replication deficient retrovirus core and as such are only 
capable of a single round of infection (24, 171), allowing one to investigate 
the primary steps of HCV entry in isolation from downstream replication 
events. To optimise HCVpp infection of PHHs, cells were infected after 1, 2 
and 3 days post seeding in the presence or absence of HCV entry inhibitors 
ITX5061 (ITX) that targets SR-BI (389) and anti-CD81 antibody (154) that 
blocks HCV engagement of CD81. PHHs were infected with lentiviral 
pseudotypes expressing HCV strain H77 genotype-1a glycoproteins 
(H77pp) or control vesicular stomatitis virus glycoprotein G (VSV-Gpp) for 
72 hours and infection assessed by measuring luciferase activity, as 
previously reported (81, 171, 260). As a control cell line, we used Huh-7.5 
cells which have been reported to support efficient HCV entry 1 day post 
seeding (171). H77pp infected PHHs resulted in 4- and 5-fold increased 
luciferase signals after 2 and 3 days post seeding respectively, compared 
to cells infected 1 day post seeding (Figure 3-2 A). 
H77pp infected Huh-7.5 cells yielded 60-, 14- and 17-fold higher luciferase 
signals than PHHs at days 1, 2 and 3, respectively (Figure 3-2 A). ITX5061 
and anti-CD81 inhibited H77pp infection of PHHs and Huh-7.5 cells at all 
time points confirming receptor-dependent entry. Importantly, VSV-Gpp 
infected both cell types at comparable levels regardless of time in culture 
and HCV entry inhibitors had no effect, demonstrating a HCV specific 
blocking effect (Figure 3-2 B). These data demonstrate that PHHs support 
optimal HCVpp entry at 2 days post seeding.  
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Figure 3-2. Optimization of HCVpp infection of primary human 
hepatocytes. 
 A.  PHHs seeded at a density of 4x104 cells/ml were infected with H77pp 
after 1, 2 and 3 days post seeding. Huh-7.5 cells seeded at the same 
density were infected 1 day post seeding which is the optimal time for 
HCVpp infection of these cells. White bar shows control untreated cells, 
grey bar depicts cells that were treated with HCV entry inhibitor ITX5061 
(ITX) [5µM] and black bars show cells that were treated with anti-CD81 
monoclonal antibody [2s131] (5µg/ml). B. VSV-Gpp infection of PHHs and 
Huh-7.5 cells. Pseudo-particle infectivity is presented as relative light units 
(RLU) from which a no envelope control value was subtracted. The no 
envelope RLU values were in the order of 2 x 103 for both cell types. Data 
is representative of 2 independent experiments performed in triplicate. 
Error bars indicate standard deviation from the mean (n=3). *** P = 
0.0001 (t test).  
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3 . 1.3 HCV receptor expression and localization in primary 
human hepatocytes.  
To ascertain whether optimal HCVpp entry into PHHs at day 2 reflects 
changes in HCV receptor levels, we monitored mRNA and protein 
expression and localization. Claudin-1 and Occludin demonstrated a 
predominantly intracellular staining pattern with discontinuous plasma 
membrane expression at day 1 (Figure 3-3 A). The plasma membrane 
expression of Claudin-1 and Occludin increased at days 2 and 3 in line with 
the HCV infection data. CD81 localized strongly to the plasma membrane 
on day 1; however, on days 2 and 3 CD81 membrane distribution was faint 
concomitant with increased intracellular staining (Figure 3-3 A). Our anti-
SR-BI antibodies fail to detect SR-BI expression by confocal techniques. 
Nevertheless, PHHs express SR-BI as shown by western blotting and its 
expression level increased over time in culture (Figure 3-3 B). The levels of 
CD81, Claudin-1 and Occludin were also assessed by western blotting. 
CD81 expression was stable over time; in contrast, Claudin-1 and Occludin 
expression levels increased between day 1 and day 3 (Figure 3-3 B).  
We also evaluated the mRNA levels of all four receptor proteins over time. 
As a control we compared the mRNA levels to those in Huh-7.5 cells at day 
1 post seeding (Figure 3-3 C). HCV receptor mRNA levels increased over 
time in PHHs, comparable levels of SR-BI, Claudin-1 and Occludin mRNAs 
were detected at days 1-3. There was a modest increase in CD81 mRNA 
over time that was comparable to the levels seen in Huh-7.5 cells.  At days 
2 and 3 SR-BI, Claudin-1 and Occludin mRNA levels were comparable to 
Huh-7.5 cells (Figure 3-3 C). In summary, these data demonstrate that 
PHHs express all four receptor molecules required for HCV entry and 
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optimal H77pp entry at day 2 is consistent with increased receptor 
expression levels and localization at the plasma membrane.   
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Figure 3-3. HCV receptor expression in primary human 
hepatocytes.  
A. Confocal imaging of CD81, Claudin-1 and Occludin in PHHs cultured for 
1, 2 and 3 days, scale bars represent 20µm. B. Western blot detection of 
HCV receptors over time in culture.  C. HCV receptor mRNA levels in PHHs 
cultured for 1, 2 and 3 days and Huh-7.5 cells cultured for 1 day, where 
the data represents 2 independent experiments and presented relative to 
the housekeeping gene GAPDH. Error bars indicate mean from standard 
deviation (n=3).   
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3.1.4 Primary human hepatocytes support diverse HCVpp 
infection.  
Previous studies have shown that HCVpp encoding glycoproteins from 
diverse HCV genotypes show different abilities to to infect hematoma cells, 
suggesting that genotypic differences define HCV-receptor interactions 
(122). To ascertain whether PHHs from multiple donors support diverse 
HCVpp infection we screened a panel of HCVpp glycoprotein variants 
(S11c1, S11c3, S28c1, S28c2 and S28c3) cloned from two patients S11 
and S28 with acute genotype 1a and 1b infections, respectively (97). Cells 
were infected for 8 hours, unbound virus removed by washing and 
infectivity determined 72 hours later by measuring luciferase activity. PHHs 
from three independent donors (Figure 3-4 A-B) supported comparable 
levels of infection for all HCVpp strains tested, with typical luciferase 
values in the order of 7 x 104 relative light units (RLU). VSV-Gpp yielded 3 
logs higher luciferase values and were comparable irrespective of PHH 
donor (Figure 3-4 B). These data demonstrate that PHHs from several 
donors support diverse HCVpp entry and donor variation has minimal effect 
on viral entry.  
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        *NHBD = non-heart-beating donor 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4. Diverse HCVpp infection of primary hepatocyte from 3 
donors.  
A. Primary hepatocyte donor information. B. PHHs from 3 donors were 
seeded at 4x104 cells/ml and grown for 2 days in culture followed by 
infection with HCVpp strains or VSV-Gpp. Infection was analysed 72 hours 
later by measuring luciferase activity. Data is presented as relative light 
units (RLU) from which a no envelope control value was subtracted. The 
specific infectivities for HCVpp strains and VSV-Gpp were in the order of 7 
X104 and 1.8 x 107 RLUs, respectively. The no envelope values were 2 x 
103. Data represents standard deviation from the mean (n=3).  
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3 . 1.5 Comparison of HCVpp entry into primary human 
hepatocytes and hepatoma cells.  
In addition to Huh-7.5’s several other hepatoma cells including HepG2 and 
Hep3B cells have been reported to support HCV entry (254, 260, 349). 
Both Huh-7.5 and Hep3B cells express all four HCV receptor molecules; in 
contrast, HepG2 cells do not express CD81 making them non-permissive 
for infection (254). However, ectopic CD81 expression (HepG2-CD81) 
conferred susceptibility to HCV infection (254, 260). We compared HCVpp 
infection of different hepatoma cells to PHHs isolated from three 
independent donors (Figure 3-5 A). VSV-Gpp infection was comparable for 
all cell types except HepG2-CD81 cells which demonstrated a 10 fold 
reduction (Figure 3-5 B). HCVpp strains demonstrated a 1 log range in 
luciferase values in Huh-7.5 and Hep3B cells; however, this pattern was 
not seen with PHHs or HepG2-CD81 cells which showed comparable 
luciferase values (Figure 3-5 A). A non-parametric analysis of the median 
luciferase values from Huh-7.5 and Hep3B cells showed significant 
heterogeneity across the different HCVpp strains resulting in the log range 
(P=0.0027, Kruskal-Wallis test).  
Variable HCVpp infection values, whether luciferase or GFP reporter 
viruses, have been interpreted to mean differences in HCV glycoprotein 
dependent entry. However, reporter gene signals are likely to be affected 
by cell division, leading to progeny daughter cells that will express the 
reporter gene. In the following section we describe the effects of cell 
division on HCVpp luciferase signals. 
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Figure 3-5. Comparison of HCVpp entry into primary human 
hepatocytes and hepatoma cells..   
Primary hepatocytes from three donors (PHH-1, - 2 and -3) and hepatoma 
cell lines were compared for their permissivity to support HCVpp and VSV-
Gpp infection. Cells were seeded at equal densities and infected with a 
panel of HCVpp strains (A.) or control VSV-Gpp (B.). HCVpp entry was 
measured 72 hours later by detection of the luciferase activity. Data is 
presented as relative light units (RLU) from which a no envelope control 
value was subtracted. The median luciferase values were significantly 
different between HCVpp strains infecting hepatoma cells (**P = 0.0027, 
Kruskal-Wallis test).  
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3 . 1.6 The effect of cell division on HCVpp reporter signals.  
We investigated whether cell division affects HCVpp luciferase signals. In 
contrast to PHHs, hepatoma cells divide in culture with a doubling time in 
the order of 24-27h (101, 436). Division of an infected cell may result in 
two progeny daughter cells bearing the reporter virus. We measured cell 
division with an MTT (3-[4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) assay; MTT is reduced by enzymes in 
metabolically active cells to generate a signal that can be read 
calorimetrically. A linear relationship exists between cell number and the 
signal produced which is represented as optical density (OD). Firstly, we 
determined the doubling ability of each cell type. Cells were seeded at an 
equal density and treated with mitomycin C or γ-irradiation which cross-
links cellular DNA to render cells mitotically inactive. 24 hours later MTT 
activity of control and treated cells was measured. Huh-7.5 and Hep3B 
cells showed increased cell division compared to PHHs (Figure 3-6 A). 
Similarly HepG2-CD81 divided in culture over 24 hours although the rate of 
division was lower compared to Huh-7.5 and Hep3B cells. Mitomycin C or 
γ-irradiation treatment of hepatoma cells decreased cell division that was 
indistinguishable from PHHs (Figure 3-6 A). Importantly, both treatments 
had minimal effects on PHHs (Figure 3-6 A). To ascertain whether cell 
proliferation affects HCVpp luciferase signal, cells were treated with 
mitomycin C or γ-irradiation followed by HCVpp infection and luciferase 
activity measured 72 hours later. Mitomycin C and γ-irradiation had 
minimal effects on HCVpp luciferase signals in PHHs consistent with their 
non-dividing nature (Figure 3-6 B). Treatment of HepG2-CD81 cells 
reduced HCVpp luciferase signals by 25% compared to control untreated 
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cells (Figure 3-6 C) consistent with the reduced doubling rate of these 
cells. In contrast, both treatments reduced the luciferase activity of most 
viral strains by 50% in Huh-7.5 and Hep3B cells resulting in luciferase 
signals that were comparable to PHHs and HepG2-CD81, with the 
exception of H77 and S11c1pp where the luciferase activity was reduced 
by 25% (Figure 3-6 D-E). These data suggest that factor(s) other than cell 
division potentiate H77 and S11c1pp infection of Huh-7.5 and Hep3B cells. 
In summary, we demonstrate that cell division increases HCVpp luciferase 
signals in Huh-7.5 and Hep3B cells independent of viral glycoprotein 
diversity. Inhibition of cell division reduced HCVpp luciferase signals to 
levels seen in PHHs with the exception of H77 and S11c1pp.  
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Figure 3-6. The effect of cell division of HCVpp entry.  
A. The effect of mitomycin C and γ-irradiation on cell division. Cells were 
treated with mitomycin C (10µg/ml) or γ-irradiation (32mSV); 24 hours 
later cell proliferation was assessed. B-E. The effect of cell division on 
HCVpp infection. Control and treated cells were infected with HCVpp or 
VSV-Gpp and luciferase activity measured 72 hours later. Data is 
presented as relative light units (RLU) from which a no envelope signal was 
subtracted and plotted relative to control untreated cells. Data represents 
2 independent experiments performed in triplicate, error bars indicate the 
standard deviation from the mean (n=3) **P = 0.01, *** P = 0.001 (t 
test). 
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3 . 1.7 HCVpp decay affects infection rates. 
We noted elevated luciferase signals for H77 and S11c1pp infection of 
Huh-7.5 and Hep3B cells independent of cell proliferation. This was not 
apparent with other HCVpp strains suggesting that properties unique to 
H77 and S11c1 glycoproteins were responsible for the effect. Data from 
our lab has shown that HCVcc particles are highly labile at 37˚C with a half 
life of 2-3 hours (Michelle Farquhar, unpublished observations). However, 
the labile nature of HCVpp particles has not been investigated; we 
therefore studied whether H77 and S11c1pp degrades slower at cultured 
conditions (37˚C) compared to other HCVpp strains resulting in increased 
luciferase signals.    
We compared the decay rates of H77, S11c1, S11c3 and S28c1pp; VSV-
Gpp was used as control. S11c3 and S28c1pp were used as comparisons 
because both viral strains demonstrated comparable luciferase signals in 
all cell types after cell division was inhibited (Figure 3-6). HCVpp strains 
and VSV-Gpp were incubated in 3% DMEM at 37˚C for 0, 12, 24, 36 and 
48 hours. Viruses from each time point were used to infect hepatoma and 
PHHs for 4 hours. Unbound virus was removed by washing and luciferase 
activity measured 48 hours later. The infectivity of all HCVpp strains tested 
decreased over time, consistent with prolonged incubation at 37˚C (Figure 
3-7 A-D). All viral strains demonstrated a similar decay slope; however, 
when we compared the half-lives, S11c3 and S28c1 had a half-life of 
around 6 hours for all cell types tested (Figure 3-7 E). In contrast, H77 and 
S11c1pp strains showed an extended infectivity half-life of 11 hours for 
Huh-7.5 and Hep3B cells compared to 5 hours for PHH and HepG2-CD81 
cells. The decline in VSV-G infectivity was comparable for all cell types 
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(Figure 3-7 A-E). In summary, these data show that H77 and S11c1pp 
degrades slower on Huh-7.5 and Hep3B cells which may explain the 
increased luciferase signals for both viral strains in these cell lines.  
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H77 S11c1 S11c3 S28c1 VSV-G
PHH 6.31 6.17 6.23 6.34 20.54
HepG2-CD81 7.35 7.39 7.50 6.87 17.32
Huh-7.5 11.88 11.30 5.5 1 5.36 20.82
Hep3B 11.35 11.42 5.0 5.72 20.69
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7 The effect of degradation on HCVpp infectivity.  
HCVpp and VSV-G viruses were incubated at 37˚C for different time points 
(0, 12, 24, 36 and 48 hours) and their infectivity for PHHs, HepG2-CD81 
and Huh-7.5 cells evaluated. A-D shows virus infectivity over time plotted 
as relative light units (RLU). E. Shows the half-life of each virus strain. 
Data represents 3 independent experiments performed in triplicate and 
error bars indicate the mean from the standard deviation (n=3). A no 
envelope signal was subtracted from each value.  
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3 . 1.8 Primary human hepatocytes support HCVcc replication.  
The data presented thus far describes HCV infection at the level of entry 
only. To ascertain whether PHHs support HCV replication, we utilized the 
HCVcc system that allows us to study virus replication and assembly of 
infectious particles in vitro (225, 415). To determine the optimal time point 
for HCVcc infection of PHHs, cells were infected at 1, 2 and 3 days post 
seeding with HCVcc genotype 1b strain J6/JFH-1. SR-BI inhibitor (ITX5061) 
and anti-CD81 monoclonal antibody were included to evaluate receptor 
dependency and Huh-7.5 cells at day 1 in culture were used as controls. 
Infection was quantified by qRT-PCR 72 hours later and the data presented 
as HCV genome copies relative to the house-keeping gene GAPDH. PHHs 
support J6/JFH-1 infection in a SR-BI and CD81 dependent manner (Figure 
3-8 A). JFH-1 infection of PHHs was optimal at day 2 post seeding where 
the level of HCV RNA was 100-fold lower than Huh-7.5 cells (Figure 3-8 A). 
HCVcc replication is associated with the secretion of infectious virus 
particles into the culture media which can be harvested and used to infect 
naive target cells. Media was harvested from infected PHHs and control 
Huh-7.5 cells at 72 hours post infection and their infectivity for naïve Huh-
7.5 cells tested. Figure 3-8 B shows that PHH secrete fewer infectious virus 
particles compared to Huh-7.5 cells. However, after normalizing 
extracellular infectious virus to viral genomic burden PHHs secrete 
comparable levels of infectious virus to Huh-7.5 cells (Figure 3-8 C).  
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Figure 3-8. Primary human hepatocytes support HCVcc replication. 
A. PHHs and Huh-7.5 cells treated with ITX 5061 (ITX) [5µM] or anti-CD81 
(5µg/ml) were infected with HCVcc J6/JFH-1 at 1, 2 and 3 days post 
seeding to determine optimal time point for infection. As a control Huh-7.5 
cells at day 1 in culture were infected, 72 hours later the HCV RNA burden 
was quantified. Data is presented as HCV copy numbers relative to GAPDH. 
B. Extracellular virus secreted from PHHs (infected at day 2 in culture) and 
Huh-7.5 (infected at day 1 in culture) with HCVcc stains J6/JFH-1 or 
SA13/JFH-1 were used to infect naive Huh-7.5 cells and infection 
quantified 72 hours later by staining for the virus antigen NS5A. Data is 
presented as focus forming units/ml (FFU/ml). C. The HCV RNA burden of 
both cell types was normalized to the level of secreted virus to show virus 
release from both cell types. *** P = 0.001, * P = 0.05 (t test).  
Day 1 Day 2 Day 3 Huh-7.5
100
101
102
103
104
105
106
Con ITX CD81
*** ***
H
C
V
 c
o
p
ie
s
/G
A
P
D
H
JFH-1 SA13
102
103
104
105
106
Huh-7.5
PHH
*** *
E
x
tr
a
c
e
ll
u
la
r 
In
fe
c
ti
o
u
s
v
ir
u
s
 (
F
F
U
/m
L
)
JFH-1 SA13
0.00
0.25
0.50
0.75
1.00
Huh-7.5
PHH
N
o
rm
a
li
z
e
d
 e
x
tr
a
c
e
ll
u
la
r
v
ir
u
s
 r
e
la
ti
v
e
 t
o
 R
N
A
 l
o
a
d
A. 
B. 
C. 
127 
 
3 . 1.9 Donor variation affects HCVcc replication in primary 
human hepatocytes.  
We have shown comparable HCVpp infection of PHHs from three donors, 
suggesting that donor variation does not affect HCV infection at the level of 
entry. To ascertain whether PHHs from the same donors support 
comparable HCVcc replication, cells were infected with HCVcc strain 
J6/JFH-1 (genotype 1b) or strain SA13/JFH-1 (genotype 5a).  72 hours 
later the cells were lysed for qRT-PCR quantification of HCV genomic copy 
numbers. Figure 3-9 shows that HCV RNA levels were significantly higher 
in PHHs from donor 2 (PHH-2) compared to cells from donors 1 and 3, 
suggesting that donor variation affects HCV replication.  
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Figure 3-9 The effects of donor variation on HCVcc replication.  
PHHs from 3 donors were infected 2 days post seeding with HCV strains 
J6/JFH-1 and SA13/JFH-1. The genomic RNA burden was quantified by 
qRT-PCR 72 hours later. Data is presented as HCV genomic copy number 
relative to the house keeping gene GAPDH. ***P = 0.001 (t test).  
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3.2 Discussion  
The advent of HCVpp and HCVcc systems has enabled studies on the 
complete viral lifecycle in hepatoma cells. The next major challenge is to 
unify observations made using these systems with physiological relevant 
cell culture models. To date a comparative analysis of HCV infection of 
PHHs and hepatoma cell lines has not been reported. Here, we have 
utilized the HCVpp and HCVcc systems to compare virus entry and 
replication in PHHs and several hepatoma cell lines. Several studies have 
documented the use of PHHs for HCV studies (60, 127, 337); however, the 
performance of primary cell cultures has varied from one lab to another 
due to differences in culture conditions or inherent donor variability (141).  
A major hindrance for HCV research is the limited availability of PHHs for 
experimental use. We have obtained cryopreserved PHHs isolated under 
good laboratory practice guidelines that improve uniformity and 
reproducibility (272). These PHHs are routinely used in a clinical setting for 
transplantation purposes (328). Cultured PHHs demonstrated hepatocyte 
metabolic function and differentiation features for up to 10 days and 
supported HCVpp infection in a SR-BI and CD81 dependent manner that 
was optimal at day 2 post seeding. This was consistent with increased SR-
BI expression and localization at the cell membrane and a reduction in 
CD81 expression. These data suggest that thresholds of membrane-
expressed pools of HCV receptors are required for maximal infection of 
PHHs. Indeed, studies have shown that Claudin-1 (434) and SR-BI (364) 
become enriched at sites of cell-cell contacts as cells become more 
confluent in culture which in turn enhances HCV infection. Although PHHs 
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are non-dividing, areas of cell-cell contact increase over time in culture as 
the cells spread. 
HCVpp variants expressing glycoproteins cloned from recent 
seroconverters (97) infect PHHs from several donors at comparable levels 
suggesting that the initial stages of HCV infection are not restricted by 
donor differences. In contrast, HCVcc replication differed in hepatocytes 
from the different donors to corroborate a previous report (69). Marukian 
et al, (245), utilized primary human fetal cells from several donors to 
study the induction of interferon stimulated genes (ISGs) following HCVcc 
infection. The authors demonstrate variable induction of type III 
interferons and ISGs among donors. Stimulation of ISGs limit HCV spread 
in a donor dependent manner suggesting that inherent differences in the 
innate immune response may affect the outcome of HCV replication. These 
data provide a potential explanation for differences we observed in HCVcc 
replication in hepatocytes from different donors. 
HCVpp infected PHHs at a lower level than Huh-7.5 and Hep3B cells. 
Interestingly, HCVpp infection of PHHs was almost indistinguishable from 
the levels of infection seen in HepG2-CD81 cells. HepG2-CD81 cells are 
considered to be more physiologically relevant compared to Huh-7.5 cells 
due to their ability to maintain hepatocyte features such as polarity and 
detoxifying enzymatic functions (88). The HCVpp system only allows for 
pseudo-particle infection of 1 target cell and does not transmit to 
neighbouring cells. Our data indicate that progeny daughter cells may 
acquire the luciferase gene via hepatoma cell division, resulting in 
increased luciferase values which are normally interpreted as authentic 
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HCV entry. However, inactivation of cell division by mitomycin C or -
irradiation resulted in HCVpp infection of Huh-7.5 and Hep3B cells that was 
reduced by 50% for all strains tested and was comparable to the levels 
seen in HepG2-CD81 and PHHs except for strains H77 and S11c1pp which 
were reduced by 25%. 
Our data shows that H77 and S11c1pp particles demonstrate reduced 
degradation at 37°C compared to other HCVpp strains. Both viruses had a 
half-life of 11.8 and 11.3 hours respectively for Huh-7.5 and Hep3B cells 
compared to 5.5 and 5.3 hours for S11c3 and S28c1pp. In contrast, all 
virus strains demonstrated comparable half-lives to infect PHHs and 
HepG2-CD81 cells. These data provide further insights into the increased 
permissivity of Huh-7.5 and Hep3B cells to HCVpp infection. Viruses are 
susceptible to environmental changes including pH and temperature. Such 
changes can induce structural rearrangements of the viral capsid leading to 
instability and degradation, reviewed in (247). Kamili and colleagues (186) 
showed that HCV plasma was still infectious after storage at room 
temperature for 16 hours. More recently, Song et al, (380) showed that 
HCVcc in culture was still infectious in a genotype specific manner after 
incubation at room temperature or 37˚C for 16 days. Together, these data 
suggest that HCV particles demonstrate increased conformational stability 
over time which may be affected by genotype specific differences that are 
unknown. The properties governing virus decay are unclear; however, 
studies have shown the formation of virus aggregates, a phenomenon 
where virus particles aggregate via hydrophobic interactions in response to 
environmental changes (197, 339, 340). This feature reduced the efficacy 
of neutralizing antibodies and prevented virus degradation. Our data 
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suggest the tantalizing possibility that fractions of H77 and S11c1pp form 
aggregates that slows degradation. The mechanisms governing reduced 
HCVpp decay on Huh-7.5 and Hep3B cells warrants further study as it is 
unclear why two viral strains are preferentially infectious for these cell 
types. 
We previously reported that CD81 and Claudin-1 co-receptor complexes in 
HepG2 cells play an essential role in HCV entry (154, 155); it is unknown 
whether HCV receptors interact in a comparable manner in other hepatoma 
and PHHs. Recent data from our lab using fluorescent recovery after photo 
bleaching (FRAP) and single particle tracking imaging techniques show the 
dynamic diffusion of HCV receptors through the plasma membranes of 
HepG2-CD81 cells (Harris et al, manuscript in preparation). However, 
further studies are required to ascertain whether HCV receptor dynamics 
are similar in other cell types including PHHs. Additional data from our 
group suggest that HCV receptor endocytosis is important for virus entry. 
Indeed, HCV receptor specific antibodies or infection induced the 
internalization of HCV receptors in Huh-7.5 cells in a time dependent 
manner (Farquhar et al, submitted manuscript). It remains to be seen 
whether the kinetics of HCV induced receptor internalization is comparable 
in PHHs; an interesting area for future studies.  
A recent study by Podevin et al (320) showed that the expression and 
maintenance of hepatocyte differentiation makers is important for HCVcc 
replication in PHHs. Due to increased cell death caused by virus infection 
we were unable to study HCV replication in primary culture beyond day 5 
to ascertain the true effects of hepatocyte differentiation on virus 
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replication. Although PHHs support lower levels of HCVcc replication 
compared to Huh-7.5 cells we observed increased virus replication at day 
2, which could partly represent increased virus transmission in the infected 
culture or correct receptor expression and distribution. However, unlike 
infected Huh-7.5 cells where one can identify and enumerate viral antigen 
expressing cells, PHHs are highly autofluorescent making it difficult to 
measure the frequency of infected cells using fluorescent based 
techniques. Ploss and colleagues recently reported restricted HCV spread in 
micro-cultures of PHHs (318). The authors argued that virus spread may 
have been restricted by an inherent or acquired refractory nature of some 
cells in the population or heterogeneous expression of host factors critical 
for virus entry. Whilst the above reasons are valid, it is difficult to ascertain 
whether some cells are refractile and we did not detect regions of 
significant heterogeneous viral receptor distribution in our cells.   
PHHs supported the release of extracellular virus that was infectious for 
Huh-7.5 cells. Normalization of HCV RNA burden to extracellular virus 
showed that PHHs secrete comparable levels of infectious virus to Huh-7.5 
cells. Virus particles secreted from PHHs were reported to demonstrate a 
lower buoyant density (320) characteristic of particles associated with low 
density lipoproteins that are produced during in vivo infection (226). These 
properties were lost after culture in Huh-7.5 cells suggesting that genuine 
virus production can only be recapitulated with PHHs. It would be 
interesting to establish whether secreted virus from cryopreserved PHHs 
demonstrate authentic HCV properties, a potential avenue for future 
studies.  
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To conclude, we demonstrate that hepatoma proliferation led to increased 
HCVpp luciferase signals that was previously interpreted as increased virus 
entry. Inhibition of cell proliferation resulted in comparable virus entry into 
PHHs and hepatoma cell lines with the exception of H77 and S11c1pp, both 
viruses demonstrated increased stability for Huh-7.5 and Hep3B cells. 
These data indicate the need for caution when interpreting absolute HCVpp 
infection of dividing hepatoma cells. Importantly, PHHs support HCVcc 
replication and release comparable levels of infectious virus to permissive 
Huh-7.5 cells. In the absent of a small animal model to study HCV 
infection, PHHs are thought to be the most physiologically relevant cell 
culture model representing authentic HCV infection in vivo. However, they 
are difficult to obtain and last for a short time in culture making long term 
HCV studies impossible. Our study validates the use of immortalized 
hepatoma models as viable tools for HCV infection studies in vitro 
providing proliferation rates and virus particle properties are accounted for 
when interpreting HCV infection of hepatoma cells.  
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4. RESULTS 
4.1 Mechanism(s) of hepatitis c virus perturbation of 
hepatocellular polarity.  
Hepatitis C virus (HCV) induces chronic liver injury that can lead to 
progressive fibrosis and is one of the leading causes of HCC (111). HCV 
replicates in the cytoplasm of hepatocytes without integration into the host 
genome. The role of HCV infection in the carcinogenic process is unclear, in 
part due to the limited availability of small animal models that support HCV 
replication and technical difficulties in detecting HCV antigen expressing 
cells in the human liver (221). Reports demonstrating that HCV encoded 
proteins interact with cell cycle regulators and tumour suppressors, along 
with the development of HCC in some HCV transgenic lineages, suggest 
that HCV proteins may be directly oncogenic (reviewed in (253). 
Furthermore, HCV associated HCC has been reported to be associated with 
increased recurrence after liver resection (174) suggesting that HCV may 
drive the malignant process and metastasis. 
As previously discussed HCV utilizes the tight junction proteins Claudin-1 
(108) and Occludin (316) to enter target cells. Tight junctions are crucial 
for the establishment and maintenance of cell polarity and aberrant tight 
junctions are a feature of many malignant tumours including HCC (82, 
293). Previous studies have shown that HCV glycoproteins induced a 
relocalization of Occludin to intracellular sites in Huh-7 cells (30) 
suggesting that infection modulates tight junction localization. However, 
due to the non-polarizing nature of Huh-7 cells (259), the authors were 
unable to study the functional consequences of viral glycoprotein on cell 
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polarity.  In this chapter we utilize HepG2 cells which polarize in culture 
(88, 260) to study the functional consequences of HCV infection and 
glycoprotein expression on polarity.  
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4.1.1 HCV glycoproteins perturb tight junction protein 
expression and localization.  
To investigate the functional effect(s) of HCV E1E2 glycoproteins on 
hepatocellular polarity we transfected HepG2-CD81 cells to stably express 
HCV strain H77 (genotype 1a), JFH-1 (genotype 2a) glycoproteins or 
control vesicular stomatitis virus encoded glycoprotein-G (VSV-G). Stable 
cell populations expressing the respective glycoproteins were selected for 
study where the majority of cells expressed HCV E2 at comparable levels 
to HCVcc infected hepatoma cells. The majority of infected cells also 
expressed the viral antigen NS5A (Figure 4-1 A and B). Tight junction 
protein localization and expression in parental and transfected HepG2 was 
assessed by confocal microscopy, western blotting and flow cytometry. 
Occludin localized as discrete bands surrounding the bile canaliculi in 
parental and VSV-G expressing cells, whereas in H77 and JFH-1 E1E2 
expressing cells Occludin localization was modulated and showed reduced 
expression levels by western and flow cytometry (Figure 4-1 C and Figure 
4-2 A and B). Claudin-1 was detected at both the bile canalicular and 
basolateral membranes. HCV glycoproteins promoted Claudin-1 expression 
levels with no discernable effect on protein localization (Figure 4-1 C and 
Figure 4-2 A and B). In contrast, HCV glycoproteins had no detectable 
effect on the expression levels of HCV entry factors CD81 and SR-BI. 
To confirm Occludin relocalization to the basolateral membrane in HCV 
glycoprotein expressing cells, we studied tight junction solubility to 
detergent treatment. Tight junction-associated proteins reside in Triton X-
100 detergent resistant microdomains (288) such that bile canalicular-
localized Claudin-1 and Occludin in parental and VSV-G HepG2-CD81 cells 
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was  detergent insoluble, whereas basolateral pools of Claudin-1 were 
Triton X-100 soluble (Figure 4-2 C). In contrast, Occludin was soluble to 
Triton X-100 in HCV glycoprotein expressing cells, confirming protein re-
localization from the apical bile canaliculi membrane to the basolateral 
membrane.  
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Figure 4-1. HCV glycoproteins perturb tight junction expression 
and localization.  
A. Flow cytometric detection of HCV E2 and VSV-G, cells were stained with 
anti-E2 (3/11) or anti-VSV-G. The filled histograms depict an irrelevant 
isotype control and unfilled histograms shows E2 and VSV-G expression, 
respectively. B. E2 expression in HCV infected Huh-7.5 cells, image shows 
HCV NS5A protein expression (red) used as a marker HCV infection where 
80% of cells in culture were infected. Unfilled histogram shows E2 
expression in the infected culture and filled histogram depicts an irrelevant 
isotype control. C. Confocal imaging of Occludin and Claudin-1 (green) 
localization in parental, HCV glycoprotein and VSV-G expressing cells, 
where cell nuclei are counterstained with DAPI (blue); scale bar represents 
20 µm. 
A. 
B. 
C. 
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Figure 4-2. HCV receptor expression levels in parental and 
glycoprotein expressing HepG2-CD81 cells.  
A. Quantification of HCV receptor levels in parental and glycoprotein 
expressing cells by western blotting. Antibodies specific for Occludin, 
Claudin-1, CD81 and SR-BI were used to show receptor expression levels. 
B. Flow cytometry detection of HCV receptor expression levels, where data 
is presented as mean fluorescent intensity (MFI) from which an irrelevant 
isotype control value was subtracted. C. Detergent solubility of tight 
junction proteins; cells were grown for 5 days in culture to polarize 
followed by treatment with 0.01% triton X-100. Confocal imaging of 
Claudin-1 and Occludin (green) distribution is shown in triton X-100 
treated or untreated cells. The cell nucleus is shown in grey and the scale 
bar represents 20µm. ***P = 0.001. 
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4 . 1.2 Tight junction protein localization in normal and 
diseased liver tissue.  
To optimise staining conditions for tight junction protein expression in the 
liver tissue, a serial dilution of antibodies specific for Claudin-1 and 
Occludin was performed. Final antibody working concentrations are listed 
in (Table 2-4). The staining pattern of Occludin and Claudin-1 in paraffin 
embedded specimens were compared to acetone fixed frozen tissues to 
ensure that formalin fixation and paraffin processing did not alter the 
expression pattern. Both proteins demonstrated comparable distribution in 
paraffin embedded and frozen sections (Figure 2-6).  
We utilized formalin fixed paraffin sections to investigate Occludin and 
Claudin-1 localization in normal liver tissue; sections were stained with 
antibodies specific for each protein. Hepatocytes and bile ducts express 
Occludin and Claudin-1; Occludin was only detected at the bile canalicular 
membrane of hepatocytes (Figure 4-3). In contrast, Claudin-1 staining was 
apparent at both the apical-canalicular and basolateral-sinusoidal 
membranes with the dominant expression pattern at the apical-canalicular 
membrane (Figure 4-3). These results demonstrate that hepatocytes of the 
liver express Occludin and Claudin-1 consistent with HCV tropism and 
previous reports (341).  
To investigate whether HCV infection perturb Occludin and Claudin-1 
localization in vivo, formalin fixed paraffin embedded specimens of human 
liver samples from normal, HCV infected, non-alcoholic steatohepatitis 
(NASH) and hepatitis B virus (HBV) infected donors with early and late 
stage liver disease, diagnosed according to the severity of fibrosis, where 
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early = no/mild fibrosis (Ishak stage <2) and late = cirrhosis were stained 
for tight junction proteins.  
Occludin demonstrated increased basolateral localization in all inflamed 
liver tissue samples, consistent with a reduction in apical canalicular 
expression compared to normal liver tissue (Figure 4-4 A and B). Similarly 
Claudin-1 demonstrated increased basolateral distribution consistent with a 
reduction in apical canalicular expression as the disease progress from 
early to late stage (Figure 4-5 A and B). A wide spread reorganization of 
Occludin and Claduin-1 was observed in all samples, independent of 
disease aetiology, suggesting an indirect inflammatory response that is not 
specific to the HCV infected liver. 
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Figure 4-3. Tight junction protein localization in normal liver tissue.  
Representative immunohistochemical staining (5 cases) of Occludin and 
Claudin-1 in normal liver tissue at x200 and 600 magnification. Arrows 
indicate Occludin and Claudin-1 expression on the bile canalicular (BC)) 
and basolateral membranes (BM) of hepatocytes, BD shows the expression 
of each protein on bile ducts.  
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Figure 4-4. Occludin localization in normal and diseased liver 
tissue.  
A. Representative immunohistochemical stains of Occludin localization in 
normal, early and late stage HCV infected liver (x200). Arrow indicates 
Occludin at bile canalicular (BC) or basolateral (BM) hepatocyte 
membranes. B. The canalicular and basolateral distribution of Occludin in 5 
cases of normal, HCV infected, NASH inflamed and HBV infected tissue 
were graded as follows: 0=<5%; 1=5-33%; 2=33-66% and  3=>66%. 
The basolateral distribution in all inflamed phenotypes was significantly 
higher compared to normal tissue. *P < 0.01, (Dunn’s test). 
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Figure 4-5. Claudin-1 localization in normal and diseased liver 
tissue.  
A. Representative immunohistochemical stains of Claudin-1 in normal, 
early and late stage HCV infected liver (x200). Arrow indicates Claudin-1 at 
bile canalicular (BC) or basolateral (BM) hepatocyte membranes. B. The 
canalicular and basolateral distribution of Claudin-1 in 5 cases of normal, 
HCV infected, NASH inflamed and HBV infected tissue were graded as 
follows: 0=<5%; 1=5-33%; 2=33-66% and  3=>66%. The basolateral 
distribution in all inflamed phenotypes was significantly higher compared to 
normal tissue. *P < 0.01, (Dunn’s test). 
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4 . 1.3 HCV glycoproteins modulate HepG2 polarity and tight 
junction integrity. 
HepG2 cells polarize overtime in culture and provide a model system to 
study the effects of HCV on hepatocellular polarization. Since HCV 
glycoproteins perturbed Occludin and Claudin-1 expression we wanted to 
investigate the potential consequences for cell polarization. HepG2 polarity 
can be quantified by enumerating the frequency of cells expressing apical 
MRP-2 positive bile canaliculi structures per 100 nuclei to give a polarity 
index (Figure 2-4 A). HepG2 cells form an increasing number of bile 
canaliculi overtime with approximately 39 bile canaliculi structures 
detected per 100 cells 5 days post seeding (Figure 4-6 A). Since a 
minimum of two cells is required to form a bile canaliculus, 39 bile 
canaliculi per 100 cells corresponds to at least 78% of cells demonstrating 
a polarized phenotype after 5 days in culture. We show that H77 and JFH-1 
glycoproteins significantly reduced HepG2 polarity compared to parental 
and VSV-G cells (Figure 4-6 A). Furthermore, both HCV glycoprotein 
strains reduced the ability of MRP-2 expressing bile canaliculi to retain 
fluorescent CMFDA dye, demonstrating an increased permeability and loss 
of tight junction integrity compared to parental and VSV-G expressing cells 
(Figure 4-6 B).  
To ascertain whether diverse HCV glycoproteins modulate polarity in a 
comparable manner to H77 and JFH-1 E1E2, cells were transfected with 
HCV strains Con-1 (genotype 1b), J6 (1a) and OH8 (1b). Diverse HCV 
gycoproteins significantly reduced polarity in a comparable manner to H77 
and JFH-1 glycoproteins (Figure 4-6 C). Wild type HepG2 cells do not 
express CD81 and the data presented thus far describes experiments 
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performed using HepG2 cells transduced to express CD81 (HepG2-CD81). 
To investigate whether HCV glycoproteins perturbed HepG2 polarity 
independent of CD81 expression, we studied the effects of HCV H77 and 
JFH-1 glycoproteins on polarity in wild type and HepG2-CD81 cells (Figure 
4-6 D). HCV glycoproteins significantly reduced polarity irrespective of 
CD81 expression. These data demonstrate that our observations of altered 
protein expression and impaired tight junction function are independent of 
HCV engagement of CD81. 
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Figure 4-6. HCV glycoproteins perturb HepG2 polarity and tight 
junction integrity.  
A. HepG2-CD81 cells were grown in culture for 1, 3 and 5 days and their 
polarity assessed by enumerating the number of MRP-2 positive bile 
canaliculi per 100 nuclei in 5 independent fields of view to achieve the 
polarity index. B. HepG2-CD81 cells were allowed to polarize for 5 days 
and tight junction (TJ) integrity quantified by determining the number of 
canalicular structures retaining CMFDA. C. HepG2-CD81 cells transfected 
with diverse HCV glycoproteins were grown for 5 days their polarity index 
quantified. D. Polarity index of wild type (HepG2) and HepG2-CD81 cells 
transfected with HCV E1E2 or VSV-G glycoproteins  ***P < 0.001 (t test).  
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4 . 1.4 HCV glycoproteins perturb tight junction formation and 
increase sensitivity to the permeating effects of cytokines.  
Tight junction formation and maintenance is calcium dependent and 
depletion of cellular calcium leads to a reversible loss of epithelial 
permeability allowing one to study the kinetics of tight junction formation. 
We monitored tight junction formation by enumerating CMFDA retention at 
the bile canaliculi in parental, HCV gycoprotein and VSV-G transfected cells 
overtime. Tight junction integrity in parental or VSV-G expressing cells was 
restored by 50% within 5.6h following calcium addition, with complete 
restoration observed by 10h (Figure 4-7 A). In contrast, HCV glycoprotein 
expressing cells demonstrated a significant delay in tight junction 
restoring, with a 50% recovery time of 8h (Figure 4-7 A).  
Cytokine-mediated changes in epithelial permeability cause a variety of 
inflammatory disorders (58). To investigate whether HCV glycoproteins 
modulate HepG2 sensitivity to the permeating effect(s) of cytokines, 
parental and viral glycoprotein expressing HepG2 cells were incubated with 
increasing concentrations of TNFα and IFNγ for 24h (Figure 4-7 B). HepG2 
cells expressing HCV glycoproteins demonstrated an increased sensitivity 
to TNFα compared to parental or VSV-G expressing cells, with significantly 
lower concentrations of TNFα required to break 50% of tight junctions in 
these cells (Figure 4-7 B). In contrast, HCV glycoprotein expressing cells 
demonstrated comparable sensitivity to IFNγ mediated effects on tight 
junction integrity to parental and VSV-G expressing cells. The mechanism 
underlying TNFα and IFNγ perturbation of hepatocellular permeability is 
unknown; however, studies with other epithelial and endothelial cell types 
suggest different mechanisms of action involving actin restructuring and 
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myosin light chain kinase activation, respectively (57). In summary, these 
data highlight a role for the viral glycoproteins in perturbing tight junction 
protein function that may result in an abnormal ‘leaky’ hepatic barrier in 
vivo. 
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Cell line INFγ (IC50) TNFα (IC50)
Parental 73 ± 6 71 ± 8
H77 E1E2 64 ± 4 34 ± 5*
JFH-1 E1E2 66 ± 7 36 ± 2*
VSV-G 70 ± 5 69 ± 3 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7. Tight junction dynamics in glycoprotein expressing 
cells.   
A. Tight junction (TJ) reformation in parental and glycoprotein expressing 
HepG2-CD81 cells. Polarized cells (5 days in culture) were depleted of 
calcium for 16h, media containing calcium was added and the cells 
monitored for their ability to retain CMFDA. T50% is the time required for 
50% of bile canalicular structures to re-form; which was 5.6h for 
parental/VSV-G cells and 8h for HCV glycoprotein expressing cells. B 
Polarized cells were treated with increasing concentrations of TNFα or IFNγ 
and tight junction permeability assessed by CMFDA retention. Table shows 
the concentration of TNFα and or IFNγ required to permeabilize 50% (IC50) 
of tight junctions in HepG2 cells expressing strain H77 and JFH-1 
glycoproteins compared to parental and VSV-G cells. *P < 0.05. 
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4 . 1.5 HCV glycoproteins perturb hepatocellular polarity via 
indirect mechanism(s).  
Benedicto and colleagues (30) showed that a direct association between 
HCV glycoproteins and Occludin perturbed Occludin localization at the 
plasma membrane in infected Huh-7 cells. To investigate whether there is 
a direct interaction between HCV glycoproteins and Occludin in our HepG2 
clones, we co-immunoprecipitated lysates from glycoprotein expressing or 
HCVcc J6/JFH-1 infected cells. Previous reports have shown a direct 
interaction between CD81 and HCV E2 glycoprotein (254), as such CD81-
E2 association was used as control. Our data showed a direct association 
between E2 and CD81 in HCV glycoprotein expressing and infected cells 
compared to parental and VSV-G cells. In contrast, we failed to detect an 
association between Occludin and E2 in glycoprotein expressing or infected 
cells, suggesting that HCV glycoproteins modulate hepatocellular polarity 
via indirect means (Figure 4-8).  
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Figure 4-8. HCV E2 glycoprotein does not interact with Occludin.  
Lysates from glycoprotein or HCVcc J6/JFH-1 infected cells were 
immunoprecipitated with anti-E2 monoclonal antibody (3/11) or an isotype 
matched control (IgG). Figure shows western blot analysis of 
immunoprecipitated lysates for E2, Occludin and CD81 protein using 
specific antibodies for each protein. Arrows indicate the specific band for 
each protein with molecular weight shown in kilo Daltons (kDa).    
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4 . 1.6 Mechanism(s) of HCV glycoprotein modulation of 
hepatocellular polarity.  
Recent studies have demonstrated that HCV infection induces an ER-stress 
response leading to mitochondrial dysfunction and the generation of 
reactive oxygen species (ROS) (280). ROS have been reported to stabilize 
HIF-1α (280) and activate PI3K, MAPK and NF-kB pathways that promote 
VEGF and TGFβ expression (224, 326). To ascertain whether HCV 
glycoproteins increase ROS expression; we studied parental, glycoprotein 
expressing and infected hepatoma cells for ROS expression by flow 
cytometry. Increased levels of ROS were observed in HCV glycoprotein 
expressing cells (Figure 4-9). HepG2 cells expressing VSV-G demonstrated 
increased ROS production although the levels were significantly less 
compared to cells expressing HCV glycoproteins (Figure 4-9). Importantly, 
these results were confirmed with HCVcc J6/JFH-1 infected Huh-7.5 cells. 
These findings suggest that HCV glycoproteins have the potential to 
modulate hepatocellular polarity through an oxidative stress pathway.   
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Figure 4-9. ROS production in HCV glycoprotein expressing cells.  
ROS production was determined using a cell-permeable fluorogenic probe 
(DCFH-DA), which diffuses into cells and is deacetylcated by cellular 
esterases into the non-fluorescent DCFH when ROS levels are low. In the 
presence of elevated ROS, DCFH is rapidly oxidized to highly fluorescent 
DCFH. Fluorescence levels were quantified by flow cytometry.  
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4 . 1.7 Stabilization of HIF-1α in HCV glycoprotein expressing 
cells.  
Since ROS expression is associated with HIF-1α stabilization; we 
investigated whether HCV glycoproteins stabilizes HIF-1α. HIF-1α is a 
transcription factor that regulates many genes including VEGF and TGFβ 
that are involved in tumour invasion and metastasis (264, 280). Parental 
and glycoprotein expressing cells plated at comparable seeding densities 
were stained for HIF-1α and media analysed for cytokine expression. HCV 
glycoproteins stabilize HIF-1α under normoxic conditions (Figure 4-10 A) 
and led to a significant increase in VEGF and TGFβ expression (Figure 4-10 
B). Individual neutralizing antibodies targeting VEGF or TGFβ partially 
restored tight junction integrity in glycoprotein expressing HepG2 cells, 
whereas neutralizing both cytokines gave a phenotype that was 
indistinguishable from parental HepG2 cells (Figure 4-10 C).  
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Figure 4-10. Stabilization of HIF-1α in HCV glycoprotein expressing 
cells.  
A. HCV glycoproteins and VSV-G stabilize HIF-1α: nuclear HIF-1α was 
visualized with anti-HIF-1α mAb (green) and confocal microscopy; scale 
bar represents 20µm. B. Media was harvested from parental and 
glycoprotein expressing cells and screened for VEGF and TGF-β expression, 
where the data shows cytokine production per 4x104 cells over a 24h time 
period. C. Cells were allowed to polarize over 5 days and treated with anti-
VEGF (1.5µg/ml) or anti-TGF-β (1.5µg/ml) neutralizing antibodies for 24h 
and tight junction integrity enumerated. *P < 0.05, **P < 0.01, ***P < 
0.001 (t test). 
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Since VEGF and TGFβ are regulated by HIF-1α (264, 280), we evaluated 
the effects of HIF-1α inhibitor NSC-134754 (NSC) on polarity and tight 
junction integrity. NSC was identified as a novel compound that inhibits 
hypoxia or growth factor induction of HIF-1α (67). Different concentrations 
of NSC were studied to ascertain its effect on cell growth and HIF-1α 
expression, at 1µM concentration NSC inhibited HIF-1α and had minimal 
effects on cell growth (67).  
We demonstrate HIF-1α stabilization in HepG2-CD81 cells propagated 
under hypoxic conditions (1% O2). Importantly, 1µM NSC treatment 
reduced HIF-1α expression (Figure 4-11 A) and restored polarity and tight 
junction integrity in HCV glycoprotein expressing cells (Figure 4-11 B), 
suggesting that HCV glycoproteins modulate HepG2 polarity indirectly via a 
HIF-1α driven VEGF and TGFß-dependent pathway.  
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Figure 4-11. The effects of HIF-1α on HepG2 polarity.  
A. Confocal images of HIF-1α expression (green) in control or NSC (1µM) 
treated HepG2-CD81 cells grown under hypoxic (1% O2) or normoxic 
conditions (20% O2), scale bar represents 20µm. B. Cells were treated 
with HIF-1α inhibitor NSC (1µM) for 24h and the polarity index and tight 
junction integrity quantified. ***P < 0.001 (t test).  
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4.1.8 HCVcc infection stabilizes HIF-1α and perturbs Occludin 
localization. 
Thus far, the majority of our observations have been based on regulated 
viral protein expression. To confirm our findings in the context of HCV 
infection, we used HCVcc strain J6/JFH to infect HepG2-CD81 cells and 
assessed the effects of virus infection on tight junction localization and 
HIF-1α stabilization. We confirmed that HCVcc infection stabilized HIF-1α 
and induced a relocalization of Occludin to the basolateral membrane, 
consistent with reduced polarity and tight junction integrity (Figure 4-12 A 
and B). Furthermore, infection of Huh-7.5, HepG2-CD81 and PHHs 
increased VEGF and TGF-β expression (Figure 4-12 C). We also observed 
hepatocellular HIF-1α expression in chronic HCV infected liver tissue 
(Figure 4-13), demonstrating a focal nuclear staining pattern that was 
consistent with the staining pattern seen in HCC liver tissue. This staining 
pattern was not observed in normal or primary billiary cirrhosis (PBC) liver 
samples suggesting that HIF-1α is stabilized during HCV infection in vivo. 
In summary, we found that HCV infection stabilized HIF-1α leading to 
altered tight junction protein localization. 
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Figure 4-12. HCVcc infection stabilizes HIF-1α.  
A. HCVcc J6/JFH infection (viral NS5A antigen is shown in red) of HepG2-
CD81 cells stabilized HIF-1α (green) and perturbed Occludin (turquoise) 
localization, scale bar depicts 20µm. B. Polarity and tight junction integrity 
(TJ) in infected HepG2-CD81 cells; the data is presented relative to 
uninfected (mock) cells. C. VEGF and TGFβ expression in mock and HCVcc 
J6/JFH-1 infected Huh-7.5, HepG2-CD81 and PHHs, where the HCV RNA 
burdens were 2.4 x 106, 3.8 x 105 and 4.1 x 105 HCV RNA copies/104 cells, 
respectively. *P < 0.05, **P < 0.01, ***P < 0.001 (t test). 
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Figure 4-13. HIF-1α expression in normal and diseased liver tissue.  
Immunohistochemical staining of HIF-1α in normal, primary billary 
cirrhosis (PBC), hepatocellular carcinoma (HCC) and HCV infected liver 
samples, where the arrow head indicates nuclear HIF-1α localization. 
Images are representative of 5 independent cases from each disease 
category.  
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4 . 1.9 Increased migration and de-differentiation in HCV 
glycoprotein expressing cells. 
Our observation that HCV promotes TGFβ expression, a growth factor 
linked to aggressive tumors (265), led us to assess the effect(s) of 
infection and viral glycoprotein expression on hepatoma migration. HCV 
glycoprotein expressing HepG2 clones showed a significantly increased 
migratory capacity compared to parental or VSV-G expressing cells. 
Furthermore, expression of the cell adhesion molecule, E-Cadherin, was 
reduced (Figure 4-14 A and B), consistent with a mesenchymal phenotype. 
To ascertain whether the viral glycoproteins promote a de-differentiation 
process reminiscent of epithelial to mesenchymal transition (EMT) which is 
associated with increase migration (248, 398, 432), we investigated the 
expression of EMT associated transcription factors, Snail and Twist (303). 
Both viral glycoproteins promoted Snail and Twist expression (Figure 4-14 
B). Importantly, neutralizing TGFβ or treating cells with HIF-1α inhibitor 
NSC reduced the migration of HCV glycoprotein expressing cells to levels 
seen with parental and VSV-G expressing cells (Figure 4-14 C). In 
contrast, neutralizing VEGF had no detectable effect on hepatoma 
migration (Figure 4-14 C), consistent with experiments showing that 
exogenous TGFβ promotes HepG2 migration and VEGF had no detectable 
effect (Figure 4-14 D).  
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Figure 4-14. HCV glycoprotein promotes HepG2 migration and de-
differentiation.  
A. Increased migration of HCV glycoprotein expressing HepG2 cells; where 
migration was determined over a 24h period in a scratch-wound assay. 
Data is presented as percentage migration. B. Western blot detection of E-
cadherin and EMT transcription factors Snail and Twist. C. The effect of 
anti-VEGF (1.5µg/ml), anti-TGF-β (1.5µg/ml) neutralizing antibodies and 
HIF-1α inhibitor NSC (1µM) on HepG2 migration. Cells were treated with 
the respective compounds for 24h and the difference in migration 
calculated using a scratch wound assay. D. The effect of recombinant VEGF 
and TGFβ on HepG2 migration, parental HepG2 cells were treated with the 
respective compounds for 24 hours and their migration assessed via a 
scratch wound assay. **P < 0.01, ***P < 0.001 (t test).   
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4 . 1.10 HCV infection promotes hepatoma migration and 
differentiation.  
To confirm our observations of increased migration and expression of EMT 
transcription factors with full-length infectious virus, we assessed the 
effect(s) of HCVcc infection on hepatoma migration using two model 
systems: a scratch wound assay that measures cell migration within the 
context of a monolayer and a collagen invasion assay that quantifies 
hepatoma migration through an extracellular matrix. Infection significantly 
increased HepG2-CD81 and Huh-7.5 migration in both assays (Figure 4-15 
A and B) and promoted Snail and Twist expression in hepatoma and PHHs 
(Figure 4-15 C). Furthermore, inhibiting HIF-1α restored the migratory 
capacity of infected hepatoma cells and ablated nuclear Snail and Twist 
expression (Figure 4-15 A-D), demonstrating a HIF-1α dependent process.  
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Figure 4-15. Increased migration and expression of EMT 
transcription factors in HCVcc infected cells.  
HepG2-CD81 (A) and Huh-7.5 cells (B) were infected with HCVcc J6/JFH-1 
and their migratory capacity assessed after 48h in a scratch wound and 
collagen invasion assay respectively, in the presence or absence of NSC 
(1µM). Data is presented relative to control untreated cells. HepG2-CD81 
cells are less permissive for HCVcc infection compared to Huh-7.5 cells and 
the mean level of NS5A positive infected cells per well was 1.7 x 103   and 9 
x 104, respectively. C. Western blot detection of Snail and Twist in mock 
and HCV infected hepatoma and primary human hepatocytes (PHHs) D. 
NSC treatment (1µM) ablated Snail and Twist expression. The infected 
PHHs contained 4.1 x 105 HCV RNA copies/104 cells. **P < 0.01.  
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HIF-1α regulates EMT transcription factors through direct and indirect 
mechanisms (reviewed in (303, 359). Directly, HIF-1α binds to the hypoxic 
responsive element in EMT transcription genes to initiate expression. 
Indirectly, HIF-1α may upregulate additional target genes which in turn 
activate EMT signalling. Oft et al (289), showed that exogenous TGFβ 
triggers EMT in cancer cells, confirming that HIF-1α driven indirect signals 
from the micro-environment can activate this pathway. To investigate 
whether HIF-1α directly or indirectly promote Snail and Twist expression; 
Huh-7.5 cells were infected with HCVcc at a low multiplicity of infection 
(0.01) to achieve distinct populations of infected and uninfected cells. We 
then assessed the distribution of HIF-1α, Snail and Twist in the culture. 
HIF-1α was only detected in cells expressing the HCV antigen NS5A (Figure 
4-16 A), consistent with the focal HIF-1α staining observed in HCV infected 
liver tissue which may indicate regions of viral antigen expression in vivo 
(Figure 4-16 B). In contrast, the majority of cells in the infected population 
expressed Snail and Twist, independent of viral antigen expression, 
suggesting a bystander effect that may be mediated by HIF-1α 
upregulation of TGFβ (Figure 4-16 A).  We studied the effects of 
neutralizing TGFβ and VEGF antibodies on Snail and Twist expression in the 
infected population. Neutralization of VEGF had no effect on Snail and 
Twist expression. In contrast, anti-TGFβ ablated the nuclear expression of 
both transcription factors to confirm a HIF-1α targeting of TGFβ effect 
(Figure 4-17).  
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Figure 4-16. HIF-1α, Snail and Twist distribution in HCV infected 
cells.  
A. Huh-7.5 cells were infected with HCVcc J6/JFH-1 at a low multiplicity of 
infection (0.01) for 48h to study HIF-1α, Snail, Twist and viral antigen 
NS5A expression. Cells were fixed and co-stained for NS5A (red), HIF-1α, 
Snail and Twist (green), and nuclei counterstained with DAPI (grey); scale 
bar represents 20µm. B. HIF-1α localization in HCV infected liver tissue. 
Representative image of HIF-1α distribution in a HCV cirrhotic nodule, 
arrow heads indicate the nuclear localization of HIF-1α. Box shows a 
magnified area from the image.  
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Figure 4-17. The effects of TGFβ on Snail and Twist expression.  
Huh-7.5 cells were infected with HCVcc J6/JFH-1 at a low multiplicity of 
infection (0.01) for 48h in the presence or absence anti-VEGF (1.5µg/ml) 
and anti-TGFβ (1.5µg/ml). Cells were fixed and co-stained for the viral 
antigen NS5A (red), Snail and Twist (green), and nuclei counterstained 
with DAPI (grey); scale bar represents 20µm.  
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4 . 1.11 A role for HIF-1α in the HCV lifecycle.  
Our observation that HCV stabilized HIF-1α, suggest that HCV induces a 
cellular state of low oxygen which affects cellular metabolic pathways. 
Indeed previous reports have shown cellular reprogramming induced by 
HCV including, perturbation of glycolysis and the pentose phosphate 
pathway which favours biosynthetic activities to support virus replication 
(90). We investigated the effects of hypoxia on HCV replication, hypoxia 
significantly increased HCVcc infection of Huh-7.5 and HepG2-CD81 cells 
and treatment of infected cultures with NSC reduced viral infection (Figure 
4-18 A and B). We confirmed these findings using primary human 
hepatocytes as treatment of infected hepatoma and PHHs with NSC 
significantly reduced HCV genomic RNA burden (Figure 4-18 C), 
demonstrating a positive regulatory role for this transcription factor in HCV 
infection. To ascertain whether HIF-1α regulates HCV infection at the level 
of entry, we investigated the effect of hypoxia on HCVpp entry into Huh-
7.5, HepG2-CD81 and PHHs. As control we studied VSV-Gpp entry. 
Hypoxia had minimal effects on H77 and VSV-Gpp infection; moreover, 
HIF-1α inhibitor NSC had no effect confirming a positive regulatory role for 
HIF-1α during HCV replication (Figure 4-19 A and B). Taken together, 
these data provide a new paradigm for HCV to modulate HIF-1α dependent 
pathways that promote HCV replication and underlie virus induced HCC 
growth.  
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Figure 4-18. The effects of HIF-1α on HCVcc replication.   
A. The effect of hypoxia on HCV infection of hepatoma cells; cells were 
infected with HCVcc J6/JFH-1 virus under hypoxic (1% O2) or normoxic 
(20% O2) conditions and infection determined 48h later by enumerating 
NS5A antigen expressing cells, data is presented relative to normoxic 
conditions. B. Treatment of infected cells with HIF-1α inhibitor NSC (1µM) 
reduced viral infection; data is presented relative to untreated (control) 
cells. C. HCV replication in Huh-7.5 cells and PHHs in the presence or 
absence of HIF-1α inhibitor NSC (1µM). Data is presented as HCV copy 
numbers relative to the housekeeping gene GAPDH.*P < 0.05, **P < 0.01 
(t-test).  
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Figure 4-19. The effects of HIF-1α on HCVpp entry.   
A. The effect of hypoxia on HCVpp entry; PHHs and hepatoma cells were 
infected with H77pp under hypoxic (1% O2) or normoxic (20% O2) 
conditions in the presence or absence of HIF-1α inhibitor NSC (1µM) and 
luciferase activity, shown as relative light units (RLU) was measured 72 
hours later. Data is presented relative to normoxic conditions or control 
untreated cells. B. The effects of hypoxia on VSV-Gpp entry; data is 
presented relative to normoxic conditions or control untreated cells. H77pp 
infectivity values were 1 x 106, 7 x104 and 6 x104 for Huh-7.5, PHHs and 
HepG2-CD81 respectively. VSV-Gpp infection values were 2 x107 for Huh-
7.5 and PHHs and 7 x 105 for HepG2-CD81 cells.  
N
o
rm
o
x
ia
H
y
p
o
x
ia
N
o
rm
o
x
ia
H
y
p
o
x
ia
N
o
rm
o
x
ia
H
y
p
o
x
ia
0
20
40
60
80
100
120
H
e
p
G
2
-C
D
8
1
H
u
h
 7
.5
P
H
H
H77pp
R
e
la
ti
v
e
 H
C
V
 e
n
tr
y
 (
R
L
U
)
C
o
n
tr
o
l
N
S
C
C
o
n
tr
o
l
N
S
C
C
o
n
tr
o
l
N
S
C
0
20
40
60
80
100
120
H
e
p
G
2
-C
D
8
1
H
u
h
 7
.5
P
H
H
H77pp
R
e
la
ti
v
e
 H
C
V
 e
n
tr
y
 (
R
L
U
)
N
o
rm
o
x
ia
H
y
p
o
x
ia
N
o
rm
o
x
ia
H
y
p
o
x
ia
N
o
rm
o
x
ia
H
y
p
o
x
ia
0
20
40
60
80
100
120
H
e
p
G
2
-C
D
8
1
H
u
h
 7
.5
P
H
H
VSV-Gpp
R
e
la
ti
v
e
 V
S
V
-G
 e
n
tr
y
 (
R
L
U
)
C
o
n
tr
o
l
N
S
C
C
o
n
tr
o
l
N
S
C
C
o
n
tr
o
l
N
S
C
0
20
40
60
80
100
120
H
e
p
G
2
-C
D
8
1
H
u
h
 7
.5
P
H
H
VSV-Gpp
R
e
la
ti
v
e
 V
S
V
-G
 e
n
tr
y
 (
R
L
U
)
A. 
B. 
173 
 
4.2 Discussion 
Our studies show that HCV infection and the viral encoded glycoproteins 
reduce hepatoma polarity and increase cell migration by stabilizing HIF-1α 
expression and upregulating downstream effectors, VEGF and TGFβ. 
Neutralization of both growth factors or inhibition of HIF-1α restored the 
polarity and reduced the migratory capacity of infected cells. Furthermore, 
inhibiting HIF-1α significantly reduced HCV replication in both hepatoma 
cell lines and primary hepatocytes, highlighting a dual role for this 
transcription factor in hepatoma migration and the viral lifecycle.  
HIF-1α expression has been reported to associate with EMT, a reversible 
developmental process where epithelial cells reduce intercellular adhesion 
and acquire fibroblastoid properties that promote an invasive and 
metastatic phenotype (398, 406). EMT is reported to play a major role in 
the invasive and metastatic potential of human cancers (73, 152). EMT 
transcription factors Snail and Twist are expressed in 40-70% of HCCs and 
correlate with evidence for adherens junction disruption and worse 
prognosis (387, 432). Similarly, ectopic expression of Snail or Twist in 
hepatoma cell lines with low endogenous expression enhances cell motility 
and invasiveness (248, 432). Yang and co-authors reported that increased 
Twist expression was more frequently observed in HCC associated with 
HCV infection than with other liver diseases (432). The poor prognosis of 
HCC is largely due to the invasive nature of the tumour, with frequent 
intrahepatic and extrahepatic metastases (231). Therapeutic options for 
patients with HCC are limited. Curative approaches, including surgical 
resection and liver transplantation are attempted in approximately 30% of 
patients, and even in these cases the rate of cancer recurrence is in the 
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order of 60-70% within 5 years (230). Our findings provide a potential 
explanation for the clinical observation that HCV associated HCC is 
frequently more aggressive (174). Our data showing that HCV glycoprotein 
expression and infection promotes Snail and Twist expression highlights a 
potential mechanism for HCV to accelerate the malignant process.  
HCV infection is one of the leading indications for liver transplantation and 
the number of patients requiring transplantation for chronic hepatitis C is 
increasing. HCV infects the newly transplanted liver in all cases, leading to 
a more rapidly progressive disease and frequent graft loss (332). 
Recurrent HCV is recognised as one of the major challenges facing liver 
transplantation in the next decade (350). Currently available antiviral 
treatments are poorly tolerated and have limited efficacy in patients after 
transplant and novel therapies are urgently required. Injury to the liver at 
the time of transplantation (i.e. ischaemia reperfusion injury, IRI) has been 
associated with more aggressive recurrent HCV disease (252); however, 
the factors governing viral replication rate(s) in the newly transplanted 
liver are poorly understood. Our demonstration that hypoxia, a key event 
during hepatic IRI, increases virus replication provides a potential 
explanation for these clinical observations and highlights the potential 
value of short term anti-oxidant or HIF-1α inhibitor treatment at the time 
of liver transplantation to limit HCV replication.  
Recent reports demonstrate that HCV promotes TGFβ expression by 
inducing reactive oxygen species and activating p38MAPK, JNK, ERK and 
NF-κB pathways (224, 326), consistent with reports of increased TGFβ 
levels in HCV infected patients (36). TGFβ promotes EMT and is thought to 
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play a major role in the dissemination of malignant hepatocytes during 
HCC progression (129, 139). Our current data showing a role for TGFβ in 
the increased migratory capacity of HCV infected hepatoma cells support a 
role for HCV in promoting tumour spread rather than a direct role in the 
oncogenic process per se. We failed to observe any morphological 
fibroblast features of infected or HCV glycoprotein expressing hepatoma 
cells, suggesting a partial de-differentiation process in vitro. Mazocca et al. 
recently reported that inhibition of TGFβ receptor I kinase blocked HCC 
growth, supporting a rationale for therapeutic targeting of TGFβ signalling 
in HCC (250). 
Our observation that VEGF and TGFβ perturb tight junction function 
supports our in vivo observations demonstrating a widespread 
reorganization of Occludin in diseased human liver. In contrast, Benedicto 
and colleagues reported that HCV glycoproteins directly associate with 
Occludin and alter protein trafficking in Huh-7 cells (30). We failed to co-
immunoprecipitate Occludin with the HCV glycoproteins in a variety of cell 
lines transduced to express HCV E1E2 or in HCV infected cells, in 
agreement with a recent report (270). Importantly, VEGF or TGFβ had no 
detectable effect on the expression or localization of Occludin in Huh-7 
cells, suggesting that these cells are refractory to these cytokines (258). 
In summary, we have shown that HIF-1α is involved in stimulating VEGF 
and TGFβ that alter hepatocyte behaviour and promote malignancy in the 
HCV infected microenvironment. We have also demonstrated a role for 
HIF-1α in HCV infection. These findings highlight a potential role of HIF-1α 
inhibitors as therapeutics in patients with both HCC and HCV infection. 
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5. RESULTS  
5.1 The effects of glucocorticoids on HCV infection and 
hepatocellular      biology. 
HCV infects the newly transplanted liver in all cases, leading to rapid and 
progressive disease culminating in frequent graft loss. There is a significant 
reduction in peripheral HCV RNA levels in the first 24 hours following liver 
transplantation followed by a rapid increase in viral load due to infection of 
the new graft (65, 263, 416). This exacerbated infection is likely to 
contribute to rapid liver failure that compromises patient and graft 
survival. The underlying mechanisms for the more aggressive nature of 
HCV infection and deterioration of the new graft are unclear; however, 
several factors including donor age and HCV genotype have been 
implicated with the progressive nature of the virus post liver 
transplantation (110, 164). Several studies have called into question the 
use of glucocorticoid immunosuppressive drugs for HCV infected patients 
undergoing liver transplantation. High doses and repeat usage of 
glucocorticoids such as prednisolone, cyclosporin A and hydrocortisone 
have been linked to increased fibrosis and poor long-term graft survival 
(33, 134). More recently, Ciesek and colleagues reported that 
glucocorticoid treatment of hepatoma cells increased HCV replication (76). 
Despite these observations, steroids continue to be used in the liver 
transplant, largely since the mechanism(s) of steroid associated 
exacerbation of HCV infection are unknown. In this chapter, we shed light 
on the potential mechanism(s) of glucocorticoid enhanced HCV infection 
and the consequences for hepatocyte biology.  
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5.1.1 Prednisolone increases HCVpp entry into hepatoma and 
primary human hepatocytes. 
We evaluated the effects of prednisolone on HCVpp entry into hepatoma 
and PHHs. Cells were treated overnight with increasing concentrations of 
prednisolone and infected the following day with H77pp. We also evaluated 
the effects of prednisolone on cell viability using an MTT assay (Figure 5-1 
A). Prednisolone increased H77pp entry into Huh-7.5 and PHHs in a dose 
dependent manner whilst having minimal effect on cell viability. The dose 
dependent response plateau at 100nm in both cell types suggesting a 
threshold for prednisolone mediated boost in H77pp entry. Prednisolone 
enhanced H77pp entry 3- and 4.5- folds in PHHs and Huh-7.5 cells 
respectively, and had no effect on VSV-Gpp entry (Figure 5-1 B and C). To 
confirm prednisolone mediated boost in H77pp entry, cells were treated 
with Mifepristone (RU-486) a glucocorticoid receptor (GR) antagonist that 
binds the receptor with  high affinity (238). RU-486 had no effect on virus 
entry and ablated the enhancing effects of prednisolone (Figure 5-1 B), 
demonstrating a role for glucocorticoid signalling in HCV entry.  
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Figure 5-1. Prednisolone increases HCVpp infection of primary 
human hepatocytes and Huh-7.5 cells.  
A. The effect of prednisolone on HCVpp entry and cell viability. PHHs were 
infected after 2 days in culture and Huh-7.5 cells after 1 day. Cells were 
treated with increasing concentrations of prednisolone overnight followed 
by infection with H77pp or the measurement of cell viability using an MTT 
assay. Infected cells were lysed after 72 hours and luciferase activity 
measured. Data is plotted relative to control untreated cells and presented 
as relative light units (RLU). B-C. Cells were treated overnight with 
prednisolone (100nM) or RU-486 (5µg/ml) and infected with H77 or VSV-
Gpp. Infected cells were lysed after 72 hours and luciferase activity 
measured. Data is presented as virus infectivity relative to control 
untreated cells. H77pp infection of PHH was 7.0 x 104 and 2.4 x 105 RLUs 
in control and prednisolone treated cells respectively. For Huh-7.5 cells 
H77pp infection was 1.2 x 106 and 5.7 x 106 respectively. VSV-Gpp 
infection of both cell types was 2.3 x 107  RLUs and prednisolone treatment 
had no effect. *** P <0.001 (t test).  
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5 . 1.2 Prednisolone increases HCVcc replication.  
There are conflicting reports regarding the effects of prednisolone on 
distinct phases of the virus lifecycle. For example a study by Ciesek et al 
reported that prednisolone enhanced HCV entry and reduced replication 
(76). In contrast, Henry and colleagues reported increased HCV replication 
as a result of prednisolone treatment (164). The discrepancies between 
these two studies could be the result of differences in Huh-7 clones and 
viral strains used; we aimed to expand on these studies by confirming our 
findings in PHHs. We studied the effects of prednisolone on HCV strain 
J6/JFH-1 replication in PHHs and Huh-7.5 cells. Prednisolone significantly 
increased HCVcc RNA levels in both cell types (Figure 5-2 A). To confirm a 
positive role for prednisolone in the viral replication cycle we studied the 
effect of prednisolone on HCV replicon RNA levels; which are  genetic 
elements that replicate autonomously (20) and allow the study of genome 
replication without particle assembly. Cells expressing full length HCV JFH-
1 and subgenomic (comprising the non-structural proteins NS3-NS5) 
replicons were treated overnight with prednisolone/RU-486 and HCV RNA 
levels measured by qRT-PCR. Prednisolone increased the levels of HCV 
RNA in both cell types (Figure 5–2 B), demonstrating that prednisolone 
acts on the entry and replication phases of the virus life cycle.  
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Figure 5-2. Prednisolone enhances HCVcc replication.  
A. HCVcc replication in PHHs and Huh-7.5 cells. Cells were treated 
overnight with prednisolone (100nM), RU-486 (5µg/ml) or a combination 
of both compounds and infected with J6/JFH-1. Infection was analysed 72 
hours later by qRT-PCR. Data represents HCV genomic burden relative to 
control untreated cells. PHHs contained 3.7 x 105 HCV RNA copies/104 cells 
and prednisolone treatment increased HCV RNA copy number to 7.1 x 105 
RNA copies/104 cells. Huh-7.5 cells contained 1.6 x 106 and 4 x 106 HCV 
RNA copies in control and prednisolone treated cells respectively. B. Huh-7 
cells expressing full length (JFH-1FL) or sub-genomic (JFH-1SGR) HCV 
replicons were treated with prednisolone or RU-486 overnight. Data 
represents HCV RNA levels relative to control untreated cells, where the 
RNA copy numbers for JFH-1FL were 5.4 x 10
5 and 1.3 x 106 in control and 
prednisolone treated cells respectively. JFH-1SGR cells contained 3.9 x 10
5 
and 1.4 x 106 RNA copies in control and prednisolone treated cells 
respectively. ***P < 0.001 (t test).  
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5 . 1.3 The effect of prednisolone on cell-cell HCV 
transmission.  
HCVcc infection can be quantified by staining for the viral expressed 
antigen NS5A that is distributed focally in an infected culture (225). We 
noted an increase in focal size in prednisolone treated cells infected with 
J6/JFH-1 and even though this phenotype was apparent in untreated cells 
it was more defined in treated cells (Figure 5–3 A). Larger focus sizes are 
generally indicative of enhanced cell-cell transmission or secondary 
infection of neighbouring cells.  We quantified the differences in focus size 
by enumerating the number of infected cells per focus in treated and 
untreated cells. Focus size were classified as small (1-2 cells/focus); 
medium (3-15); large (16-40) and very large (41-100) (Figure 5-3 B). 
Prednisolone increased the frequency of large and very large foci; whereas 
RU-486 had no effect of the number of infected cells within each foci.  
Treatment of cells with both compounds reduced the frequency of large 
and very large foci to comparable levels seen in untreated cells, confirming 
a GR dependent effect (Figure 5–3 B). In prednisolone treated cells around 
75% of infected cells resided in large or very large foci compared to 25% 
in untreated cells, suggesting increased cell-cell transmission.  
We and others have reported that HCV can initiate infection by cell-free 
particle release and direct cell-cell contact dependent route of transmission 
(50, 401, 422). To examine whether prednisolone can increase cell-cell 
transmission, naive Huh-7.5 cells were pre-treated with prednisolone 
overnight followed by co-culture with J6/JFH-1 infected Huh-7.5 cells, 48 
hours later cell-cell transmission from infected to naive cells was measured 
by flow cytometry quantification of NS5A antigen expressing cells. 
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Prednisolone enhanced HCV cell-cell transmission (Figure 5–3 C), 
consistent with our observation of increased focus size (Figure 5–3 B). RU-
486 alone had no effect on virus transmission and ablated the effects of 
prednisolone (Figure 5-3 C). These data show that prednisolone may 
potentiate cell-cell HCV transmission; however, further studies are 
required to ascertain this as the efflux of CMFDA from the cells may be 
altered by prednisolone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
183 
 
Control Prednisolone
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3. Evidence of HCV cell-cell transmission in prednisolone 
treated cells.  
A. Huh-7.5 cells treated overnight with prednisolone (100nM) and infected 
with J6/JFH-1 for 48 hours. Images show foci formation in infected cells. 
Foci were detected by staining for HCV NS5A protein (green). Scale bar 
represents 20µm. B. Focus size was distributed across 4 categories 
according to the number of infected cells/focus (1-2, 3-15, 16-40 and 41-
100). The % total of infected cells that is present within category is shown. 
75% of infected cells resided in large or very large foci in prednisolone 
treated cells compared to 25% for RU-486 or control cells. C. Prednisolone 
enhances HCV cell-cell transmission; Huh-7.5 naive target cells were 
treated with prednisolone overnight and co-cultured in a 1:1 ratio with 
J6/JFH-1 infected producer cells labelled with CMFDA (80% of producer 
cells expressed NS5A). 48 hours later virus transmission from producer to 
target cells was measured using a flow cytometry based assay. Data 
represents 2 independent experiments. ***P = <0.001. 
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5 . 1.4 Prednisolone increases SR-BI and Occludin expression.  
We previously reported that SR-BI over expression in hepatoma cells 
promoted HCV foci size (146) and enhanced cell-cell HCV transmission 
(50). This finding suggests that an increase in HCV receptor expression 
levels promotes HCV transmission. Our observation that prednisolone 
increased cell-cell transmission is reminiscent of the enhanced HCV 
transmission observed in cells transduced to over-express SR-BI reported 
by Grove et al (146), we therefore investigated the effects of prednisolone 
on HCV receptor expression levels. Western blot analysis demonstrated 
increased SR-BI and Occludin expression in PHHs and Huh-7.5 cells treated 
with prednisolone; in contrast CD81 and Claudin-1 expression levels were 
unaffected (Figure 5-4 A). In addition, flow cytometric staining showed 
increased SR-BI cell surface expression (Figure 5-4 B); unfortunately, due 
to the lack of antibodies recognising extracellular epitopes of Occludin we 
were unable to confirm its expression at the cell surface by flow cytometry. 
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Figure 5-4. Prednisolone upregulates SR-BI and Occludin 
expression.  
A. Western blot detection of HCV receptors in control and prednisolone 
(100nM overnight) treated PHHs and Huh-7.5 cells. B. Flow cytometric 
analysis of HCV receptor expression at the cell surface in control and 
prednisolone treated PHHs and Huh-7.5 cells. We do not have antibodies to 
detect Occludin at the cell surface and were unable to confirm its 
upregulation by flow cytometry. Data is presented as mean fluorescent 
intensity (MFI) from which an isotype specific control value was subtracted. 
***P = <0.001. 
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5 . 1.5 Prednisolone enhanced HCV infection is SR-BI 
dependent. 
We investigated whether prednisolone mediated increase in HCV infection 
is dependent on up-regulation of host factors SR-BI and Occludin. Firstly, 
we investigated the role of SR-BI using an anti-SR-BI neutralizing antibody 
and a small molecule inhibitor of SR-BI (ITX 5061) (389). ITX 5061 is a 
clinical stage small molecule compound that promotes HDL levels in 
animals and patients by targeting the SR-BI pathway. Recently ITX 5061 
has entered clinical trials for its efficacy to inhibit HCV infection of the graft 
in patients undergoing liver transplantation. In vitro ITX 5061 is thought to 
inhibit HCV entry by blocking virus engagement of SR-BI. Prednisolone 
treated cells were infected with H77 or control VSV-Gpp and the effects of 
anti-SR-BI and ITX 5061 on virus infection evaluated. Both compounds 
reduced H77pp infection by almost 95% whereas VSV-Gpp infectivity was 
unaffected (Figure 5-5 A). Furthermore, we evaluated both compounds for 
their ability to reduce HCVcc infection of prednisolone treated cells and 
found similar results (Figure 5 -5 B).  
We do not have neutralizing agents to study the role of Occludin in HCV 
infection; therefore to study HCV dependency on Occludin expression 
levels we transduced Huh-7.5 cells with GFP tagged Occludin via a TRIP 
lentivirus vector. Lentiviral transduction increased Occludin expression to 
comparable levels seen following prednisolone treatment (Figure 5-6 A). 
Confocal microscopy assessment of Occludin localization in transduced 
cells, showed increased staining at the plasma membrane with some 
evidence of intracellular staining, consistent with the pattern seen in 
prednisolone treated cells (Figure 5-6 B). HCVpp and HCVcc infection of 
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Huh-7.5 cells was unaffected by increased Occludin expression (Figure 5-6 
C). In summary, we show that Occludin over expression does not affect 
HCVpp entry, indicating that the prednisolone mediated boost is SR-BI 
dependent.   
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Figure 5-5. Prednisolone enhanced HCV entry is SR-BI dependent.  
A. PHHs and Huh-7.5 cells treated with prednisolone (100nm overnight) 
were infected with H77 or VSV-Gpp in the presence of SR-BI inhibitors ITX 
5061 (5µM) and anti SR-BI (5µg/ml). Virus infection is presented relative 
to control cells where the specific infectivity of H77pp was 2 x 105 and 1.6 
x 106 relative light units (RLU) in PHHs and Huh-7.5 cells respectively. 
VSV-Gpp infection was 2.5 x 107 and 2.7 x 107 RLUs respectively for PHHs 
and Huh-7.5 cells. B. PHHs and Huh-7.5 cells treated with prednisolone 
were infected with HCVcc J6/JFH-1 in the presence of HCV entry inhibitors 
anti SR-BI and ITX 5061. Data represent HCV genomic copies and is 
presented relative to control cells. PHHs and Huh-7.5 cells contained 6.7 x 
105 and 3.6 x 106 RNA copies/104 cells respectively. ***P = <0.001 (t 
test). 
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Figure 5-6. The role of Occludin in prednisolone enhanced HCV 
infection.  
A. Flow cytometric detection of Occludin in parental, TRIP and prednisolone 
treated Huh-7.5 cells. Data represents total Occludin expression in 
permeabilized cells. Tables show the mean fluorescent intensity (MFI) of 
Occludin and an isotype specific (IgG) control stain. B. Confocal images of 
Occludin (green) localization in Huh-7.5 cells, DAPI staining of the nucleus 
is shown in blue and the scale bar represents 20µm. C. HCV and VSV-Gpp 
infection of Huh-7.5 cells over expressing Occludin. Data is presented 
relative to parental Huh-7.5 cells. H77 and VSV-Gpp infection of cells was 
1.0 x 106 and 2.3 x 107 relative light units (RLUs), respectively. HCVcc 
J6/JFH-1 infected cells contained 1.6 x 106 HCV RNA copies/104 cells.    
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5 . 1.6 The effects of prednisolone on pseudoparticles bearing 
diverse HCV glycoproteins.  
We hypothesize that if SR-BI is the major receptor promoting HCV entry, 
then viruses with reduced sensitivity to prednisolone may infect 
independently of SR-BI. To this end, we measured the effect(s) of 
prednisolone on a range of HCVpp strains to infect PHHs and Huh-7.5 cells. 
We studied HCV glycoprotein clones from several patients; patient H (H77, 
H91A6) who has chronic HCV infection; patient S11 (S11c1, S11c3); 
patient S18 (S18c1, S18c2) and patient S28 (S28c1, S28c2 and S28c3) 
are all acutely infected. HCV glycoproteins from each patient were 
incorporated into the HCVpp system and screened for their ability to infect 
cells.  
The majority of glycoprotein variants were sensitive to prednisolone 
treatment and showed an increased infection, albeit to varying levels 
(Figure 5-7 A). However, viruses expressing envelope glycoproteins H91A6 
and S18c2 were resistant to prednisolone. Similar results were observed 
when cells were treated with dexamethasone an analogue of prednisolone 
(Figure 5-7 A). Furthermore, anti-SR-BI preferentially inhibited 
glycoprotein variants that were sensitive to prednisolone treatment, whilst 
having negligible effects on H91A6pp and S18c2pp entry (Figure 5-7 B). In 
summary, these data show that prednisolone enhances the entry of SR-BI 
dependent viral strains, lending further to an essential role for SR-BI 
expression levels in defining prednisolone enhancement of HCV entry. 
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Virus Prednisolone (nM) Dexamethasone (nM)
PHH             Huh-7.5 PHH                   Huh-7.5
H77 3 4 4 5
H91A6 0 0 0 0
S11c1 6 7 7 7
S11c3 5 6 4 5
S18c1 5 6 5 5
S18c2 1 1 1 1
S28c1 5 6 5 5
S28c2 2 2 1 2
S28c3 3 4 3 4
VSV-G 0 0 0 0
 
 
 
 
 
 
 
 
 
 
Figure 5-7. Diverse HCVpp sensitivity to prednisolone treatment. 
A. The effects of prednisolone (100nM) and dexamethasone (100nM) 
overnight treatments on diverse HCVpp infection of PHHs and Huh-7.5 
cells. Table shows the fold increase of HCVpp entry when cells were 
treated with the above compounds relative to untreated cells. Viruses 
highlighted in red demonstrated increased susceptibility to glucocorticoid 
treatment, whereas viruses highlighted in black showed a minimal boost 
effect. B. Anti-SR-BI (5µg/ml) neutralization of diverse HCVpp entry into 
PHHs and Huh-7.5 cells shows that HCVpp strains with reduced 
susceptibility (black bars) to glucocorticoid treatment were resistant to 
anti-SR-BI neutralization. Data is presented as HCVpp infectivity relative to 
control untreated cells.  
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5 . 1.7 Prednisolone enhances ITX 5061 neutralizing efficacy.  
HCV infected patients are given steroid boluses as immune modulators 
immediately after liver transplantation which continues for up to 90 days to 
ensure immune tolerance of the new liver or graft (355). Since ITX 5061 is 
currently undergoing clinical trials as an HCV entry inhibitor in the liver 
transplant setting, we asked whether ITX 5061 function is altered in 
conjunction with prednisolone. We measured the levels of ITX 5061 
required to neutralize HCVpp infection in the presence or absence of 
prednisolone treatment. As a control we evaluated the effect of 
prednisolone treatment on anti-CD81 monoclonal antibody neutralizing 
efficacy. ITX 5061 showed a dose-dependent inhibition of H77pp and 
S11c1pp infection with IC50 values of 0.8 and 1.1µM respectively, whereas 
in the presence of prednisolone ITX 5061 IC50 values were reduced to 0.3 
and 0.5µM, respectively (Figure 5-8 A).  
ITX 5061 had minimal effect on H91A6pp infection, consistent with our 
earlier observation of reduced SR-BI dependency (Figure 5-7 A). In 
contrast, prednisolone had no effect on the levels of anti-CD81 monoclonal 
antibody required to neutralize HCVpp strains (Figure 5-8 B). In summary, 
ITX 5061 is still effective to neutralize HCV infection in the presence of 
prednisolone. Furthermore, its neutralizing efficacy is enhanced by 
prednisolone treatment.  
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Figure 5-8. The effects of prednisolone on ITX 5061 efficacy.  
A. ITX 5061 dose dependent neutralization of H77pp, H91A6pp and 
S11c1pp entry into Huh-7.5 cells. Cells were treated with prednisolone 
(100nM) overnight followed by treatment with increasing concentrations of 
ITX 5061 for 4 hours. Cells were infected with HCVpp strains and luciferase 
activity measured 72 hours later. The IC50 of ITX 5061 on H77pp infection 
was 0.8 ± 3 and 0.3 ± 1µM for control and prednisolone treated cells 
respectively. For S11c1pp ITX 5061 IC50 was 1.1 ± 4 and 0.5 ± 2µM in 
control and treated cells respectively. B. Anti-CD81 neutralization of 
H77pp, H91A6pp and S11c1pp entry in a dose dependent manner. Control 
and prednisolone cells were treated with anti-CD81 monoclonal antibody 
clone [2s131] for 4 hours followed by infection. Luciferase activity was 
determined 72 hours later. Data is presented as percentage neutralization. 
Anti-CD81 IC50 was 0.5 ± 2µg/ml irrespective of prednisolone treatment.  
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5 . 1.8 Heterogeneous SR-BI distribution in normal and HCV 
infected liver tissue. 
Given our data showing the importance of SR-BI expression levels in HCV 
transmission in vitro we were interested to study SR-BI expression in the 
liver. Sequential paraffin embedded sections from normal and HCV infected 
livers were stained with a serial dilution of anti SR-BI monoclonal antibody 
to ascertain SR-BI expression levels across the parenchyma. Figure 5-9 
shows representative images of sections stained with 1.0 and 0.06µg/ml 
dilutions of anti-SR-BI monoclonal antibody, where SR-BI is predominantly 
expressed on the sinusoidal endothelium  consistent with published 
observations (341). Although there was a clear reduction in SR-BI staining 
with lower concentrations of monoclonal antibody, expression at the peri-
portal and peri-septal regions of normal and HCV infected tissue 
respectively were visible, suggesting increased SR-BI expression in these 
regions (Figure 5-9). In addition, SR-BI expression in HCV infected liver 
was strong compared to normal liver (Figure 5-9), suggesting altered SR-
BI expression during chronic HCV infection.  
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Figure 5-9. Immunohistochemical staining of SR-BI in normal and 
HCV infected liver tissue.  
Representative image of SR-BI expression in normal and HCV infected 
livers (5 cases in each category) using two concentrations of anti SR-BI 
monoclonal antibody (x100). Arrows indicate enriched sites of SR-BI 
expression around peri-portal areas in normal liver and peri-septal areas of 
HCV infected liver.   
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5 . 1.9 The effects of glucocorticoids on SR-BI distribution in 
vivo.    
To investigate whether glucocorticoid treatment alters SR-BI expression 
and distribution in the liver, we stained liver biopsies collected at defined 
times post transplant liver for SR-BI expression. Table 5-1 shows the 
patient history of and collection times of biopsies studied. Biopsies 
collected during liver reperfusion (time 0) before the patients were 
immunosuppressed, 2 weeks post liver transplantation when patients were 
in receipt of immunosuppression, and 12 months post liver transplantation, 
when immunosuppression was no longer administered, were studied. 
Biopsies (n=5 patients) from each time point were co-stained for von 
Willebrand factor (vWF) which is expressed on the sinusoidal endothelium 
and SR-BI which is expressed on hepatocytes and the sinusoidal 
endothelium. vWF enables us to distinguish between hepatocyte and 
sinusoidal SR-BI expression (Figure 5-10). At time 0 and 2 weeks post 
transplantation SR-BI was expressed on the sinusoidal endothelium and 
hepatocytes, however, by 12 months post transplantation SR-BI was 
predominantly expressed on the sinusoidal endothelium with minor 
hepatocellular staining (Figure 5-10). These data show hepatocyte SR-BI 
expression in biopsies from the reperfusion (time 0) and 
immunosuppressive (2 weeks) periods, suggesting that SR-BI distribution 
during initial stages after liver transplantation may promote HCV infection.  
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Patient ID Diagnosis Time 0 2 Weeks 12 months
1 PBC/ALD No steroids Prednisolone (20mg/day) No steroids
2 AIH No steroids Prednisolone (20mg/day) No steroids
3 NASH No steroids Prednisolone (20mg/day) No steroids
4 PBC No steroids Prednisolone (20mg/day) No steroids
5 ALD No steroids Prednisolone (20mg/day) No steroids
 
 
 
 
Table 5-1. List of biopsies used in this study.  
Biopsies (n=5) were taken at the reperfusion stage (time 0) before steroid 
treatment, 2 weeks post liver transplantation (steroid treatment) and 12 
months later (no steroid treatment). Table also shows the disease 
aetiology of all patients; biopsies from HCV infected patients were excluded 
from the study to avoid any bias which may have resulted from virus 
infection. PBC; Primary Billiary Cirrhosis, ALD; Alcoholic Liver Disease, 
AIH; Auto Immune Hepatitis, and NASH; Non-Alcoholic Steatohepatitis.  
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Figure 5-10. SR-BI distribution in specimens from liver transplant 
patients in receipt of glucocorticoid therapy.  
Representative confocal images of SR-BI expression in biopsies obtained 
from 5 liver transplant patients before (time 0), during (2 weeks) and after 
(12 months) glucocorticoid treatment. Liver tissue at each time point was 
co-stained for the endothelial marker von Willebrand factor (vWF) (green) 
and SR-BI (red). Boxes indicate the area from which the enlarged images 
were taken. Hepatocyte (open arrow heads) and sinusoid (closed arrow 
heads) SR-BI staining is shown. Scale bar represents 20µm.  
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Patient ID AST level (IU/L)
1 449 (day 1)
2 2188 (day 1)
3 3403 (day 1)
4 2210 (day 2)
5 987 (day 1)
5 . 1.10 Hypoxia increases SR-BI expression in vitro. 
In normal liver tissue SR-BI is predominantly expressed at the sinusoidal 
endothelium with minimal hepatocyte expression (341) and is therefore 
reflective of the 12 month biopsy. Our in vitro findings demonstrate a role 
for GR signaling in promoting SR-BI expression and we anticipated that 
increased hepatocyte SR-BI expression would be found in the 2 week 
biopsies only due to glucocorticoid treatment. Nevertheless, our 
observation of increased SR-BI expression on hepatocytes in time 0 
specimens suggests that factors associated with graft reperfusion affects 
SR-BI expression. The liver sustains injury from ischemic preservation and 
reperfusion leading to parenchymal changes during the post-operative 
period. Ischemia reperfusion injury (IRI) is associated with increased 
serum aspartate transaminase (AST) levels. Normal AST levels ranges 
between 5-43 IU/L, AST levels of <400 IU/L 1 day post liver 
transplantation is associated with mild IRI and day 1 AST of >2000 IU/L is 
associated with severe IRI (283, 315). The majority of specimens studied, 
were from patients with severe IRI in the early post-operative period due 
to elevated AST (Table 5-2).  
 
 
 
 
 
 
Table 5-2. AST levels in the early post operative period.  
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IRI is associated with hypoxia due to diminished oxygen levels (59). To 
ascertain whether hypoxia modulate SR-BI expression; we quantified SR-
BI expression in Huh-7.5 and liver sinusoidal endothelial cells (LSEC) 
grown under hypoxia and normoxia. Hypoxia increased SR-BI expression in 
Huh-7.5 and LSEC’s (Figure 5-11). Interestingly, cultured Huh-7.5’s 
showed higher levels of SR-BI expression compared to LSEC’s; in contrast, 
SR-BI is predominantly expressed on the sinusoidal endothelium in vivo 
(341) suggesting that its expression on LSEC’s is affected by isolation from 
the liver tissue. These data demonstrate that hypoxia promotes SR-BI 
expression levels in cells representing hepatocytes (Huh-7.5) and the 
sinusoidal endothelium (LSEC). Therefore, the increased hepatocyte SR-BI 
noted in the time 0 biopsy may be indicative of a cellular response to 
hypoxia.    
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Figure 5-11. Hypoxia upregulates SR-BI expression in vitro.  
Huh-7.5 and LSEC’s were grown in hypoxic or normoxic conditions 
overnight and SR-BI expression monitored by flow cytometry. Histograms 
show SR-BI expression at the cell surface. Tables show the mean 
fluorescent intensities (MFI) of SR-BI and an isotype matched (IgG) control 
antibody stain.  
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5 . 1.11 Increased cholesterol production in prednisolone 
treated cells.  
Studies have shown increased cholesterol levels in prednisolone treated 
transplant patients (42, 133, 150, 330). SR-BI has been reported to 
regulate various aspects of cholesterol metabolism; including the removal 
of unesterified cholesterol from the periphery leading to altered cholesterol 
distribution in the plasma membrane (243). Together, these data suggest 
a link between SR-BI, prednisolone and cellular cholesterol levels. We 
investigated whether prednisolone altered cellular cholesterol levels in 
vitro. Prednisolone significantly increased total cholesterol levels in PHHs 
and Huh-7.5 cells by 2-fold (Figure 5-12 A). Moreover, HCVcc infection 
increased PHH and Huh-7.5 cholesterol to comparable levels observed in 
prednisolone treated cells (Figure 5-12 B).  
Since HCV infection increases cellular cholesterol, we hypothesized that 
virus infection may affect glucocorticoid receptor (GR) signaling. The 
glucocorticoid receptor resides in the cytoplasm in its dormant  phase, 
steroid engagement of GR induces a relocalization to nucleus where it acts 
as a transcription factor regulating many target genes including cytokine 
production and cholesterol synthesis (Figure 5-13) (408). We studied 
whether HCV infection modulates GR signalling. Prednisolone treatment of 
Huh-7.5 cells induced a nuclear localization of GR and this was blocked by 
co-treatment with RU-486 (Figure 5-12 C). Furthermore, we observed 
nuclear GR expression in HCV infected Huh-7.5 cells compared to mock 
cells; interestingly, RU-486 treatment had no effect on GR localization in 
infected cells suggesting that HCV modulation of GR signaling occurs via 
unknown mechanism(s) (Figure 5-12 C). In summary, we show that HCV 
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infection perturbs GR signaling leading to increased cholesterol production. 
These findings may help to shed light on increased steatosis seen in HCV 
infected individuals.   
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Control Prednisolone Prednisolone/RU-486
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Figure 5-12. The effects of HCV infection on cholesterol efflux and 
glucocorticoid receptor signalling.  
A. Prednisolone treatment (100nM) overnight increases cholesterol levels 
in PHHs and Huh-7.5 cells. Data is shown as the µM of cholesterol/105 
cells. B. HCVcc J6/JFH-1 infection increases cellular cholesterol levels. Cells 
were infected for 48 hours and cholesterol measured. The infected cells 
contained 2.2 x 105 and 1.6 x 106 HCV RNA copies/105 cells for PHHs and 
Huh-7.5 cells respectively. C. Glucocorticoid receptor (green) localization in 
prednisolone treated and J6/JFH-1 infected Huh-7.5 cells, DAPI staining is 
depicted in grey and the scale bar represents 20µm. The infected cells 
were treated with RU-486 (5µg/ml) and contained 8 x 105 RNA copies/105 
cells. 
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Figure 5-13. Schematic outline of the glucocorticoid receptor 
signalling. 
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5.2 Discussion  
Prednisolone treatment of PHHs and Huh-7.5 cells increased their 
susceptibility to HCVpp and HCVcc infection in a SR-BI dependent manner. 
This was associated with increased GR signaling and cholesterol 
production. Moreover, SR-BI expression in the liver is heterogeneous 
suggesting a rate limiting role for this receptor in the HCV lifecycle.  
A previous report suggested that enhanced HCV entry by prednisolone was 
mediated through SR-BI and Occludin (76). Although have we confirmed 
an increase in Occludin expression by prednisolone, over expression of 
Occludin in Huh-7.5 cells did not confer an increased susceptibility to HCV 
infection. In contrast, HCVpp strains demonstrating reduced SR-BI 
dependency were resistant to the effects of prednisolone. Furthermore, 
anti-SR-BI neutralizing antibody and HCV entry inhibitor ITX 5061 ablated 
HCV infection of prednisolone treated cells by up to 95%, suggesting a role 
for SR-BI in the prednisolone mediated effects. Studies have shown that 
the Occludin gene contains a glucocorticoid response element (GRE) 
explaining the increase in Occludin expression following steroid treatment 
(125, 153). There are no studies showing a GRE promoter region in SR-BI; 
however, SR-BI plays an integral role in the steroidogenic pathway by 
providing cholesterol substrate necessary for steroid synthesis (55, 397).  
Glucocorticoids have been reported to increase epithelial Caco-2 cell 
polarity (43) and to protect the integrity of the blood brain barrier against 
the permeating effects of proinflammatory cytokines (124). These data 
suggest a role for glucocorticoids in the maintenance and regulation of 
epithelial polarity. We have previously shown that polarity restricts HCV 
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entry into HepG2 hepatoma cells (260). It is therefore interesting, that 
prednisolone would increase virus entry whilst protecting polarity. Since 
Huh-7.5 cells do not polarize (259), HepG2 cells were treated with 
prednisolone and the polarity index determined. Prednisolone had no effect 
on HepG2 polarity; in contrast prednisolone restricted the flux of 70kDa 
FITC dextran across a Caco2 monolayer, suggesting differential regulatory 
mechanism(s) of epithelial and hepatic polarity (data not shown).  
Henry et al studied the effects of glucocorticoids on HCV replication and 
observed a decrease in virus replication in vitro. In contrast, glucocorticoid 
treatment increased viral RNA levels in vivo (164). The authors attributed 
this to a dampening of the immune system by steroid treatment and thus 
the effects were indirect. Our findings shed further light on the potential 
mechanistic of glucocorticoids enhanced HCV replication. We noted an 
increase in HCV RNA levels induced by prednisolone treatment of Huh-7.5 
cells in the absence of a host immune response. This effect was coupled 
with increased GR signalling; GR activity is associated with enhanced lipid 
metabolism (reviewed in (302)), and lipidomic profiling of HCV infected 
cells show the perturbation of lipid species believed to play an important 
role in virus replication and assembly (90). Together, these data suggest 
that GR signaling modulates the lipid profile of infected cells which may in 
turn augment viral RNA replication.  
Our laboratory previously reported that HCV can transmit in cell-cell 
contact dependent manner. Although all the viral receptors are necessary 
for this to occur, this mode of transmission is highly dependent on SR-BI 
expression levels (50). HCV strains with limited SR-BI dependence show 
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minimal cell-cell spread and disseminate predominantly via the cell-free 
route. These data support our current observation that prednisolone 
increased the infectivity of HCVpp expressing glycoproteins that were 
readily neutralized by anti SR-BI and ITX5061, whereas strains H91A6 and 
S18c2 that were insensitive to neutralizing agents targeting SR-BI were 
resistant to prednisolone. These findings support a model where strains 
that are highly dependent on SR-BI will transmit preferentially in a cell-cell 
fashion; furthermore, glucocorticoid treatment may favour the 
transmission of such viruses in the newly transplanted liver.  
We observed heterogeneous SR-BI staining in the liver, with enriched 
areas adjacent to peri-portal areas which border the peripheral blood flow. 
Oxygen is supplied to the liver via the blood; our data showing enriched 
SR-BI near the blood flow suggest a putative role for oxygen levels in 
regulating SR-BI expression. HCV circulates in the peripheral blood before 
coming into contact with hepatocytes. Our observation of enriched SR-BI 
expression at peri-portal regions supports a model where HCV interacts 
with receptor complexes that are highly expressed on the basolateral 
hepatocellular membrane adjacent to the peripheral blood flow. HCV 
infects the liver allograft in 100% of cases concomitant with a rapid decline 
in peripheral HCV RNA levels in the first few days after liver transplantation 
(263). Several groups have monitored HCV replication kinetics in the liver 
immediately after transplantation and found an increase in HCV viral load 
as early as 12 hours post graft reperfusion, reaching pre-transplantation 
levels within 4 days in the majority of individuals and exceeding these 
levels by up to two logs by 12 weeks (75, 135, 325, 331, 333). Recent 
findings from our laboratory show two distinct patterns of HCV replication 
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kinetics in the post transplant setting; typified by a prolonged decline in 
HCV RNA levels followed by a late rebound 14 days later or an initial 
decline and rapid rebound 48 hours after liver transplant (Ian Rowe, 
personal communication). The increase in HCV viremia post-transplant 
suggests that viral replication is efficient and represents de novo infection 
of new target cells.  Recently, Mensa and colleagues (263), studied SR-BI 
expression levels in the liver post liver transplantation and showed an 
association between increased SR-BI expression in the reperfusion biopsy 
and reduced peripheral HCV RNA levels in the first 24 hours following liver 
transplantation, suggesting that SR-BI levels modulate early infection 
kinetics.  
SR-BI is a scavenger receptor molecule that mediates binding and lipid 
transfer from different classes of lipoproteins accounting for its role in 
cholesterol metabolism including the removal of peripheral unesterified 
cholesterol, steroidogenesis, bile acid synthesis and secretion (200). In 
vivo HCV particles associate with lipoproteins and cholesterol is a central 
component of lipoproteins suggesting an essential role in the virus life 
cycle. We noted increased cholesterol levels in HCV infected and 
prednisolone treated cells. Of note, SR-BI regulates the bidirectional flux of 
free cholesterol between lipoproteins and cells resulting in increased 
cellular cholesterol mass (191, 298). Increased cholesterol levels during 
HCV infection and a rapid decline in peripheral HCV RNA levels post-
reperfusion suggest that enhanced SR-BI scavenging activity increases the 
uptake of HCV particles in the new allograft. Furthermore, steroid bolus is 
associated with increased cholesterol levels in transplant patients (150, 
330), suggesting the intriguing possibility that glucocorticoids exacerbate 
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HCV infection by increasing cholesterol levels resulting in enhanced SR-BI 
expression and activity that is essential  for cholesterol regulation. We 
noted reduced hepatocyte SR-BI distribution in biopsies from post 
transplant patients after the glucocorticoid administration period (12 
months later) compared to biopsies taken at time 0 (graft reperfusion), 
and 2 weeks after liver transplantation which demonstrated a mixture of 
hepatocyte and sinusoidal endothelium SR-BI localization. At time 0 
patients were steroid free and during the first 3 months patients were in 
receipt of immunosuppression therapy to prevent graft rejection by the 
immune system. These findings show comparable hepatocyte SR-BI 
distribution before and during glucocorticoid therapy representing a 
paradox as we anticipated increased hepatocyte SR-BI distribution in the 
steroid treatment period only. These data suggest that the outcome of HCV 
infection post liver transplant is multifactorial. For example, ischemia 
reperfusion injury (IRI); liver tissue damage caused by blood reperfusion 
during transplant has been linked to recurrent HCV disease (reviewed in 
(252)). In the previous chapter, we showed that hypoxia a key regulator of 
IRI promotes HCV replication suggesting that injury sustained during organ 
transplant potentiates HCV infection. Furthermore, it is likely that IRI 
upregulates hepatocyte SR-BI expression to comparable levels seen in 
biopsies from immunosuppressed patients. To date, there are no studies 
showing a hypoxia responsive region in the SR-BI genome; however, CD36 
another member of the family of scavenger receptors contains a functional 
HIF-1 binding site which is upregulated during hypoxia (278) suggesting 
the possibility that the SR-BI promoter region contains a hypoxia 
responsive element (HRE). We show that hypoxia increases SR-BI 
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expression in Huh-7.5 and LSEC’s to confirm a putative HRE in the SR-BI 
promoter.    
Our observation that HCV infection perturbs GR signaling is intriguing and 
provides a potential explanation for hepatic steatosis observed in HCV 
patients (reviewed in, (175)). Glucocorticoid treatment precipitates 
steatohepatitis by increasing insulin resistance, diabetes and 
hypertriglycerridemia, resulting in severe scarring of the liver (96, 114). 
The mechanism underlying HCV perturbation of GR activity is unclear as 
GR antagonist RU-486 inhibited GR transcriptional activity in prednisolone 
treated cells but not HCV infected cells. A recent study by Sun et al showed 
increased GR transcriptional activity is associated with HIF-1α stabilization 
in oligodendrocytes (388), highlighting the possibility that HCV stabilization 
of HIF-1α modulates GR signaling events which in turn favours increased 
HCV replication kinetics. These findings provide avenues for future studies 
looking at the effects of HIF-1 inhibitors on GR transcriptional activity. In 
summary, these studies provide unique insights into the mechanisms of 
glucocorticoids induced exacerbation of HCV infection of the newly 
transplanted liver.    
What are the clinical implications and outlook for these findings? 
The kinetics of HCV infection is exacerbated post liver transplantation, 
culminating in graft failure within 5 years. Our findings suggest that high 
glucocorticoid doses may account for the increased viral load after liver 
transplant. Although the factors governing accelerated HCV re-infection of 
the liver are likely to be multiple, including host immune response, viral 
genotype and hypoxia. Reports have shown that non-steroid based 
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immunosuppression reduced the severity of recurrent hepatitis post 
transplant, suggesting a prominent role for glucocorticoids in augmenting 
HCV infection (76). However, steroid boli are continually prescribed as they 
provide the most potent way of combating immune intolerance leading to 
graft rejection. As such, a delicate balance is required to control rejection 
and viremia, on one hand lowering the steroid dose may reduce HCV 
infection but increases the likelihood of graft failure or rejection. Non-
steroid based therapy such as Cyclosporin A may provide an alternative for 
the current regimen. HCV infection in the absence of glucocorticoids 
perturbs glucocorticoid receptor activity indicating that virus infection is 
capable of augmenting this pathway to potentially promote its lifecycle. In 
this regard, non-steroid immune modulators in conjunction with 
glucocorticoid receptor antagonists may prove beneficial to HCV 
transplanted patients. Nevertheless, the exact nature of glucocorticoid 
enhanced HCV infection or perturbation of hepatocyte biology requires 
further investigation which may in turn aid in the development of improved 
immunosuppressive drugs for HCV infected patients.  
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6. CONCLUDING REMARKS 
6.1 HCV infection of primary human hepatocytes and hepatoma 
cells. 
Significant progress has been made in the development of in vitro models 
to study the HCV lifecycle over the last two decades. As such, key aspects 
of HCV entry, replication, assembly and release have been reported. Our 
understanding of the HCV lifecycle has been shaped through the use of 
hepatocellular carcinoma cell lines that enable robust virus entry and 
replication. However, it is becoming clear that hepatoma cell lines such as 
Huh-7.5 cells may not reflect hepatocytes in vivo. Huh-7.5 cells fail to 
polarize in culture and do not induce an interferon response to virus 
infection (259, 386). It is believed that cultured PHHs represent a closely 
matched physiological model of hepatocytes in vivo. Nevertheless, there 
are few reports of HCV infection of PHHs; this is in part due to difficulties in 
obtaining them and their short lifespan in culture. To date, it is not known 
whether HCV infection of hepatoma cell lines is comparable to PHHs. In 
this study, we employed the HCVpp and HCVcc systems to investigate 
virus entry and replication respectively, in hepatoma and PHHs. We have 
demonstrated that PHHs support HCV entry and replication which was 
optimal at day 2 post seeding consistent with the formation of cellular 
contacts that increases HCV receptor expression at the cell surface. We 
were able to show comparable HCVpp entry kinetics in PHHs and hepatoma 
cell lines in the absence of hepatoma cell division. In vivo, hepatocytes are 
quiescent (393), importantly cultured PHHs maintains this phenotype. In 
contrast, hepatoma cells divide in culture; we provide the first evidence 
that cell division increases HCVpp luciferase signals which is regularly 
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reported as authentic virus entry. Our data suggest the need for caution 
when interpreting absolute HCVpp luciferase activity in dividing hepatoma 
cells. We propose a model whereby HCV infection of hepatocytes in vivo is 
restricted to a small percentage of hepatocytes, supported by Liang and 
colleagues who showed that only a small proportion of hepatocytes express 
HCV antigens in vivo, this may in part be due to a lack of cell division 
(221). Reagents that inactivate cell division resulted in comparable HCVpp 
entry in both cell types. Interestingly, H77pp and S11c1pp were highly 
stable on Huh-7.5 cells compared to PHHs in the absence of cell division. 
To date there are no reports on the effects of HCVpp stability in 
determining infection kinetics. Or data provides novel insights into cellular 
and viral factors that determine the outcome of HCVpp entry.  
Importantly, PHHs supported HCVcc replication and released comparable 
infectious virus particles to Huh-7.5 cells. HCVcc strains demonstrated 
variable replication in PHHs from multiple donors. In contrast, donor 
variation did not affect HCVpp entry. These data suggest that inherent 
donor differences including variabilities in interferon response to virus 
infection affect HCV replication.  
Overall, we have shown that in the absence of cell division, hepatoma cells 
represent a closely matched physiological model for HCV infection of 
hepatocytes. Our findings shed light on the mechanistic driving increased 
HCVpp luciferase activity in hepatoma cells and validate their use as robust 
in vitro models to study HCV infection.  
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6.2 HCV induced hepatocellular injury          
We showed that HCV infection and glycoprotein expression modulate tight 
junction protein expression and localization resulting in reduced polarity 
and increased migration. Both phenotypes are associated with intrahepatic 
cholestasis and HCC malignancy (9, 166). Indeed, HCV infection is 
associated with cholestatic liver disease and HCC (115, 277). The role of 
HCV in the carcinogenic process is thought to be indirect as HCV is non-
cytopathic (49). We show the promotion of EMT transcription factors Snail 
and Twist associated with HIF-1α stabilization and increased expression of 
its target genes VEGF and TGFβ. Neutralizing antibodies targeting TGFβ 
and not VEGF ablated Snail and Twist expression and restored polarity to 
demonstrate a HIF-1α driven TGFβ process.  
During liver repair the liver reverts to an early developmental stage 
reminiscent of EMT induced by cytokines and growth factors. Growth 
factors associated with liver repair includes VEGF and TGFβ (393). Most 
EMT cells undergo MET to signal the end of the repair process enabling the 
liver to return to its normal homeostasis (72). Our data suggest that HCV 
infection induces liver injury via HIF-1α stabilization resulting in an 
inflammatory response including VEGF and TGFβ that primes the livers 
repair mechanisms including fibrogenesis induced by stellate cells. In a 
healthy liver, hepatocytes are highly ordered and compact; thus, they are 
likely to restrict virus transmission. HCV could become opportunistic during 
the repair process when some cells de-differentiate. Indeed, a recent study 
showed that a mesenchymal phenotype increases cellular permissiveness 
to HCV replication, consistent with previous data showing that HCV 
perturbation hepatocellular metabolism favours the viral lifecycle (71, 90). 
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Studies of oncogenic Epstein Barr virus (EBV) showed that EBV induced 
EMT does not promote the virus lifecycle per se but contributes to the 
metastatic nature of a tumour (169, 239). HIF-1α and TGFβ can directly 
induce EMT which is associated with carcinogenesis (184, 303, 433). Our 
data showing increased migration and virus replication in HIF-1α stabilized 
cells suggest a dual role for this transcription factor in the HCV lifecycle 
and hepatocellular migration. It is likely that HCV modulates the liver 
repair mechanisms by prolonging MET signaling resulting in sustained EMT 
which promotes HCC pathogenesis. These data suggest that HCV injures 
the liver via indirect means consistent with our observation that HCV 
gyclopropteins does not interact with Occludin. Furthermore, our study 
suggests that a cellular response to virus infection promotes signalling 
pathways that drives HCC. These data provide insights into the effects of 
HCV infection on hepatocyte biology. Figure 6-1 shows HIF-1α signaling 
induced by HCV infection.  
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Figure 6-1. The cellular response to HCV infection.  
HCV infection of hepatocytes stabilizes HIF-1α which induces the 
expression of many genes including those implicated in angiogenesis and 
HCV transmission (VEGF, TGFβ); proteins involved in metastatic signalling 
(TGFβ, Smad, Wnt/β catenin); extracellular matrix lysyl oxidase proteins 
(LOX and LOXL); EMT transcription factors (SNAIL and TWIST); regulators 
of cell proliferation and invasion, (chemokine receptor 4 [CXCR4], matrix 
metalloproteinase [MMF2] and the cell morphology protein [PaI1]. These 
HIF-1α driven pathways may act in concert or independently to drive HCC 
pathogenesis.  
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6.3 Glucocorticoid receptor transcription and HCV infection. 
In order to prevent rejection of the new graft, HCV infected patients are 
treated with glucocorticoids post liver transplantation. It has been reported 
that glucocorticoids enhances HCV infection offering insights into rapid 
reinfection of the new allograft culminating in liver failure a few years post 
transplantation (77, 325). However, there are limited studies addressing 
the mechanisms of glucocorticoid induced exacerbation of HCV entry. We 
have shown that the glucocorticoid prednisolone enhanced HCV entry into 
hepatoma and PHHs by upregulating the viral receptor SR-BI. 
Glucocorticoid actions are mediated through the glucocorticoid receptor 
(GR) expressed in the cytoplasm. When activated by glucocorticoids, GR 
functions as a transcription factor for various genes including NF-ќB 
signalling and cholesterol production (2). We demonstrate that HCV 
infection perturbs GR localization concomitant with elevated cholesterol 
levels, increased HCV entry, replication and transmission. These data 
offers further insights into cellular pathways modulated by HCV to further 
its lifecycle and potentiate liver injury.  
We studied liver biopsies from transplant patients taken before, during and 
after glucocorticoid treatment for SR-BI expression and localization. SR-BI 
demonstrated increased hepatocyte distribution in biopsies taken at graft 
reperfusion prior to glucocorticoid treatment and during the treatment 
period. In contrast, biopsies taken after glucocorticoid treatment showed a 
predominant sinusoidal endothelial SR-BI expression pattern. It is believed 
that hepatocyte expressed forms of HCV receptors in vivo potentiate HCV 
entry. Our data showing increased hepatocyte SR-BI expression prior to 
steroid treatment suggest that multiple factors in vivo may potentiate HCV 
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reinfection of the transplant liver. Graft reperfusion is associated with 
elevated AST resulting in IRI. In addition, IRI is regulated by HIF-1α 
suggesting the intriguing possibility that HIF-1α plays a role in virus uptake 
during the transplant setting (87). One study has shown that GR activity is 
regulated by HIF-1α (215), indicating that HCV stabilization of HIF-1α may 
prime GR dependent pathways resulting in a dampened immune response 
and increased viral receptor expression that favours HCV uptake and 
transmission. Furthermore, Kodama and colleagues have shown that GR 
transcriptional activity up-regulates HIF-1α dependent genes through an 
association with the transactivational domain of HIF-1α (195). Together, 
these data suggest that both transcriptional factors positively regulate 
each other in an HCV inflamed liver and will ultimately dictate the course of 
HCV pathogenesis. GR signaling is also associated with steatosis and 
insulin resistance (96) and similar traits have been reported in a significant 
percentage of  HCV related liver disease (14, 351). Our observation that 
HCV infection modulates GR signaling suggests a role for GR is driving HCV 
associated steatosis.  
Taken together, our findings validate the use of hepatoma cell lines as in 
vitro tools to study HCV infection. We provide insights on the mechanisms 
of HCV induced injury of the liver. HCV infection perturbs liver functions via 
HIF-1α and GR transcription activity. Both pathways de-regulate genes 
involved in metabolism, cell proliferation, cholesterol production, immune 
regulation, insulin resistance and hepatic carcinogenesis. In doing so, HCV 
primes the hepatic environment to favour virus replication and 
transmission. A detailed understanding of HCV pathology is required for 
the development of anti-virals and the prevention of HCV related liver 
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injury. We show that HIF-1α inhibitors neutralize the effects of virus 
infection on hepatocyte biology accompanied by reduced virus replication. 
HIF-1α inhibitors may therefore represent a novel therapeutic for HCV 
induced HCC. In addition, we show that GR antagonist RU-486 ablated the 
effects of GR transcription on HCV entry and hepatocyte biology offering 
hope for the use of GR antagonists to treat HCV related steatosis.   
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